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ABSTRACT 
 
 
FINITH E. JERNIGAN, III: Synthesis and Development of Proteasome and Kinase 
Fluorescent Assays for Quantitation of Enzyme Activity.  
 
Under the direction of David S. Lawrence. 
 
 
Enzyme activity is a major component of signal transduction. However, many current 
methods of enzyme detection, such as fluorophore-labeled antibodies or western blotting, 
quantitate enzyme concentration and lack the ability to determinate activity levels. This can 
lead to imprecise depictions of signal transduction pathways. For example, the cyclic-AMP 
dependent protein kinase (PKA) is ubiquitously expressed, but activity is highly regulated. 
Near the mitochondria, PKA activity is responsible for the activation of apoptotic pathways 
and as a consequence is highly regulated. For a complete understanding of apoptotic signal 
transduction, it is necessary to precisely define PKA activity. Gaining an increased 
understanding of enzyme activity is the goal of this thesis.  
In pursuit of this goal, we have developed chemical tools for the quantitation of PKA 
activity, as well as the activities of the proteasome. An assay for PKA activity was developed 
termed “deep quench” using primarily electrostatic interactions between a positively charged 
fluorescently-labeled PKA substrate and a negatively charged non-fluorescent quenching 
dye. Upon phosphorylation of the fluorescently-labeled peptide substrate by PKA, interaction 
between the positively charged residues of the substrate and the negatively charged dye 
weaken, causing a lower affinity for quenching dye. Since the quenching dye has an 
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absorbance near the emission of the PKA-substrate fluorophore, the energy transfer between 
the fluorophore and dye weakens as well, producing extraordinary fluorescent enhancements 
(up to 150-fold).  
Using the “deep quench” system, suborganelle mitochondrial PKA activity was 
revealed as a relative matrix/intermembrane space/outer membrane (85:6:9) distribution of 
PKAin bovine heart mitochondria. While this sensor works beautifully in vitro, applying the 
system in an intracellular fashion has proven difficult due to the system’s bimolecular nature. 
We have attempted to solve this problem by covalently linking the non-fluorescent dye 
carboxy Acid Blue 40 (cAB40) to the fluorescently labeled PKA substrate. However, due to 
the FRET mechanism of fluorescent quenching, no fluorescent increase was observed upon 
substrate phosphorylation. To solve this problem, the cAB40 and fluorescent PKA substrate 
were attached to 100 nm silica nanoparticles. Upon phosphorylation, a 2.2-fold fluorescent 
increase was observed. cAB40 was more completely characterized and found to quench 
fluorophores with a wide range of spectral properties. In further studies, Trypsin substrates 
were assembled, as well as a photolabile cassette, which furnished up to 110-fold 
enhancements in fluorescence. After demonstrating the utility of the cAB40 quenching dye, 
the technology was applied to biosensors for the Caspase-like (proteasome β1-subunit), 
Trypsin-like (proteasome β2-subunit), and Chymotrypsin-like (proteasome β5-subunit) 
activities of the proteasome. The specificity for the Caspase-like (proteasome β1-subunit) and 
Chymotrypsin-like (proteasome β5-subunit) activities of the proteasome was demonstrated. 
Overall this body of work demonstrates the utility of the “deep quench” PKA and proteasome 
sensors towards the goal of quantifying enzyme activity. 
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CHAPTER 1 
INTRACELLULAR KINASE AND PROTEASOME ACTIVITY: AN 
INTRODUCTION 
 
SIGNIFICANCE 
Intracellular enzyme activity plays a key role in the coordination of cell processes such as 
mitosis, apoptosis, and cytotaxis. For example, the activity of the small nuclear GTPase Ran is 
responsible for control of assembly of the mitotic spindle, nuclear-envelope dynamics, and the 
timing of cell-cycle transitions during mitosis.1 Additionally, cyclic-AMP dependent protein 
kinase (PKA) activity near the mitochondria regulates apoptosis through phosphorylation of the 
proapoptotic factor BAD (a BCL-2 family member protein).2 Many methods provide a way to 
quantitate protein expression, such as antibody labeling or western blotting, among others. 
However, assessments of protein expression do not provide information on activity, which is 
generally responsible for signal transduction. For example, PKA is ubiquitously expressed, but 
PKA activity near the mitochondria is responsible for regulation of apoptosis.3 Quantitative 
assessments of enzyme activity are essential for further understanding of signal transduction 
pathways. Unfortunately, few chemical probes exist with robust enzyme activity
                                                          
1 Clarke, P. R.; Zhang, C. Nature reviews. Molecular cell biology 2008, 9, 464–77. 
 
2 Harada, H.; Becknell, B.; Wilm, M.; Mann, M.; Huang, L. J.; Taylor, S. S.; Scott, J. D.; Korsmeyer, S. J. 
Molecular cell 1999, 3, 413–22. 
 
3 Pidoux, G.; Taskén, K. Journal of molecular endocrinology 2010, 44, 271–84. 
2 
 
measurement capabilities that are easily delivered to the cytoplasm. During this investigation we 
focused on development of chemical fluorescent biosensors capable of PKA activity quantitation 
and quantitation of the catalytic activities of the proteasome. As mentioned above, mitochondrial 
PKA activity is involved in the regulation of apoptosis through phosphorylation of the cytosolic 
protein Bcl-2-associated death promoter (BAD).  The proteasome plays a large role in signal 
transduction through digestion of signaling proteins, therefore preventing participation of the 
digested proteins in signal transduction pathways. Due to this, measurement of intracellular 
proteasome activity can provide information on the regulation of a wide range of proteins. It has 
already been demonstrated that unusual fluctuations of proteasome activity are telltale sign of 
malignancies, making the proteasome an attractive target of chemotherapeutics.4 Through this 
work, we have developed chemical biosensors of PKA and the proteasome and employed them 
towards the measurement of PKA and proteasome activity. 
 
AN OVERVIEW OF BIOSENSORS FOR INTRACELLULAR IMAGING  
 
Cells rely on vast signal transduction networks to respond to stimuli such as external 
force,5 oxidative stress,6 and chemotaxis.7 Through study of cellular responses to stimuli, it has 
become abundantly clear that study of signal transduction requires quantitation of enzyme 
                                                          
4 Yang, H.; Zonder, J. A.; Dou, Q. P. Expert opinion on investigational drugs 2009, 18, 957–71. 
 
5 Janmey, P.; McCulloch, C. Annual review of biomedical engineering 2007, 9, 1–34. 
 
6 Cataldi, A. Current pharmaceutical design 2010, 16, 1387–95. 
 
7 Emonet, T.; Cluzel, P. Proceedings of the National Academy of Sciences of the United States of America 2008, 
105, 3304–9. 
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Figure 1.1 Reprinted from Kiyokawa, E.; Aoki, K.; Nakamura, T.; Matsuda, M. Annual 
review of pharmacology and toxicology 2011, 51, 337–58. with permission from Annual 
Reviews. Structure of genetically encoded Förster resonance energy transfer (FRET) probes. 
(a) Intermolecular FRET probes are designed to detect the protein-protein interaction. The 
donor and acceptor fluorophores are fused to the pair of proteins. When they form a complex, 
the distance between the donor and acceptor becomes close enough to cause FRET. (b) FRET 
can be used to detect the conformational change of proteins. In the simplest design of the 
intramolecular FRET probe, donor and acceptor fluorophores are fused to the proper position 
of the proteins of interest so that conformational change of the proteins alters the distance 
and/or topology of the donor and acceptor fluorophores, thereby resulting in an increase or a 
decrease in FRET efficiency. (c) The conformational change of the proteins of interest is 
often minute. Typical examples are the GTP-GDP exchange of small GTPases and 
phosphorylation of proteins. The domain that displays minimal conformational change upon 
signal perception is termed the sensor domain. This sensor domain is linked to the binder 
domain, which binds only when the sensor domain exhibits conformational change. The 
donor and acceptor sandwich the sensor domain–linker–binder domain complex so that the 
binding increases FRET. 
A 
B 
C 
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activity. Activity/functional relationships have been discovered in a wide range of enzymes 
including kinases,8 the proteasome,9 GTPases,10 and caspases.11 Sensors capable of elucidating 
activity/function relationships have followed one of two distinct techniques: (1) FRET Green 
Fluorescent Protein (GFP)-based sensors employing phosphopeptide binding domains to yield 
measureable changes in fluorescence or (2) chemical probes employing bond cleavage, metal 
chelation, electrostatic interactions or environmentally-sensitive fluorophores to yield 
measurable changes in fluorescence upon enzyme action. 
GFP-based sensors function through changes in Förster resonance energy transfer 
between a donor and acceptor fluorescent protein of properly selected photophysical properties. 
Changes in energy transfer efficiencies modulate the fluorescence of a donor and an acceptor 
GFP, resulting in a measurable signal. Actions resulting in measureable fluorescent changes of 
GFP-based sensors include: (a) protein-protein interactions, (b) conformational changes of a 
substrate, or (c) conformational changes between a fusion protein containing a sensor domain 
and binding domain (Figure 1.1).12 Intermolecular GFP sensors of the first type are primarily 
used as sensors of protein-protein interaction, which is beyond the scope of this work (Figure 
1.1a).  Typical FRET-based GFP sensors for enzyme catalyzed reactions function via 
conformational change of the protein after catalysis (Figure 1.1b) or in the case of lack of 
conformation change, a change induced after interaction with a binding domain (Figure 1.1c).   
                                                          
8 (1) Scott, J. D.; Newton, A. C. BMC biology 2012, 10, 61. (2) Yudushkin, I.; Schleifenbaum, A.; Kinkhabwala, A.; 
Neel, B. G.; Schultz, C.; Bastiaens, P. I. H. Science 2007, 315, 115–9. 
 
9 Finley, D. Annual review of biochemistry 2009, 78, 477–513. 
 
10 Kiyokawa, E.; Aoki, K.; Nakamura, T.; Matsuda, M. Annual review of pharmacology and toxicology 2011, 51, 
337–58. 
 
11 Cataldi, A. Current pharmaceutical design 2010, 16, 1387–95. 
 
12 Kiyokawa, E.; Aoki, K.; Nakamura, T.; Matsuda, M. Annual review of pharmacology and toxicology 2011, 51, 
337–58. 
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  As an example (Figure 1.1b), the cyclic-AMP (cAMP) FRET sensor ICUE1 (Indicator 
for cAMP using Epac) functions using the Epac1 (Exchange Protein Activated by cAMP) 
binding domain located between a FRET GFP pair. A conformational change occurs upon cAMP 
binding resulting in a fluorescence change.13 This strategy has been widely employed in many 
cases where proteins undergo a large conformational change upon activation.14 However, many 
proteins do not undergo conformational changes upon activation. In this case, an additional 
binder domain is necessary to produce a conformational change (Figure 1.1c).15 This strategy has 
been employed in the case of FRET reporters of glycosylation,16 methylation,17 
phosphorylation,18 and ubiquitination.19 Although GFP-based FRET reporters are useful tools for 
enzyme activity imaging, the system does have disadvantages including: (1) difficulties 
establishing mammalian cells lines expressing the reporter, (2) the small dynamic range of the 
fluorescent readout, and (3) difficulty using multiple probes in microscopy due to 
spectrophotometric overlap.20  
  Chemical probes offer many advantages over GFP-based FRET sensors. Chemical probes 
                                                          
13 DiPilato, L. M.; Cheng, X.; Zhang, J. Proceedings of the National Academy of Sciences of the United States of 
America 2004, 101, 16513–8. 
 
14 (1) Calleja, V.; Alcor, D.; Laguerre, M.; Park, J.; Vojnovic, B.; Hemmings, B. a; Downward, J.; Parker, P. J.; 
Larijani, B. PLoS biology 2007, 5, e95. (2) Fujioka, A.; Terai, K.; Itoh, R. E.; Aoki, K.; Nakamura, T.; Kuroda, S.; 
Nishida, E.; Matsuda, M. The Journal of biological chemistry 2006, 281, 8917–26. (3) Ananthanarayanan, B.; 
Fosbrink, M.; Rahdar, M.; Zhang, J. The Journal of biological chemistry 2007, 282, 36634–41. 
 
15 Aye-Han, N.-N.; Ni, Q.; Zhang, J. Current opinion in chemical biology 2009, 13, 392–7. 
 
16 Carrillo, L. D.; Krishnamoorthy, L.; Mahal, L. K. Journal of the American Chemical Society 2006, 128, 14768–9. 
 
17 Lin, C.-W.; Jao, C. Y.; Ting, A. Y. Journal of the American Chemical Society 2004, 126, 5982–3. 
 
18 Zhang, J.; Allen, M. D. Molecular bioSystems 2007, 3, 759–65. 
 
19 Perroy, J.; Pontier, S.; Charest, P. G.; Aubry, M.; Bouvier, M. Nature methods 2004, 1, 203–8. 
 
20 Kiyokawa, E.; Aoki, K.; Nakamura, T.; Matsuda, M. Annual review of pharmacology and toxicology 2011, 51, 
337–58. 
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are: (1) capable of modification and use with a wide variety of commercially available 
fluorophores, (2) applicable to a wide variety of cell lines, and (3) can be used as part of a 
multicolor system capable of monitoring the activity of multiple enzymes. However, it can be 
difficult to devise an activation strategy that yields a fluorescent change upon enzymatic action. 
A recent review catalogs six methods of fluorescent quenching of small molecule fluorophores 
capable of producing a fluorescent increase upon action21: 
(1) Fluorophore self-quenching (homo-FRET) 
(2) Quencher-fluorophore FRET quenching 
(3) Autoquenching via attached protein/peptide residues 
(4) H-type dimer formation 
(5) Photon induced electron transfer (PeT) 
(6) A dual function activable fluorophore based on a combination of 
mechanisms 
Using these methods of small-molecule fluorophore fluorescent quenching, a variety of chemical 
probes have been synthesized according to common paradigms. A recent review identified four 
common paradigms used in chemical-based approaches to fluorescent assays (Figure 1.2).22 Four 
common examples include: (1) sensors for proteolysis23 which rely on bond cleavage to abrogate 
                                                          
21 Kobayashi, H.; Choyke, P. L. Accounts of chemical research 2011, 44, 83–90. 
 
22 Morris, M. C. Cell biochemistry and biophysics 2010, 56, 19–37. 
 
23 (1) Chen, J. Circulation 2002, 105, 2766–2771. (2) Jaffer, F. a; Kim, D.-E.; Quinti, L.; Tung, C.-H.; Aikawa, E.; 
Pande, A. N.; Kohler, R. H.; Shi, G.-P.; Libby, P.; Weissleder, R. Circulation 2007, 115, 2292–8. (3) Kozloff, K. 
M.; Quinti, L.; Patntirapong, S.; Hauschka, P. V.; Tung, C.-H.; Weissleder, R.; Mahmood, U. Bone 2009, 44, 190–8. 
(4) Neefjes, J.; Dantuma, N. P. Nature reviews. Drug discovery 2004, 3, 58–69. (5) Wunder, A.; Tung, C.-H.; 
Müller-Ladner, U.; Weissleder, R.; Mahmood, U. Arthritis and rheumatism 2004, 50, 2459–65. 
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intramolecular FRET (2) kinase sensors24 with attached environmentally sensitive fluorophores 
causing a fluorescence change upon addition of a negatively charged phosphate (3) nucleotide 
sensors25 that show enhancement of fluoresce upon incorporation into DNA and (4) interfacial 
sensors that show enhancements in fluorescence upon binding to an active target. Although many 
fluorescent probes seem promising for in vitro work, difficulties do exist with probe delivery to 
the cytoplasm and selective activation of the biosensor by the observer, which are not issues in 
                                                          
24 (1) Chen, C.-A.; Yeh, R.-H.; Yan, X.; Lawrence, D. S. Biochimica et biophysica acta 2004, 1697, 39–51. (2) 
Sharma, V.; Wang, Q.; Lawrence, D. S. Biochimica et biophysica acta 2008, 1784, 94–9. (3) Wang, Q.; Cahill, S. 
M.; Blumenstein, M.; Lawrence, D. S. Journal of the American Chemical Society 2006, 128, 1808–9. (4) Wang, Q.; 
Lawrence, D. S. Journal of the American Chemical Society 2005, 127, 7684–5. (5) Chen, C.-A.; Yeh, R.-H.; 
Lawrence, D. S. Journal of the American Chemical Society 2002, 124, 3840–1.  (6) Yeh, R.-H.; Yan, X.; Cammer, 
M.; Bresnick, A. R.; Lawrence, D. S. The Journal of biological chemistry 2002, 277, 11527–32. (7) Lawrence, D. 
S.; Wang, Q. Chembiochem : a European journal of chemical biology 2007, 8, 373–8. 
 
25 (1) Cochran, J. C.; Sontag, C. a; Maliga, Z.; Kapoor, T. M.; Correia, J. J.; Gilbert, S. P. The Journal of biological 
chemistry 2004, 279, 38861–70. (2) Webb, M. R.; Corrie, J. E. Biophysical journal 2001, 81, 1562–9. (3) Webb, M. 
R. Molecular bioSystems 2007, 3, 249–56. (4) Webb, M. R.; Reid, G. P.; Munasinghe, V. R. N.; Corrie, J. E. T. 
Biochemistry 2004, 43, 14463–71. 
 
Figure 1.2 Reprinted with permission from Kobayashi, H.; Choyke, P. L. Accounts of 
chemical research 2011, 44, 83–90. Copyright 2011 American Chemical Society. Common 
examples of fluorescence-based biosensors. (a) peptide-based biosensor of proteolytic 
activity through cleavage-induced abrogation of intramolecular FRET, (b) peptide-based 
biosensor of protein phosphorylation thorough enhancement of environmentally sensitive 
fluorophore fluorescence, (c) Nucleotide-based sensors consist of fluorescently labeled 
nucleotide analogs whos fluorescence is enhanced upon incorporation into DNA. (d) 
interfacial biosensors consist of polypeptide domains or sequences that bind to a specific 
target, thereby generating an enhancement in fluorescence. 
A B C D 
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the case of FRET-based GFP probes (although plasmid transfection with the corresponding GFP-
based sensor can sometimes be difficult). Today, cytoplasmic biosensor delivery relies on the use 
of protein transduction domains (PTDs)26 or cell penetrating peptides (CPPs),27 along with 
mechanical or physical techniques.28 Once delivered, the biosensor must be in an inert form to 
prevent enzymatic action before observation. Photodeprotection,29 through incorporation of a 
photolabile protecting group, provides the observer with control of the t = 0 observation point. 
Using these techniques, many disadvantages of chemical probes have been overcome, yet many 
challenges remain. 
 
MITOCHONDRIAL CYCLIC-AMP DEPENDENT PROTEIN KINASE ACTIVITY 
NEAR THE CYTOPLASM  
 
Mitochondria are often referred to as the “energy power house” of the cell due to the key 
role they play in cell respiration. However, signal transduction pathways near mitochondria have 
been linked to the regulation of the cell-cycle, cellular development and maturation, antiviral 
responses, cell death, among other cell processes, making the mitochondria much more integral 
                                                          
26(1) Schwarze, S. R.; Hruska, K. a; Dowdy, S. F. Trends in cell biology 2000, 10, 290–5. (2) Snyder, E. L.; Dowdy, 
S. F. Expert opinion on drug delivery 2005, 2, 43–51. 
 
27 (1) Deshayes, S.; Morris, M. C.; Divita, G.; Heitz, F. Cellular and molecular life sciences : CMLS 2005, 62, 
1839–49. (2) Morris, M. C.; Deshayes, S.; Heitz, F.; Divita, G. Biology of the cell / under the auspices of the 
European Cell Biology Organization 2008, 100, 201–17. 
 
28 McNeil P. L. Current Protocol in Cell Biology 2001, Chapter 20:Unit 20.1. 
 
29 (1) Mayer, G.; Heckel, A. Angewandte Chemie (International ed. in English) 2006, 45, 4900–21. (2) Lawrence, D. 
S. Current opinion in chemical biology 2005, 9, 570–5. (3) Ellis-Davies, G. C. R. Nature methods 2007, 4, 619–28. 
(4) Li, H.; Hah, J.; Lawrence, D. S. Journal of the American Chemical Society 2008, 130, 10474–5. 
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Figure 1.3 Reprinted from McBride, H. M.; Neuspiel, M.; Wasiak, S. Current biology : CB 
2006, 16, R551–60, with permission from Elsevier. Schematic summarizing major kinase 
pathways that converge on the mitochondrion. A growing body of data indicate that activated 
versions of each of these kinases (rectangles) are targeted directly to mitochondria, resulting 
in phosphorylation of mitochondrial proteins that regulate cell death (PTP, BAD, Bcl-2) and 
metabolic function (complex I, GSK3h, PDH). Phospho-ERK and PKC may also influence 
cytochrome c (Cyt c) release or membrane potential through other mechanisms (dotted 
arrows). In addition, kinases and mitochondrial anchoring proteins may participate in a novel 
mechanism for regulating mitochondrial protein expression, as illustrated by PKA- and 
AKAP-dependent targeting of MnSOD mRNA to the mitochondrion for local translation. 
Abbreviations not defined elsewhere: IGF-1, insulin-like growth factor 1; IL-3, interleukin-3; 
NO, nitric oxide; PDH, pyruvate dehydrogenase; PTP, permeability transition pore; TPA, 
12-O-tetradecanoylphorbol-13-acetate; UV, ultraviolet radiation; 6-OHDA, 6-
hydroxydopamine. 
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to signal transduction than is generally understood.30 Mitochondrial signal transduction pathways 
have been found to involve many kinases, including PKC, PKCδ, PKCα, ERK, Raf-1, JNK, 
PKA, and Akt (Figure 1.3).31 Although a wide variety of pathways are worthy of attention, this 
study chooses to focus on PKA-mediated signaling of apoptosis, of which PKA has been 
identified as a central mediator.32 
PKA is composed of a heterotetramer containing two regulatory (R) and two catalytic (C) 
subunits that are differentially expressed and regulated throughout various subcellular locations 
and cell lines.33 Regulation of PKA occurs through the localized production and degradation of 
the second messenger cAMP.34 PKA-mediated signaling begins via activation of adenylyl 
cyclase by an extracellular ligand, which increases the intracellular concentration of cAMP.35 
The second messenger cAMP then binds to the regulatory subunit of PKA (PKA-R), inducing a 
dissociation of the catalytic subunit (PKA-C), causing PKA-C activation. Phosphodiesterases 
provide a negative regulator of PKA activity, through degradation of cAMP to AMP.36 A kinase 
anchoring proteins (AKAPs) provide a further degree of sophistication by anchoring PKA-R to 
                                                          
30 McBride, H. M.; Neuspiel, M.; Wasiak, S. Current biology : CB 2006, 16, R551–60. 
 
31 Horbinski, C.; Chu, C. T. Free radical biology & medicine 2005, 38, 2–11. 
 
32 Orrenius, S. Toxicology letters 2004, 149, 19–23. 
 
33 (1) Tasken K, Skalhegg BS, Tasken KA, Solberg R, Knutsen HK, Levy FO, Sandberg M, Orstavik S, Larsen T, 
Johansen AK, Vang T, Schrader HP, Reinton NT, Torgersen KM, Hansson V, and Jahnsen T. Adv Second 
Messenger Phosphoprotein Res 1997, 1, 191–204. (2) Skalhegg BS and Tasken K. Front Biosci 5: D678–D693, 
2000. 
 
34 (1) Taskén, K.; Aandahl, E. M. Physiological reviews 2004, 84, 137–67. (2) Feliciello, A.; Gottesman, M. E.; 
Avvedimento, E. V. Cellular signalling 2005, 17, 279–87. 
 
35 Sunahara, R. K.; Dessauer, C. W.; Gilman, A. G. Annual review of pharmacology and toxicology 1996, 36, 461–
80. 
 
36 Soderling, S. H.; Beavo, J. Current opinion in cell biology 2000, 12, 174–9. 
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Figure 1.4 Reproduced from Feliciello, A.; Gottesman, M. E.; Avvedimento, E. V. Cellular 
signaling 2005, 17, 279–87. with permission from Cellular Signaling. cAMP stimulates the 
expression of AKAP121. AKAP121-PKA inhibits the mitochondrial apoptotic pathway. 
Cartoon showing the regulation of AKAP121 levels by cAMP. A cAMP increase following 
adenylyl cyclase stimulation activates a membrane-anchored PKA (included Golgi-
centrosome PKA, indicated as AKAP).  PKA catalytic subunit (C) dissociated from the 
holoenzyme enters the nucleus and phosphorylates CREB1. Transcription of AKAP121 is 
induced by cAMP. Higher AKAP121 levels target more PKA molecules to the outer wall of 
the mitochondria. The rise in cAMP concentrations dissociates mitochondrial-anchored PKA, 
PKA phosphorylates serine 155 of the proapoptotic protein BAD. BAD, a BH3-proapoptotic 
Bcl-2 family member, acts at a key nodal point in the mitochondrial apoptotic pathway. 
Unphosphorylated BAD binds and inactivates antiapoptotic Bcl-2 homologs, favoring release 
of cytochrome C from mitochondria and apoptosis. Phosphorylation by PKA blocks BAD 
association with Bcl-2 and inhibits apoptosis. Membrane bound PKA in other compartments 
cannot substitute for mitochondrial PKA. 
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membranes and providing spatial resolution.37 The coordination of adenylyl cyclases and 
phosphodiesterases, combined with AKAPs localizing PKA-R, enables signal transduction 
through the PKA pathway with high spatiotemporal definition.  
Intracellular PKA-mediated signal transduction plays large role in regulation of apoptosis 
at the mitochondria.38 This was first described by Papa et al., as it was discovered all PKA 
isoforms were present in purified mitochondria.39 Several mitochondrial proteins known to be 
PKA substrates were also present, including nuclear-encoded 18-kd subunit of complex I 
(NDUFS4), the proapoptotic BAD protein, and the steroidogenic acute regulatory protein 
(StAR), among others. The most important pathway component to this work is proapoptotic 
protein BAD, a Bcl-2 family member, and a key part of the proapoptotic pathway (Figure 1.4). 
Phosphorylation of BAD is known to inhibit apoptosis, playing a key role in cellular survival and 
death. It has been demonstrated that mitochondrial PKA-C activity is required for 
phosphorylation of BAD.40 The pathway begins with cAMP signals from adenylyl cyclase near 
cell membrane diffuse to cytosomal AKAPs and release PKA-C into the cytosol. PKA-C then 
diffuses into the nucleus causing phosphorylation of CREB1. CREB1 is responsible for 
activating transcription of AKAP121, which translocates to the mitochondrial membrane and 
binds PKA-R. Endogenous PKA-C is then recruited to the mitochondria via PKA-R binding. 
Simulation via cAMP then causes mitochondrial PKA-C to phosphorylate BAD and prevent 
                                                          
37 (1) Diviani, D.; Scott, J. D. Journal of cell science 2001, 114, 1431–7. (2) Michel, J. J. C.; Scott, J. D. Annual 
review of pharmacology and toxicology 2002, 42, 235–57. 
 
38 Feliciello, A.; Gottesman, M. E.; Avvedimento, E. V. Cellular signaling 2005, 17, 279–87. 
 
39 Papa, S.; Sardanelli, a M.; Scacco, S.; Technikova-Dobrova, Z. FEBS letters 1999, 444, 245–9. 
 
40 Affaitati, A.; Cardone, L.; de Cristofaro, T.; Carlucci, A.; Ginsberg, M. D.; Varrone, S.; Gottesman, M. E.; 
Avvedimento, E. V.; Feliciello, A. The Journal of biological chemistry 2003, 278, 4286–94. 
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apoptosis.  
 
CURRENT CAPABILITIES OF PROTEIN KINASE BIOSENSORS 
 
Our goal is to quantify PKA activity near the mitochondria, with the aim of studying the 
mitochondrial apoptotic pathway. To accomplish this, new biosensors are needed with improved 
activity measurement capabilities. Current biosensors for intracellular imaging rely primarily on 
GFP-based FRET sensors, yet chemical probes are becoming more prevalent. The first PKA 
biosensor for intracellular use was described in 1991 by Adams et al.41 At the time, fluorescent 
sensors were only available for metal ions, and few tools existed for quantitation of PKA activity 
in real time. Since this publication, the field has been greatly expanded to include sensors with 
various excitation/emissions wavelengths and for a wide range of protein kinases.  
Genetically-encoded reporters of PKA activity typically rely on a ratiometric FRET mode 
of imaging. A report by Zhang et al., described the use of a genetically encoded FRET PKA 
biosensor, named AKAR1, capable of targeting via tethering to a PKA holoenzyme (Figure 
1.5(A)).42 The four component biosensor is constructed by sandwiching a PKA substrate and the 
phosphopeptide binding domain 14-3-3τ between a YFP/CFP FRET pair (Figure 1.5(B)). The 
consensus sequence of the sensor relies on a previously described sequence specific to 14-3-3τ.43 
Flexible linkers were inserted between the C-terminal tail of 14-3-3τ and between the substrate 
                                                          
41 Adams, S. R.; Harootunian, A. T.; Buechler, Y. J.; Taylor, S. S.; Tsien, R. Y. Nature 1991, 349, 694–7. 
 
42 Zhang, J.; Ma, Y.; Taylor, S. S.; Tsien, R. Y. Proceedings of the National Academy of Sciences of the United 
States of America 2001, 98, 14997–5002. 
 
43 Yaffe, M. B.; Rittinger, K.; Volinia, S.; Caron, P. R.; Aitken, A.; Leffers, H.; Gamblin, S. J.; Smerdon, S. J.; 
Cantley, L. C. Cell 1997, 91, 961–971. 
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peptide and YFP. Mutants were constructed with varying substrate sequences and linkers to find 
the analog with the best fluorescent enhancement. Upon stimulation with FsK (Forskolin, 50 
μM), the phosphopeptide binding domain bound to the phosphorylated substrate peptide causing 
a change in the FRET ratio by 30% over 5-10 minutes  (Figure 1.5 (C)). This sensor 
demonstrates good substrate specificity versus four related kinases in vitro with a small amount 
of activity towards PKG at longer time frames (Figure 1.5(c)). 
 
After all in vitro work was performed, AKAR1 was transfected into a variety of cell lines 
including HeLa, COS-7, HEK293, and Chinese hamster ovary cells and found to be evenly 
distributed throughout the cytosol (for expression in HeLa cells, see Figure 1.6(A)). Upon 
transfection, responses to FsK (50 μM) occurred in a shorter 3-5 minute time frame and occurred 
evenly throughout the cytoplasm (Figure 1.6 (A)). Antiphospho-PKA substrate western blot 
analysis of AKAR1 from HeLa cells demonstrates FsK selective phosphorylation (Figure 1.6 
A 
B 
C 
Figure 1.5 Reproduced with permission from Zhang, J.; Ma, Y.; Taylor, S. S.; Tsien, R. Y. 
PNAS 2001, 98, 14997–5002. AKAR1 sensor described by Zhang et al. (A) Mechanism of 
biosensor. Upon phosphorylation, the phosphopeptide binding domain 14-3-3τ binds to the 
phosphorylated substrate peptide changing the FRET ratio. (B) Construction of the biosensor 
(C) Specificity of AKAR1.  
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 (A), on right). AKAR1 mutants were constructed (S475A and K280E) and found to greatly 
decrease the FRET ratio upon stimulation with FsK (50 μM, Figure 1.6(B)). One major problem 
with kinase biosensors is specificity, due to the large number of kinases and similarity of kinase 
consensus sequences. Although specificity was successfully demonstrated in vitro, intracellular 
selectivity is more difficult to achieve. However, AKAR1 was demonstrated to be 
Figure 1.6 Reproduced with permission from Zhang, J.; Ma, Y.; Taylor, S. S.; Tsien, R. Y. PNAS 
2001, 98, 14997–5002. Cellular responses of AKAR1. (A) FRET response of HeLa cells 
transfected (24 h) with AKAR1. (Left) The CFP-only image on the far left shows that the 
reporter distributes evenly throughout the cytosol. Pseudo color images depict the FRET 
response of the reporter to FsK stimulation. (Right) (Upper) The antiphospho-PKAsubstrate 
Western blot analysis of AKAR1 from HeLa cells; (Lower) the fluorescence image [470 ± 20 nm 
excitation, 530 ± 20 nm emission (YFP only)] of the same gel. Lane 1:AKAR1 from 
unstimulated cells. Lane 2: Treatment with 50 μM FsK for 30 min increases the phosphorylation 
level of the reporter. (B) FRET response of the S475A mutant (Left) and the K280E mutant 
(Right) of AKAR1. The height of the frames in A corresponds to 69 μm. Similar magnifications 
apply to B. (C) Emission ratio time courses for AKAR1 stimulated with 50MFsK in the absence 
and presence of the PKA inhibitor H89 (25 μM), and the S475A mutant and the K280E mutant 
stimulated with FsK (50 μM) in the absence of the inhibitor. (D) Emission ratio time courses of 
AKAR1 stimulated with 50 μM FsK, 1 mM Bt2cAMP, 100 μM isoproterenol, and 50 μM of 
DMNB-cAMP followed by UV uncaging. 
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unphosphorylated upon treatment with the PKA specific inhibitor H89, demonstrating specificity 
to PKA (Figure 1.6(C)).  
Since publication of Zhang et al. in 2001, similar sensors have been described with 
similar properties as AKAR1.44 However, the most important example appeared in Nature in 
2005.45 This work describes the construction of an improved PKA biosensor AKAR2. A major 
problem with the AKAR1 biosensor is the lack of control of the assay by the observer. The 
protein must be incubated for 24-48 hours before observation to allow time for expression.42 
During this time, the protein is free to be phosphorylated by endogenous PKA. In the case of 
AKAR1, binding with the phosphoserine binding domain 14-3-3τ is tight enough to prevent 
dephosphorylation by phosphodiesterases, rendering the sensor non-reversible. This creates a 
problem as the sensor may be fully phosphorylated by endogenous PKA and unable to be used 
by the observer. With chemical probes, control can be obtained using a DMNB protecting group 
(4,5-dimethoxy-2-nitrobenzyl) attached to a specific location on a chemical probe as to render 
the probe inert until selective removal by the observer at a precise moment in time. No such 
precise control currently exists with expressed FRET-based GFP biosensors. To address this 
problem, AKAR1 was reengineered to include FHA1 (forkhead associated domain 1), instead of 
the phosphoserine binding domain 14-3-3τ, due to the order of magnitude lower binding 
affinity.46 Due to the change in phosphoserine binding domain, the included PKA consensus 
sequence was modified to enhance FHA1 binding. The lower affinity of phosphoserine binding 
                                                          
44 (1) Saucerman, J. J.; Zhang, J.; Martin, J. C.; Peng, L. X.; Stenbit, A. E.; Tsien, R. Y.; McCulloch, A. D. 
Proceedings of the National Academy of Sciences of the United States of America 2006, 103, 12923–8. (2) Hu, E.; 
Demmou, L.; Cauli, B.; Gallopin, T.; Geoffroy, H.; Harris-Warrick, R. M.; Paupardin-Tritsch, D.; Lambolez, B.; 
Vincent, P.; Hepp, R. Cerebral cortex (New York, N.Y. : 1991) 2011, 21, 708–18. 
 
45 Zhang, J.; Hupfeld, C. J.; Taylor, S. S.; Olefsky, J. M.; Tsien, R. Y. Nature 2005, 437, 569–73. 
46 Durocher, D.; Taylor, I. a; Sarbassova, D.; Haire, L. F.; Westcott, S. L.; Jackson, S. P.; Smerdon, S. J.; Yaffe, M. 
B. Molecular cell 2000, 6, 1169–82. 
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in the biosensor AKAR2 makes the system susceptible to dephosphorylation by 
phosphodiesterases at the expense of biosensor dynamic range. Specificity of AKAR2 to PKA 
was demonstrated in the same manner as AKAR1 (see above). AKAR2 was used to investigate 
the effect of chronically high insulin levels on PKA activation. The authors demonstrated that 
chronic hyperinsulinaemia did not delay AKAR2 phosphorylation induced by FsK or by cAMP 
uncaging, which suggests that insulin treatment does not affect the entire pool of free PKA in 
3T3-L1 fibroblasts. These results, although important, are outside the focus of this work. The use 
of the AKAR2 biosensor is most important, as it demonstrates the need for a reversible system 
when using FRET-based GFP biosensors. The system also has a small dynamic range compared 
to AKAR1 (30%), which is, in the case of FsK induced phosphorylation 12% (Figure 1.7(A)), 
and in the case of cyclic-AMP induced phosphorylation 6% (Figure 1.7(B)).  
  Although FRET-based GFP biosensors have major advantages (e.g. ease of delivery into 
cells via transfection and reliance on molecular biology rather than chemistry for biosensor 
Figure 1.7 Reproduced from Zhang, J.; Hupfeld, C. J.; Taylor, S. S.; Olefsky, J. M.; Tsien, R. 
Y. Nature 2005, 437, 569–73. with permission from Nature Publishing Group. The insulin-
induced delay in PKA activity is specific for a b-adrenergic-coupled pool of PKA. (A) Cells 
were stimulated acutely by the addition of forskolin. Insulin-treated cells in blue and green 
triangles; control cells in black squares and red circles. (B) Cells were stimulated acutely by 
ultraviolet uncaging of DMNB-cAMP. Insulin-treated cells in blue and green triangles; 
control cells in black squares and red circles.  
A B 
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construction), major disadvantages exist. Major problems with the above FRET-based GFP 
kinase biosensors including: 
1) Lack of observer control of the starting point of the assay 
2) Small dynamic range 
3) Use of FRET requires two microscopy channels for observation 
4) Limited spectral window for multiple FRET pairs 
These problems can largely be overcome through the use of chemical probes. For example, the 
Figure 1.8 Reproduced from Lawrence, D. S. Current opinion in chemical biology 2005, 9, 
570–5. with permission from Elsevier. Design and photoactivation of a caged 
peptide/protein. A key residue in a peptide or protein is identified and transformed (see Fig. 
2) into a photo-cleavable analogue that blocks biochemical activity. Subsequent irradiation 
at the appropriate wavelength regenerates the active species. 
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UV labile DMNB (4,5-dimethoxy-2-nitrobenzyl) protecting group has been used in the design, 
use, and synthesis of light-responsive bioreagents.47 Cyclic-AMP was the first bioreagent to be 
used in this manner,48 although many other small molecules, peptides and proteins have also 
been rendered light responsive.49 As an example of the paradigm, a small peptide or proteins can 
be DMNB protected on a cysteine residue critical for protein/peptide function (Figure 1.8).50 
Nitrobenzyl labeling can be accomplished via treatment with 2-nitrobenzyl bromide or through 
incorporation during peptide synthesis. Upon illumination with ultraviolet light, a reaction occurs 
passing through an acetal intermediate to yield the unprotected cysteine. The peptide/protein is 
then activated.  
Secondly, the small dynamic range of FRET-based GFP biosensors is of considerable 
importance if the goal is to measure intercellular enzyme activity. Without a large dynamic 
range, it is difficult to precisely measure the initial rate of enzyme activity, as the assay can 
elapse before observation. For example Zhang et al.,45 incorporated caged ATP to initiate the 
assay. However, with a short five second flash, most of the initial rate data was unable to be 
collected (Figure 1.7(B)).  
Finally, a limited number of FRET pairs are capable of use intracellularly due to each 
FRET pair requiring multiple channels for observation. For example, two FRET pairs, 
ECFP/Venus and TagRFP/mPlum have recently been used for monitoring (1) small Ras GTP-ase 
activation in live cells after epidermal growth factor stimulation and (2) calcium gradients 
                                                          
47 Lee, H.-M.; Larson, D. R.; Lawrence, D. S. ACS chemical biology 2009, 4, 409–27. 
 
48 Engels, J.; Schlaeger, E. J. Journal of Medicinal Chemistry 1977, 20, 907–911. 
 
49 Mayer, G.; Heckel, A. Angewandte Chemie (International ed. in English) 2006, 45, 4900–21.  
 
50 Lawrence, D. S. Current opinion in chemical biology 2005, 9, 570–5. 
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Figure 1.9 Reproduced from Grant, D. M.; Zhang, W.; McGhee, E. J.; Bunney, T. D.; 
Talbot, C. B.; Kumar, S.; Munro, I.; Dunsby, C.; Neil, M. a a; Katan, M.; French, P. M. W. 
Biophysical journal 2008, 95, L69–71.with permission from Elsevier. FRET constructs and 
spectral channels used. (A) Binding of calcium to calmodulin domain of the YCAM3.6 
Cameleon results in a conformational change and FRET from ECFP to Venus. Activation of 
mPlum labeled H-Ras (exchange of GDP for GTP catalyzed by guanonucleotide exchange 
factor (GEF)) results in recruitment of Tag-RFP labeled Raf-Ras Binding Domain to the 
membrane and FRET between TagRFP/mPlum. (B) Absorption and emission spectra of the 4 
fluorophores. Shaded areas indicate excitation and emission bands used for imaging 
multiplexed FRET. 
A 
B 
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simultaneously.51 This was accomplished by careful selection of GFP mutants so as not to cause 
cross talk between microscope channels, and reliance on fluorescence lifetime imaging (FLIM) 
for the TagFRP/mPlum pair instead of spectral ratioing (as was used for the ECFP/Venus pair) 
(Figure 1.9A). Instead of spectral ratio imaging, which relies on monitoring changes in 
fluorescence intensity, monitoring via FLIM is indicated by a decrease in the fluorescent lifetime 
between the FRET pair. Briefly, COS-7 cells were stimulated with epidermal growth factor and 
spectral ratiometric imaging was used to monitor changes in calcium flux using the ECFP/Venus 
FRET pair. Observation of FRET between a TagRFP labeled Ras binding domain from C-Raf-
Kinase (Raf-Ras Binding Domain) and mPlum labeled H-Ras was accomplished via FLIM. As 
shown in Figure 1.9(B), use of two FRET pairs requires most of the visible imaging spectrum, 
leaving no room for imaging of additional intracellular processes. This example demonstrates the 
problems with attempting to image multiple processes simultaneously using FRET-based GFP 
biosensors. 
Chemical probes of PKA activity have advantages over FRET-based GFP PKA sensors, 
such as precise control by the observer and wide range of fluorohpores available for imaging. 
The first peptide biosensor described relied on environmentally-sensitive solvatochromic 
fluorophores to produce a fluorescent enhancement.52 A report from Veldhuyzen et al., describes 
the use of the fluorophore NBD in the creation of a closely related PKC sensor, which could 
theoretically be applied to PKA.53 The sensor was constructed via solid phase peptide synthesis 
                                                          
51 Grant, D. M.; Zhang, W.; McGhee, E. J.; Bunney, T. D.; Talbot, C. B.; Kumar, S.; Munro, I.; Dunsby, C.; Neil, 
M. A.; Katan, M.; French, P. M. W. Biophysical journal 2008, 95, L69–71. 
 
52 Loving, G. S.; Sainlos, M.; Imperiali, B. Trends in biotechnology 2010, 28, 73–83. 
 
53 Veldhuyzen, W. F.; Nguyen, Q.; McMaster, G.; Lawrence, D. S. Journal of the American Chemical Society 2003, 
125, 13358–9. 
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(SPPS) to include a PKC consensus sequence, as well as an N-terminally attached NBD 
fluorophore (Figure 1.10(a)).  The NBD fluorophore has appropriate excitation and emission 
wavelengths (ex 520, em 560) for microscopy. Upon phosphorylation, the biosensor yielded a 3-
fold enhancement in fluorescence, which is 10x the maximum response of AKAR1.  The 
addition of a 4,5-dimethoxy-2-nitrobenzyl protecting group is necessary for intracellular work to 
“cage” the substrate and render it inert prior to photolysis (Figure 1.10(B)). Using the control 
gained from nitrobenzyl caging, substrates 1.1 and 1.2 (Figure 1.10(A)) were used to investigate 
Protein Kinase C activity during Nuclear Envelope Breakdown (NEB, Figure 1.11).54 Using the 
larger dynamic range, PKC activity was monitored before and after NEB, via microinjection of 
substrates 1.1 and 1.2, along with 70 kD Texas red-dextran to provide a standard for ratiometric 
                                                          
54 Dai, Z.; Dulyaninova, N. G.; Kumar, S.; Bresnick, A. R.; Lawrence, D. S. Chemistry & biology 2007, 14, 1254–
60. 
 
Figure 1.10 Reproduced with permission from Veldhuyzen, W. F.; Nguyen, Q.; McMaster, 
G.; Lawrence, D. S. Journal of the American Chemical Society 2003, 125, 13358–9. 
Copyright 2003 American Chemical Society. (A) 1.1 NBD-labeled fluorescent PKC sensor 
1.2 A dimethoxy-2-nitrobenzyl protecting group was added to “cage” the substrate, 
rendering it inert until photolysis via UV light. (B) Intracellular fluorescence as a function 
of time following irradiation. A Sensor 1.2 irritated intracellularly. B Intracellular 
fluorescence of (B) in the absence of UV light. C Sensor irradiated in the absence of 
intracellular PKC.  
1.1 
1.2 
A 
B 
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Figure 1.11 Reproduced from Dai, Z.; Dulyaninova, N. G.; Kumar, S.; Bresnick, A. R.; 
Lawrence, D. S. Chemistry & biology 2007, 14, 1254–60. with permission from Elsevier. 
Protein Kinase Activity prior to and after Nuclear Envelope Breakdown (A) Time course of 
the phosphorylation of peptide 1.1 (Figure 1.10) prior to NEB. The nonphosphorylatable 
analog, 1.2 (Figure 1.10), and 70 kD Texas red-dextran were simultaneously microinjected 
into PtK2 cells. Cells were illuminated (1 s) during prophase (i.e., prior to NEB) to convert 
the inert sensor, 1.2 (Figure 1.10), to its active form, 1.1 (Figure 1.10), and the fluorescence 
change as a function of time was recorded with respect to NEB. Each progress curve is 
derived from a single cell, and a total of 18 cells were examined (6 of the progress curves are 
shown here). (B) Time course of the phosphorylation of peptide 1.1 (Figure 1.10) after NEB. 
PtK2 cells were treated as in Figure 2A, except that photolysis was performed after NEB. The 
progress curve represents the average fluorescence change of 16 cells (each data point 
represents the mean ± SD). (C) Fluorescence change after NEB in the presence of okadaic 
acid (1.5 mM). 
A 
B C 
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imaging (Figure 1.11A). Substrate 1.1 monitored PKC activity before NEB, as it lacked the 
DMNB protecting group. After NEB, substrate 1.2 was converted into substrate 1.1 via 
photocleavage for monitoring of PKC activity after NEB. Before NEB, fluorescent 
enhancements of between 1.4-fold and 2-fold were observed depending on the cell. After NEB, 
no PKC activity was observed after photolysis of substrate 1.2, leading the authors’ conclusion 
that PKC activity is present before, but not after, NEB (Figure 1.11B). This type of experiment 
would be extremely difficult without observer control of the intercellular assay, and a larger 
dynamic range than is possible with current FRET-based GFP PKC biosensors.  
Since the reports by Veldhuyzen et al. and Dai et al., a range of biosensors capable of 
kinase detection have been synthesized and applied to biological systems including: 
(1) Self-quenched micelles which disperse upon phosphorylation55 
(2) Genetically encoded Lanthanide-binding peptides56 
(3) “deep-quench” kinase sensors which rely on binding to a 14-3-3τ domain57 
(4) Lanthanide binding peptides relying on FRET transfer from an attached fluorophore58 
(5) Peptide substrates that rely on chelation of Ca2+ 59 
(6) Sox fluorophore-based Mg2+ chelating kinase sensors60 
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(7) Zn2+-DPA-based kinase biosensors61 
(8) Ratiometric coumarin kinase biosensors relying on a CdII-cycle moiety62 
(9) Quantum dot-based kinase biosensors63 
Although all nine systems have distinct advantages over FRET-based GFP biosensors, 
unfortunately none have found as wide spread of use as FRET-based GFP biosensors. The 
biggest shortcomings with the above probes are (1) the reliance on multiple chemical 
components and (2) intracellular delivery. In most cases, a metal cation, an antibody, or Zn2+-
DPA moiety must be present to produce a fluorescent enhancement. For intracellular use, 
delivery of multiple components to the cytosol would be required for intracellular measurement. 
Delivery of one component is non-trivial, and topic of a large body of research.64 An interesting 
unimolecular sensor paradigm was described by Kikuchi et al.62 The biosensor relies on 
phosphate displacement of a CdII-cyclen(1,4,7,10-tetraazacyclododecane) moiety to produce a 
fluorescent enhancement, which could be an issue at physiological ATP concentrations (Figure 
1.12). However, if the photophysical properties of the sensor were optimized for imaging and 
higher concentrations of ATP was demonstrated to have little effect on biosensor fluorescence, it 
would be easier to deliver than other two component systems. However, like FRET-based GFP 
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sensors, a major drawback with this system is reliance upon FRET, the disadvantages of which 
have been discussed above.  
Unfortunately, chemical probes of kinase activity have not widely been adopted by the 
biological community.65 In order for widespread adoption of chemical probes to occur, kinase 
probes must be as easy to use as FRET-based GFP kinase biosensors without requiring expertise 
in chemistry. This is currently not the case as very few kinase probes (1) are cell permeable (the 
large majority requiring microinjection) and (2) are available commercially without relying on 
the synthesis expertise of a chemist. However, chemical kinase probes have distinct advantages 
over genetically-encoded kinase reporters, including larger dynamic range, better photophysical 
properties of the fluorophores, and no reliance on multichannel FRET during microscopy. Using 
these advantages, future development of chemical kinase probes will be very promising if 
delivery can be improved.  
 
                                                          
65 Pazos, E.; Vázquez, O.; Mascareñas, J. L.; Vázquez, M. E. Chemical Society reviews 2009, 38, 3348–59. 
 
A  B  
Figure 1.12 Reproduced with permission from Kikuchi, K.; Hashimoto, S.; Mizukami, S.; 
Nagano, T. Organic letters 2009, 11, 2732–5. Copyright 2009 American Chemical Society. 
(a) Mechanism of Peptide Biosensor of PKA. Binding of phosphate causes dissociation of 
coordinated amine, creating a change in fluorescence of coumarin fluorophore. (b) 
Ratiometric change observed upon phosphorylation of biosensor. 
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THE PROTEASOME AND REGULATION OF CELLULAR PROTEINS 
 
The proteasome is often referred to as the “garbage can” of the cell due to its primary 
function in protein degradation.66 The 2.5 megadalton enzyme complex (often referred to as the 
26S proteasome complex) is a part of the ubiquitin–protease system, specifically digesting 
proteins marked for degradation with the small protein ubiquitin.67 Protein degradation occurs 
via a multi-step process including: (1) recognition of substrate, (2) protein unfolding, (3) 
translocation, (4) deubiquitination, (5) peptide-bond cleavage.68 The 26S proteasome complex 
consists of a 28-subunit barrel-like core particle (CP, also referred to as the 20S particle) and two 
19-subunit regulatory particles (RPs, also referred to as the 19S particle) on each end of the CP 
channel (Figure 1.13).69 The 20S core particle is responsible for polypeptide degradation after 
substrate recognition and processing by the 19S regulatory particle. Regulation of the 
proteasome by the 19S particle is of prime importance since an uncontrolled proteasome would 
degrade a range of intracellular proteins. Fortunately, the substrate channel is narrow and 
prevents the majority of folded proteins from entering.70 Once recognized and unfolded, proteins 
are not degraded in single amino acids but instead exit the proteasome as 
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Figure 1.13 Reproduced from Reyes-Turcu, F. E.; Ventii, K. H.; Wilkinson, K. D. Annual 
review of biochemistry 2009, 78, 363–97. with permission from Annual Reviews of 
Biochemistry. Structure of the proteasome including deubiquitinating enzymes. 
Deubiquitinating enzymes shown as red crescents, substrate polypeptide chain as a green line, 
and ubiquitin as blue ovals. POH1 catalyzes the release of a polyubiquitin chain en bloc as 
the substrate is engaged and translocated through the gate pore of the 20S protease. S5a binds 
the polyubiquitin chain, and the distal end of the chain can be removed by the action of 
Uch37 bound to Adrm1. Usp14 is bound to the proteasome via interactions with the S2 
subunit, also known as Rpn1 and probably removes monoubiquitin attached to the substrate.  
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small peptides.71 
Although study of the structure and mechanism is indeed important, this study is focused 
on the study of intracellular signal transduction. Our interest in the proteasome stems from recent 
reports implicating proteases in signal transduction pathways and a large variety of physiological 
processes.72 Intracellular protease activity has been demonstrated to be highly regulated, and 
activity imbalances are known causes of disease.73 The proteasome, as a protease, is highly 
regulated by the 19S subunit and has been implicated in number diseases as a result of changes 
in proteasome activity.74 Cell processes known to be regulated by the ubitiquin-proteasome 
system include: 
(1) Cell cycle progression75 
(2) Self-regulation of the ubitiquin-proteasome pathway76 
(3) JNK signaling pathway77 
(4) Calcineurin/NFAT signaling pathways77 
(5) Gene Transcription78 
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(6) Cell polarity of neurons79 
(7) 5’-AMP-activated protein kinase pathway80 
However, reports linking the intracellular distribution of proteasome activity with cellular 
function are lacking. Proteasome biosensors capable of intracellular use could shine light on 
location/function relationships. 
 
CURRENT CAPABILITIES OF PROTEASOME SENSORS 
 
Due to the wide variety of reports linking changes in protease activity to diseases and 
disorders,72 interest is developing in fluorescent reporters that can accurately and precisely 
measure protease activity. Fluorescent protease substrates have been developed for proteases 
such as the proteasome,81 metalloproteases,82 and cysteine proteases,83 among others. Generally 
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protease sensors function via degradation of a substrate labeled with multiple fluorophores 
and/or fluorescent quenchers (Figure 1.14).84 This contrasts with the difficulties associated with 
finding a mechanism of action for development of unimolecular kinase sensors, as 
phosphorylation has been more difficult for chemists to convert into a fluorescent response. 
Using polypeptide degradation mechanisms, protease sensors have been constructed of 
fluorescent proteasome substrates84 including:  
1) Degradation of a GFP protease substrate 
2) Ratiometric FRET using two fluorophores with an excitation emission overlap 
3) Fluorophore unquenching using a fluorophore and non-fluorescent quencher 
4) Fluorophore unquenching via fluorophore self-quenching. 
5) Ratiometric FRET using two GFP mutants with overlapping spectral properties 
 Like kinase biosensors, sensors for the proteasome fall into two categories (1) expressed 
GFP probes and (2) chemical probes. Li et al. described an expressed enhanced green fluorescent 
protein (EGFP) probe as a transcription reporter in 1998.85 Although this system was 
demonstrated as an example of transcription assay, the reporter was constructed to include 
elements known to be susceptible to proteasome degradation to decrease cytosol half-life. 
Mutations of EGFP enhanced protein stability to allow cytosolic EGFP accumulation and 
therefore easy intracellular detection. However, to construct a biosensor, the authors required 
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Figure 1.14 Reprinted with permission from Neefjes, J.; Dantuma, N. P. Nature reviews. 
Drug discovery 2004, 3, 58–69. Copyright 2004 Nature Publishing Group. (A) Destruction. 
Coupling of a degradation signal (DEG) to GFP will result in targeting of the GFP for 
ubiquitylation followed by proteasomal degradation. Degradation of the GFP substrate results 
in loss of fluorescence. (B) Fluorescence resonance energy transfer (FRET) fluorophore 
peptide substrate. A FRET peptide substrate contains a donor and acceptor fluorophore with 
spectral overlap. When the FRET probe is intact and excited with the optimal wavelength for 
the donor, acceptor fluorescence will be emitted at the expense of donor fluorescence. 
Cleavage of the FRET probe results in separation of donor and acceptor fluorophores and 
increased emission from the donor with a concomitant loss of acceptor fluorescence. (C) 
Quenching with fluorophore/quencher pair in peptide substrate. Small peptide fragments 
containing a fluorophore and a corresponding quencher will be essentially non-fluorescent. 
After cleavage, when the quencher is spatially separated from the fluorophore, the 
fluorophore will emit fluorescence. (D) Quenching with identical fluorophores in peptide 
substrate. Two identical fluorophores will quench each other. Principle as in (B). (E)  FRET 
fluorescent proteins. With CFP and YFP as donor and acceptor fluorophore, respectively. 
Principle as in (B). CFP, cyan fluorescent protein; GFP, green fluorescent protein; YFP, 
yellow fluorescent protein. 
A 
B 
C 
D 
E 
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rapid turnover of EGFP in the cytoplasm to prevent accumulation and provide a fluorescent 
readout on an hourly time frame. The long half-life of EGFP was reduced through incorporation 
of a PEST sequence (MODC(422-461)) on the EGFP C-terminus, which is known to enhance 
proteasomal protein degradation without ubiquitination.86 After incorporation of the PEST 
sequence, the authors demonstrated the utility of the biosensor in transfected CHO Tet-off cells 
using flow cytometry (Figure 1.15(A)). A comparison between EGFP and EGFP-MODC(422-461) 
before and after treatment with the transcription inhibitor cycloheximide (CHX). Over time after 
treatment with CHX, EGFP-MODC(422-461) fluorescence decreased whereas EGFP fluoresce 
remained constant (Figure 1.15(B)).  Although this biosensor was demonstrated for use as a 
reporter of transcription, this system could easily be used as a proteasome reporter by following 
the proteasome degradation used to decrease EGFP half-life.  
 A similar protein construct, ZsProSensor-1 was used as a biosensor for the measurement 
of proteasome activity in MBEC and HepG2 cells.87 The ZsProSensor-1 consists of a specific 
degradation motif of ornithine decarboxylase fused to the ZsGreen fluorescent protein.85 Like the 
EGFP-MODC(422-461) protein transcription biosensor, the ZsProSensor-1 fusion protein is rapidly 
degraded by the proteasome without ubiquitylation. First, ZsProSensor-1 was transfected into 
MBEC and HepG2 cells and intracellular fluorescence was monitored with, and without, the 
proteasome inhibitor MG132 (Figure 1.16 (A)). With inhibition of the proteasome using MG132, 
fluorescence was stabilized by the accumulation of ZsProSensor-1. In the absence of MG132, 
different levels of fluoresce are observed between each cell line, indicated differing levels of 
                                                          
86 (1) Rogers, S.; Wells, R.; Rechsteiner, M. Science (New York, N.Y.) 1986, 234, 364–8. (2) Murakami, Y.; 
Matsufuji, S.; Kameji, T.; Hayashi, S.; Igarashi, K.; Tamura, T.; Tanaka, K.; Ichihara, A. Nature 1992, 360, 597–9. 
 
87 Zheng, X.; Ruas, J. L.; Cao, R.; Salomons, F. a; Cao, Y.; Poellinger, L.; Pereira, T. Molecular and cellular 
biology 2006, 26, 4628–41. 
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Figure 1.15 Reprinted with permission from Li, X.; Zhao, X.; Fang, Y.; Jiang, X.; Duong, T.; 
Fan, C.; Huang, C. C.; Kain, S. R. The Journal of biological chemistry 1998, 273, 34970–5. 
(A), flow cytometric analysis of the fluorescence stabilities of EGFP and EGFP-MODC-
(422–461). CHO K1 Tet-off cells were transfected with the two constructs used in Fig. 1. 
After 24 h, the transfected cells were treated with 100 mg/ml CHX for 0, 1, 2, and 3 h. The 
treated cells were collected with EDTA, and 10,000 cells were subjected to FACS analysis. 
(B) The percentage of the fluorescent cells was plotted. Solid circles, EGFP; open circles, 
EGFP-MODC-(422–461). 
A 
B 
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Figure 1.16 Reprinted with permission from Neefjes, J.; Dantuma, N. P. Nature reviews. Drug 
discovery 2004, 3, 58–69. Compartmentalization of proteasome activity in MBECs and 
HepG2 cells. (A) Treatment of cells with the proteasome inhibitor MG132 leads to 
stabilization of the ZsProSensor-1 protein. pZsProSensor-1 was transfected into MBECs or 
HepG2 cells cultured at normoxia. The cells were treated with dimethyl sulfoxide (MG132) or 
10 M MG132 (MG132) for 8 h before fixation. Cells were observed with lower 
magnification. Representative images are shown. (B) Differential proteasome-mediated 
degradation of ZsProSensor-1 protein occurs in MBECs and HepG2 subcellular 
compartments. Cells were transfected with pZsProSensor-1 and cultured at normoxia. After 
treatment with 10 M MG132 for 8 h, the cells were fixed (0 h) or washed three times with 
culture medium to remove MG132 and then fixed at 4 h, 6 h, 8 h, or 10 h of incubation. Cells 
were analyzed by confocal microscopy, and representative images are presented. (C) FRAP 
analysis of cells transfected with pZsProSensor-1. Fluorescence before bleaching was 
considered 100%. Data are shown as the ratio between the fluorescence observed within the 
nuclear and cytoplasmic compartments or between cytoplasmic and nuclear compartments 
following bleaching of the nucleus or cytoplasm, respectively. The results presented are the 
average of the analysis of MBECs or HepG2 cells bleached in the nuclear compartment 
(MBEC_BN or HepG2_BN) or in the cytoplasm (MBEC_BC or HepG2_BC) after 4 h 
following MG132 removal. 
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endogenous proteasome activity, with the level of endogenous proteasome activity of HepG2 
higher than MBEC. This has been documented previously.88 Next, the authors used the 
ZsProSensor-1 to demonstrate compartmentalization of proteasome activity. MBEC and HepG2 
cells were treated with MG132 for 8 hours, after which the cells were observed at various time 
points in the absence of inhibitor. Before the addition of MG132, 92% of MBEC cells had 
uniform expression of the ZsProSensor-1 biosensor (N = C). After removal of MG132, 
ZsProSensor-1 biosensor fluorescence decreased in the nucleus (N < C; 15%, 24%, and 52% at 
4, 6, and 8 h, respectively). In the HepG2 cell line, before addition of MG132, fluorescence was 
evenly distributed throughout the cell (N = C) in 79% of the cells. However, after the addition of 
MG132, ZsProSensor-1 biosensor fluorescence decreased in the cytoplasm compared to the 
nucleus (N > C; 55% at 4 h and 67% at 6 h), although fluorescence was found mainly in the 
cytoplasm at later time frames (N < C; at 8 h, 49%; at 10 h, 28%) (Figure 1.16 (B)). These results 
are in agreement with other studies that demonstrate that during cell cycle progression 
proteasome activity is imported into the nucleus, with proteasome activity equilibrium occurring 
only after NEB.89 Next, the diffusion of proteasome activity was investigated using FRAP 
(Fluorescence Recovery After Photobleaching). MBEC and HepG2 cells were first transfected 
with GFP to establish a baseline of fluorescence recovery. Fluorescence recovery was observed 4 
to 5 minutes after photobleaching in both cell lines (Data not shown). Next, fluorescence 
recovery of MBEC and HepG2 cells transfected with the ZsProSensor-1 biosensor was 
investigated using FRAP. In the MBEC cell line fluorescence recovery was reduced, recovering 
only 50% over 10 minutes (Figure 1.16 (C)). In contrast, HepG2 cells recovered 80% of 
                                                          
88 Brush, J. M.; Kim, K.; Sayre, J. W.; McBride, W. H.; Iwamoto, K. S. International journal of radiation biology 
2009, 85, 483–94. 
89 (1) Wójcik, C.; DeMartino, G. N. The International Journal of Biochemistry & Cell Biology 2003, 35, 579–589. 
(2) Reits, E. a; Benham, a M.; Plougastel, B.; Neefjes, J.; Trowsdale, J. The EMBO journal 1997, 16, 6087–94. 
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Figure 1.17 Reprinted with permission from Urru, S. a M.; Veglianese, P.; De Luigi, A.; 
Fumagalli, E.; Erba, E.; Gonella Diaza, R.; Carrà, A.; Davoli, E.; Borsello, T.; Forloni, G.; 
Pengo, N.; Monzani, E.; Cascio, P.; Cenci, S.; Sitia, R.; Salmona, M. Journal of medicinal 
chemistry 2010, 53, 7452–60. Copyright 2011 American Chemical Society. (A) Schematic 
structure of sensor (TED) for the β5 subunit of the proteasome. The blue arrow represents the 
preferred cleavage site. The yellow arrows represent secondary cleavage sites. The red dashed 
arrows represent amino acids in the D conformation to prevent cleavage. A TAT protein 
sequence was incorporated on the C-terminus to facilitate cytoplasmic delivery. (B) EDANS 
fluorescence was monitored over 15 minutes to observe fluorescence enhancement upon 
proteolysis after incubation with 17 μM TED. 
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fluorescence in the cytosolic fraction and 102% in the nucleus. These results demonstrate greater 
proteasome activity of the HepG2 cell line, along with a greater concentration of proteasome 
activity near the nucleus.  
 Although the ZsProSensor-1 was used to elucidate proteasome activity at various 
locations in the MBEC and HepG2 cell lines, it is difficult to label the sensor as a real-time assay 
of proteasome activity. First, the sensor provides an inverse readout of proteasome activity. If 
proteasome activity is present, no measurable fluorescent signal is observed. This can create a 
problem for measuring differences in proteasome activity due to ever decreasing amounts of 
EGFP, and hence, a decreasing fluorescent signal which is more difficult to measure. Also, no 
dynamic rage data was provided, so it is difficult to calculate the limit of detection for the assay. 
A third issue is the long time frame of the assay, which makes it difficult to apply to a wide 
variety of cellular processes. Very few enzymatic processes occur on a 10 hour long time scale, 
with many processes taking place in a few minutes, making use of this sensor unfeasible. Finally, 
unlike chemical probes which can be controlled via DMNB caging, no such control exists with 
the ZsProSensor-1 biosensor (see Discussion on DMNB caging in CURRENT CAPABILITIES 
OF PROTEIN KINASE BIOSENSORS). 
Chemical probes are capable of overcoming the challenges associated with GFP-based 
proteasome biosensors. As an example of a chemical proteasome biosensor, a recent report 
describes the development of a chymotrypsin-like (proteasome β5 subunit) biosensor and its use 
intracellularly.90 The TAT-EDANS-DABCYL (TED) biosensor was constructed based on a 
known consensus sequence for the β5-subunit of the proteasome, NH2-LLVY-OH (Figure 1.17). 
                                                          
90 Urru, S. a M.; Veglianese, P.; De Luigi, A.; Fumagalli, E.; Erba, E.; Gonella Diaza, R.; Carrà, A.; Davoli, E.; 
Borsello, T.; Forloni, G.; Pengo, N.; Monzani, E.; Cascio, P.; Cenci, S.; Sitia, R.; Salmona, M. Journal of medicinal 
chemistry 2010, 53, 7452–60. 
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A fluorophore/quencher FRET pair was included on either side of the cleavage site, using 
EDANS as the fluorophore and DABCYL as a non-fluorescent quencher. Since the consensus 
sequence for the β5 subunit is negatively charged and unlikely to reach the cytoplasm, a TAT 
sequence helps facilitate entry into the cytoplasm. N-terminal D-Lysine residues were also added 
to prevent proteolysis of the substrate by other proteases. The sensor (17 μM) was incubated with 
U266 cells to yield a fluorescent increase upon proteolysis. Unfortunately, no dynamic range was 
reported or intracellular experiments to quantitate intracellular chymotrypsin-like proteasome 
activity in U226 cells. Also, although this FRET pair did succeed in their manuscript, a FRET 
pair further in the red would be advantageous in future development. 
 A second report describes 
a chemical biosensor for the 
chymotrypsin-like activity of the 
proteasome.91 This sensor 1.3 
improves on the TED sensor in 
two main ways: (1) the 
photophysical properties of the 
fluorophore and (2) the addition of 
a DMNB caging group for control 
observer control of the assay 
(Scheme 1.1). The authors 
attached a long wavelength 
                                                          
91 Wakata, A.; Lee, H.-M.; Rommel, P.; Toutchkine, A.; Schmidt, M.; Lawrence, D. S. Journal of the American 
Chemical Society 2010, 132, 1578–82. 
 
 
Scheme 1.1 Reprinted with permission from Wakata, A.; 
Lee, H.-M.; Rommel, P.; Toutchkine, A.; Schmidt, M.; 
Lawrence, D. S. Journal of the American Chemical 
Society 2010, 132, 1578–82. Copyright 2010 American 
Chemical Society. Structure of Chymotrypsin-like 
reporter of proteasome activity.  
1.3 
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fluorophore (excitation 633 nm, emission 678 nm) with a high extinction coefficient (119,000  
M-1 cm-1).92 These properties are much better than the EDANS fluorophore used for the TED 
sensor (excitation 335 nm, emission 493 nm, extinction coefficient 5,900 M-1 cm-1). 
Additionally, a DMNB caging group was included to provide observer control of the assay. 
Along with the caged derivative in Scheme 1.1, the authors synthesized four noncaged analogs 
                                                          
92 Toutchkine, A. PCT. Int. Appl., PCT/US2009/46238. 
A 
C 
Figure 1.18 Reprinted with permission from Wakata, A.; Lee, H.-M.; Rommel, P.; 
Toutchkine, A.; Schmidt, M.; Lawrence, D. S. Journal of the American Chemical Society 
2010, 132, 1578–82. Copyright 2010 American Chemical Society. (A) Table containing 
proteasome biosensor analogs, along with enzymatic data. (B) Peptide 1.3 (5.65 μM) treated 
with wild-type cell lysate (black), and preirradiated for 2 min (red) or 10 min (blue). 
B 
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and fully characterized the enzymological properties of the substrates as well as their dynamic 
ranges, which are all over 20-fold (Figure 1.18(A)). Control of the biosensor using DMNB 
uncaging was also demonstrated using cell lysates. Peptide 1.3 (5.65 μM) was treated with wild-
type yeast cell lysate containing active proteasome after irradiation for 0 min (black), 2 min (red) 
and 4 min (blue). As expected, differing amounts of substrate 1.3 were uncaged, resulting in a 
fluorescent enhancement. Although this biosensor has been applied to cell lysates, its use has yet 
to be demonstrated intracellularly.  
 
CONCLUSIONS 
 
Quantitation of enzyme activity is essential for understating signal transduction 
pathways. Many current techniques, such as western blotting or intracellular antibody labeling, 
quantitate enzyme expression levels while providing no assessment of enzyme activity. Current 
enzyme activity assays can be divided into two groups, each with unique advantages and 
disadvantages including: (1) GFP-based FRET sensors relying on polypeptide domains binding 
to a substrate as a mechanism of action and (2) chemical probes relying on bond cleavage, metal 
chelation, electrostatic interactions or environmentally-sensitive fluorophores as a mechanism of 
action. GFP-based FRET sensors are relatively easily transfected into a wide variety of cells, 
making them extremely useful to molecular biologists. However, GFP-based FRET sensors do 
have disadvantages including: (1) a lack of a large dynamic range for activity measurement and 
(2) the reliance on a large spectral window during confocal microscopy, limiting the number of 
possible readouts. Chemical probes provide the unique advantages of observer control (through 
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highly selective photodeprotection), large dynamic ranges (typically 10x (or more) larger than 
GFP-based FRET sensors), and a wide range of photophysical properties. Disadvantages 
associated with chemical probes include: (1) problems with cytoplasmic delivery of the probe 
and (2) difficulties with probe synthesis. 
This thesis focuses on three main projects in development of chemical probes for PKA 
and proteasome activity. Chapter two describes the development of an assay for PKA including a 
large dynamic range. The assay relies on electrostatic interactions between a fluorophore labeled 
peptide and dark fluoresce quencher to realize large (up to 150-fold) enhancements in 
fluorescence. The assay is the applied to measure the subcellular distribution of PKA in 
mitochondria. Chapter three focuses on the development of a non-fluorescent dark quencher 
found to quench fluorophores with a broad range of photophysical properties, including many 
suitable for fluorescent microscopy. A previously identified quencher, Acid Blue 40, was 
chemically modified to include a carboxylic acid handle. The utility of carboxy Acid Blue 40 
(cAB40) was demonstrated through construction of reporters of trypsinolysis and photolysis. 
Chapter four focuses on the synthesis and development of a unimolecular nanoparticle-based 
assay for PKA. The cAB40 quencher and a fluorescently labeled PKA substrate were attached to 
the surface of a silica nanoparticle (90 nm diameter). Upon phosphorylation a 2.2-fold 
fluorescent enhancement was observed. Chapter five focuses on the development of proteasome 
biosensors of the Caspase-like (Ca-L) and Chymotrypsin-like (Ch-L) catalytic activities of the 
proteasome. The fluorophore 5’-tetramethylrhodamine and cAB40 quencher were covalently 
attached to opposing ends of Ca-L and Ch-L consensus sequences. Selectivity of each substrate 
for each catalytic subunit was demonstrated. Overall, this body of work demonstrates substantial 
additions to the development of chemical probes for kinase and proteasome activity.  
CHAPTER 2 
SUBORGANELLE SENSING OF MITOCHONDRIAL cAMP-DEPENDENT 
PROTEIN KINASE ACTIVITY 
(Reproduced with permission from Agnes, R. S.; Jernigan, F.; Shell, J. R.; Sharma, V.; 
Lawrence, D. S. Journal of the American Chemical Society 2010, 132, 6075–80. 
 
INTRODUCTION 
 
Protein kinases are a large enzyme family that has been implicated in nearly every cell-
based behavior, from ATP generation to unrestrained growth and division.1 These enzymes are 
linked by their ability to catalyze phosphoryl transfer from ATP to the hydroxyl moieties of 
serine, threonine, and/or tyrosine residues in proteins. A variety of factors limit protein kinase-
catalyzed phosphorylation to intended protein targets: (a) the ability to phosphorylate 
serine/threonine or tyrosine, but only rarely both aliphatic and aromatic residues, (b) differential 
expression as a function of cell type, (c) recognition of specific amino acid sequences 
encompassing the hydroxyl phosphoryl acceptor moiety, and (d) localization to specific 
intracellular sites. The cAMP-dependent protein kinase (PKA) exhibits many of these attributes 
as a serine/threonine-specific protein kinase with a special preference for sequences of the 
general form Arg- Arg-Xaa-Ser/Thr-Xaa in protein substrates.2 In addition, PKA is anchored to a 
variety of intracellular sites via coordination to A-kinase anchoring proteins (AKAPs), and thus 
                                                 
1 Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. Science 2002, 298, 1912–1934. 
 
2 Shabb, J. B. Chem. Rev. 2001, 101, 2381–2411. 
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the biological consequences of its action are location-dependent.3 For example, mitochondrial 
PKA is implicated in the regulation of apoptosis and ATP synthesis.4 However, as is true for 
protein kinases in general, presumed intracellular PKA activity is commonly assessed in an 
indirect fashion: either by the mere presence of the enzyme (immunofluorescence or Western 
blots) or by the effect of small molecule modulators, such as inhibitors, on the phosphorylation 
of presumed PKA protein substrates. Unfortunately, these commonly employed methods do not 
furnish a direct measure of kinase activity. Fluorescent sensors have been used to directly and 
continuously assess kinase action.5 However, these either display a limited dynamic range or 
employ fluorophores with photophysical properties (short λex/λem,6 small ε,7 low Φ) that are 
incompatible (due to interference from autofluorescence) with cells, cell lysates, or organelles. 
With the latter limitation in mind, we report herein the application of a quenched fluorescence 
strategy6 to create a kinase sensor of unprecedented dynamic range. Sensors with a large 
dynamic range can be used in relatively small quantities, thereby diminishing the likelihood of 
interference with ongoing biochemical processes (i.e., Observer Effect).8 The favorable 
properties associated with the sensor have allowed us to assess the relative abundance of PKA in 
the major mitochondrial microenvironments (outer membrane, intermembrane space, and 
matrix).9  
                                                 
3 Smith, F. D.; Langeberg, L. K.; Scott, J. D. Trends Biochem. Sci. 2006, 31, 316–323. 
 
4 Feliciello, A.; Gottesman, M. E.; Avvedimento, E. V. Cell Signal. 2005, 17, 279–87. 
 
5 Lawrence, D. S.; Wang, Q. ChemBioChem 2007, 8, 373–278. 
 
6 Sharma, V.; Agnes, R. S.; Lawrence, D. S. J. Am. Chem. Soc. 2007, 129, 2742–2743. 
 
7 Shults, M. D.; Imperiali, B. J. Am. Chem. Soc. 2003, 125, 14248–14249. 
 
8 Sharma, V.; Lawrence, D. S. Angew. Chem., Int. Ed. 2009, 48, 7290–7292. 
 
9 (1) Ma, Y.; Taylor, S. S. J. Biol. Chem. 2008, 283, 11743–11751. (2) Sardanelli, A. M.; Signorile, A.; Nuzzi, R.; 
Rasmo, D. D.; Technikova-Dobrova, Z.; Drahota, Z.; Occhiello, A.; Pica, A.; Papa, S. FEBS Lett. 2006, 580, 5690–
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sensor (λex/λem) fluorescent fold-increase Km (μM) Vmax (μmol/min·mg) 
2.1 (420/475 nm) 152 2.2 ± 0.1 0.53 ± 0.03 
2.2 (437/477 nm) 150 1.9 ± 0.1 0.34 ± 0.04 
2.3 (450/490 nm) 28 6.2 ± 0.1 0.20 ± 0.09 
 
 
 
Table 2.1 Photophysical properties, fluorescent-fold increase, Km, and Vmax for the 
PKA-catalyzed phosphorylation of sensors 2.1-2.3 (where Sensor = Fluorophore-Aoc-
GRTGRRFSYP-amide). Kinetic properties were acquired in the presence of quencher 
2.4 and the 14-3-3τ domain. See “Acquisition of apparent Km and Vmax values”. 
 
RESULTS AND DISCUSSION 
 
The fluorophores described in this report are coumarin derivatives, which possess 
photophysical properties (Table 2.1) that are readily amenable to biological applications. Three 
coumarin-derivatized peptides (2.1-2.3, Scheme 2.1) of the general form coumarin-Aoc-
GRTGRRFSYP-amide were prepared (where Aoc = aminooctanoic acid). These positively 
charged peptides were exposed to 47 different negatively charged dyes (End of Chapter, Table 
2.2) with the expectation that complex formation would result in the quenching of coumarin 
fluorescence. In addition, we anticipated that PKA-catalyzed phosphorylation of coumarin-Aoc-
GRTGRRFSYP-amide would promote association of the phosphorylated peptide with the 14-3-
3τ domain,10 thereby releasing the quenching dye and restoring fluorescence (Figure 2.1). The 
                                                                                                                                                             
5696. (3) Chen, Q.; Lin, R. Y.; Rubin, C. S. J. Biol. Chem. 1997, 272, 15247–15257.(d) Schwoch, G.; Trinczek, B.; 
Bode, C. Biochem. J. 1990, 270, 181–188. (4) Ryu, H.; Lee, J.; Impey, S.; Ratan, R. R.; Ferrante, R. J. Proc. Natl. 
Acad. Sci. U.S.A. 2005, 102, 13915–13920. 
10 Yaffe, M. B.; Rittinger, K.; Volinia, S.; Caron, P. R.; Aitken, A.; Leffers, H.; Gamblin, S. J.; Smerdon, S. J.; 
Cantley, L. C. Cell 1997, 91, 961–971. 
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lead quencher dye for all three peptides proved to be Acid Green 27 (2.4) and the observed PKA-
catalyzed changes in fluorescence in the presence of 2.4 are: peptide 2.1 (152-fold), peptide 2.2 
(150-fold), and peptide 2.3 (28-fold) (Table 2.1). Given its large dynamic range and relatively 
high V max (Table 2.1), we decided to employ peptide 2.1 in all subsequent studies. We 
confirmed that phosphoryl transfer from ATP to the serine hydroxyl moiety of the peptide sensor 
is required for the observed fluorescent enhancement by examining analogues of the peptide 
substrate 2.1 and ATP. First, substitution of peptide 2.1 with its nonphosphorylatable Ala-for-Ser 
counterpart 2.5 fails to elicit a change in fluorescence (Figure 2.2D). Second, substitution of ATP 
with the corresponding thio-derivative, ATP(γ)S, dramatically reduces the rate of fluorescence 
Scheme 2.1 Structures of the coumarin derivatives 1-3 of the general form fluorophore-Aoc-
GRTGRRFSYP-amide. The fluorescent quencher Acid Green 27 (4) was identified from a 
library of 47 dyes (Table 2.9). 
2.1 
2.2 
2.3 
2.4 
 
47 
 
change (End of Chapter, Figure 2.3). ATP(γ)S is known to serve as a weak thiophosphoryl donor 
in protein kinase-catalyzed reactions.11 Both 14-3-3τ and the fluorescent quencher, Acid Green 
27 (2.4), are required for the large phosphorylation-induced fluorescence yield. In the absence of 
14-3-3τ (but with quencher 2.4 present), no change in fluorescence is observed (End of Chapter, 
Figure 2.4). Furthermore, there exists a direct correlation between the relative amount of 14-3-3τ 
present and the observed phosphorylation-dependent fluorescent enhancement (End of Chapter, 
Figure 2.4). Surprisingly, in the absence of quencher 2.4 (but with 14-3-3τ present), there is a 
50% decrease in observed fluorescence (End of Chapter, Figure 2.5). One possible explanation 
for the unexpected fluorescence decrease is the likely orientation of the 14-3-3τ- bound 
phosphopeptide 2.1 based on a previously described crystal 
                                                 
11 (1) Zou, K.; Cheley, S.; Givens, R. S.; Bayley, H. J. Am. Chem. Soc. 2002, 124, 8220–8229. (2) Anderson, M. P.; 
Berger, H. A.; Rich, D. P.; Gregory, R. J.; Smith, A. E.; Welsh, M. J. Cell 1991, 67, 775–784. 
 
Figure 2.1 Protein Kinase-Catalyzed Phosphorylation of a Fluorescently Quenched Peptide 
Generates a Fluorescent Response in the Presence of the Phospho-Ser 14-3-3τ Binding 
Domain. 
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structure.12 The N-terminus of the peptide, when complexed with the 14-3-3τ domain, is 
positioned adjacent to two tryptophan residues (Figure 2.6). We,13 as well as others,14 have 
shown that tryptophan can serve as a fluorescent quencher. 14-3-3τ domain-mediated quenching 
of coumarin-phosphopeptide fluorescence is intriguing since it suggests that removal of the 
tryptophan residues in the 14-3-3τ domain could furnish fluorescence fold changes even larger 
than those observed in this study. We examined the underlying assumption that the negatively 
charged quencher 2.4 engages the positively charged peptide substrate via electrostatic 
interactions. A small library of Arg to Ala substituted peptide analogues were prepared and KD 
                                                 
12 Rittinger, K.; Budman, J.; Xu, J.; Volinia, S.; Cantley, L. C.; Smerdon, S. J.; Gamblin, S. J.; Yaffe, M. B. Mol. 
Cell 1999, 4, 153 166. 
 
13 Lee, H. M.; Priestman, M. A.; Lawrence, D. S. J. Am. Chem. Soc. 2010, 132, 1446–1447. 
 
14 Doose, S.; Neuweiler, H.; Sauer, M. ChemPhysChem 2005, 6, 2277–2285. 
Figure 2.2 Fluorescence change as a function of incubation time of the PKA-catalyzed 
phosphorylation of sensors (A) 2.1, (B) 2.2, (C) 2.3, and (D) a nonphosphorylatable Ala-
for-Ser control peptide 2.5 (coumarin-Aoc GRTGRRFAYP-amide). Experiments were 
conducted in the presence of fluorescent quencher (4) and 14-3-3τ domain.  
A B 
C D 
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values were acquired for each of these with Acid Green 27, using fluorescence quenching as an 
indicator of complex formation. As is clear from Table 2.2, the quenching phenomenon is Arg 
residue-dependent, with the apparent KD displaying an approximate two orders of magnitude loss 
for every Arg replaced by an Ala. The effect is independent of the site of the Ala-for-Arg 
substitution (cf. 2.6 vs 2.7 vs 2.8), implying a diffuse electrostatic interaction between the 
negatively charged dye and the peptide substrate. Job plot analysis revealed the formation of a 
1:1 complex between 2.1 and 2.4 (Figure 2.7). The large fluorescent dynamic range of the PKA-
catalyzed phosphorylation of peptide 2.1 furnishes a sensitive measure of kinase activity. The 
catalytic activity of PKA at a concentration as low as 160 pM can be detected as demonstrated 
by the plot of initial rate versus PKA concentration (Figure 2.8). Figure 2.8 provides a standard 
curve for assessing “PKA activity equivalents” in biological systems. Although the indispensable 
nature of the PKA signaling pathway in mitochondrial physiology is beyond dispute,4 its
 
Peptide Peptide Sequence KD (μM) 
2.1 Cou-Aoc-GRTGRRFSYP-amide 0.04 ± 0.07 
2.6 Cou-Aoc-GATGRRFSYP-amide 1.6 ± 0.3 
2.7 Cou-Aoc-GRTGARFSYP-amide 2.7 ± 0.6 
2.8 Cou-Aoc-GRTGRAFSYP-amide 1.8 ± 0.2 
2.9 Cou-Aoc-GATGRAFSYP-amide 130 ± 80 
2.10 Cou-Aoc-GATGARFSYP-amide 130 ± 65 
2.11 Cou-Aoc-GRTGAAFSYP-amide 130 ± 70 
2.12 Cou-Aoc-GATGAAFSYP-amide >200 
 
Table 2.2 KD Values of Sensor 2.1 and Various Ala-for-Arg Analogues (2.6-2.12) of Sensor 
2.1, with the Fluorescent Quencher 2.4. See “Acquisition of Apparent KD Values for 2.4 
with Peptides 2.1 and 2.6-2.12” in the Material and Methods section for experimental 
details. 
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suborganelle location within the mitochondria (i.e., matrix, intermembrane space, and/or on the 
outer membrane oriented toward the cytoplasm; Figure 2.9) is enigmatic. Orr and colleagues 
demonstrated (via electron microscopy) that type-II PKA is primarily associated with the outer 
membrane of mitochondria in male germ cells.15 Indeed, a major mitochondrial A-kinase 
anchoring protein (AKAP121 in mice and AKAP149 in humans), and its splice variants, position 
PKA on the cytoplasmic face of the outer membrane.9(c) Proteolysis of this AKAP16 appears to 
promote apoptosis by releasing PKA from the outer membrane, which is known to promote 
antiapoptotic behavior.17 By contrast, Schwoch et al showed (via electron microscopy) that both 
                                                 
15 Lieberman, S. J.; Wasco, W.; MacLeod, J.; Satir, P.; Orr, G. A. J. Cell Biol. 1988, 107, 1809–1816. 
 
16 (1) Yoo, H.; Cha, H. J.; Lee, J.; Yu, E. O.; Bae, S.; Jung, J. H.; Sohn, I.; Lee, S. J.; Yang, K. H.; Woo, S. H.; Seo, 
S. K.; Park, I. C.; Kim, C. S.; Jin, Y. W.; Ahn, S. K. Oncol. Rep. 2008, 19, 1577–1582. (2) Carlucci, A.; Adornetto, 
A.; Scorziello, A.; Viggiano, D.; Foca, M.; Cuomo, O.; Annunziato, L.; Gottesman, M.; Feliciello, A. EMBO J. 
2008, 27, 1073–1084. 
 
17 (1) Affaitati, A.; Cardone, L.; de Cristofaro, T.; Carlucci, A.; Ginsberg, M. D.; Varrone, S.; Gottesman, M. E.; 
Avvedimento, E. V.; Feliciello, A. J. Biol. Chem. 2003, 278, 4286–4294. (2) Harada, H.; Becknell, B.; Wilm, M.; 
Mann, M.; Huang, L. J.; Taylor, S. S.; Scott, J. D.; Korsmeyer, S. J. Mol. Cell 1999, 3, 413–422. 
 
             Mole Fraction of Peptide 2.1 
 
Figure 2.7 Fluorescence change as a function of mole fraction of sensor 2.1. See “Job Plot 
for Determination of Stoichiometry” in the Material and Methods section for experimental 
details. 
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types-I and -II PKA are primarily associated with the mitochondrial matrix/inner membrane in 
mitochondria isolated from a wide variety of organs.9(d) Matrix localization of PKA has also been 
observed in neuronal mitochondria.9e Papa and his colleagues found that PKA is associated with 
the inner membrane of bovine heart mitochondria.18 Furthermore, these investigators reported a 
detailed electron microscopic analysis of rat heart mitochondria and concluded that more than 
90% of all mitochondrial-bound PKA is present in the inner mitochondrial compartment.9(b) 
However, an additional complication, not described by these studies, is the enzymatic reach of 
PKA. In particular, the majority of mitochondrial proteins are nuclear encoded and thus must be 
imported from the cytoplasm. Consequently, although a variety of mitochondrial proteins are 
phosphorylated in a cAMP-dependent fashion, they may suffer PKA-catalyzed phosphorylation 
during import (e.g., at the outer membrane) and thus prior to being embedded within their final 
destination (e.g., in the matrix).18 In short, the mitochondrial location of known PKA substrates 
                                                 
18 Papa, S.; Sardanelli, A. M.; Scacco, S.; Technikova-Dobrova, Z. FEBS Lett. 1999, 444, 245–249. 
 
Figure 2.8 Reaction rate (nM of phosphopeptide formation/min) as a function of PKA 
concentration (pM). 
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is not necessarily a valid indicator of microenvironmental PKA activity. Finally, the active form 
of PKA (C subunit), which is released from the inactive holoenzyme (R2C2) upon exposure to 
cAMP, can diffuse through membranes.19 Therefore, the suborganelle location of the 
holoenzyme (as determined by electron microscopy) does not necessarily recapitulate the 
location of the active form of the enzyme. With these factors in mind, we turned our attention to 
the suborganelle analysis of cAMP-activated PKA in isolated bovine heart mitochondria. 
Perhaps the most obvious approach for assessing PKA activity as a function of mitochondrial 
microenvironment is purification of the enzyme from the outer membrane, the intermembrane 
space, and the matrix. However, such a strategy is not practical for both structural and 
technological reasons. The holoenzyme resides as an AKAP-bound membrane-associated species 
on the outer membrane and likely, in an analogous AKAP-dependent fashion, at the inner 
membrane. Unfortunately, even if it were feasible to isolate and purify the outer and inner 
membrane components, it would not be clear which direction the enzyme is facing in the intact 
mitochondrion (i.e., an outer membrane bound species could be oriented outward toward the 
                                                 
19 Harootunian, A. T.; Adams, S. R.; Wen, W.; Meinkoth, J. L.; Taylor, S. S.; Tsien, R. Y. Mol. Biol. Cell 1993, 4, 
993–1002. 
 
 
Figure 2.9 Strategy for assessing PKA activity on the outer membrane (blue), in the 
intermembrane space (red), and in the matrix (yellow). PKA activity of intact mitochondria 
(A) is due to enzyme present on the outer membrane and in the intermembrane space. 
Trypsinized (i) mitochondria (B) lack outer membrane proteins and thus only intermembrane 
space PKA is present. Sonicated (ii) mitochondria (C) furnishes enzyme from all three 
compartments and thus represents total mitochondrial PKA. 
C 
A B 
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cytoplasm or inward toward the intermembrane space). An alternative approach might involve 
the cAMP-induced release of the C subunit and its subsequent isolation from the extra-
mitochondrial, intermembrane space, and matrix regions. However, as demonstrated with bovine 
heart mitochondria, the standard technique used to expose the contents of the intermembrane 
space (digitonin treatment) results in some disruption of the matrix as well, leading to 
contamination of the intermembrane space contents with components from the matrix.20 
Therefore, we resorted to the strategy depicted in Figure 2.8. We reasoned that exposure of intact 
mitochondria to cAMP should activate PKA located on the outer membrane as well as any PKA 
present in the intermembrane space (i.e., inner leaflet of the outer membrane and/or outer leaflet 
of the inner membrane). The mitochondrial outer membrane contains a channel-forming protein-
based complex (porin; also known as the voltage-dependent anion channel) that allows small 
molecules (<5000 molecular weight) to passively diffuse between the extra-mitochondrial 
environment and the intermembrane space.21 We expected that, in addition to cAMP, our PKA 
sensor 2.1 and quencher 2.4 should be able to freely migrate into and out of the intermembrane 
space and thus report any PKA activity (by contrast, the inner membrane blocks access to the 
matrix of externally added cAMP22). This approach avoids the use of digitonin and thus should 
prevent contamination by the unintended release of matrix contents. In short, cAMP-treated 
mitochondria should furnish outer membrane and inter membrane space PKA activity. 
Furthermore, since trypsin digests only outward-facing outer membrane mitochondrial 
proteins,9(a) we expected that cAMP-exposed trypsin-treated mitochondria should provide only 
                                                 
20 Burnette, B.; Batra, P. P. Anal. Biochem. 1985, 145, 80–86. 
 
21 Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. Molecular Biology of the Cell, Reference ed.; 
Garland Science: New York, 2007; pp 818. 
 
22 Acin-Perez, R.; Salazar, E.; Kamenetsky, M.; Buck, J.; Levin, L. R.; Manfredi, G. Cell Metab. 2009, 9, 265–276. 
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intermembrane space PKA activity (Figure 2.9). Finally, mitochondrial structural integrity is 
completely disrupted by sonication, and thus mitochondria treated in this fashion should yield, 
upon cAMP exposure, total mitochondrial PKA activity. These three activities can then be used 
to assign relative PKA activity to the three separate mitochondrial microenvironments. The 
purity of mitochondria isolated from bovine heart was assessed via Western blot analysis using 
antibodies against proteins that are localized to mitochondrial (cytochrome C) and 
nonmitochondrial sites, including the endoplasmic reticulum (calnexin), the plasma membrane 
(Na+/K+ ATPase), and the cytosol (GAPDH) (Figure 2.10A). The results demonstrate that the 
mitochondrial preparation is not contaminated with proteins from other membranes or the ER 
and displays only minimal contamination from the cytoplasm. Mitochondrial structural integrity 
 
 
 
 
Figure 2.10 Assessment of mitochondrial purity and extent of trypsinolysis by Western blot 
analysis. (A) The mitochondrial preparation was examined for the presence of ER (calnexin), 
plasma membrane (Na+/K+-ATPase), and cytoplasmic (glyceraldehyde phosphate 
dehydrogenase) proteins. A minimal amount of cytoplasmic contamination is observed. (B) 
Trypsin digestion of intact mitochondria. Untreated mitochondria (lane 1) and mitochondria 
treated with trypsin for 1 h at 37 °C (lane 2) were analyzed by Western blot for Hsp 60 and 
Tom 20, matrix and outer membrane markers, respectively, and the PKA catalytic subunit. 
Complete loss of Tom 20 upon trypsin exposure implies extensive trypsinolysis of the outer 
membrane surface. Complete retention of Hsp 60 implies that the mitochondrial matrix is 
preserved upon exposure to trypsin. 
A B 
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(intactness) was assessed as previously described23 and found to be greater than 90% (data not 
shown). Intact mitochondria, upon exposure to cAMP, exhibit an initial rate of PKA activity 
equivalent to 29 (4 pg PKA/μg mitochondria. By contrast, in the absence of cAMP, 
phosphorylation activity is minimal (Figure 2.11); demonstrating that sensor 2.1 is 
phosphorylated in a cAMP dependent fashion. Indeed, previous studies have shown that active-
site directed sequences, similar to the sequence employed in sensor 2.1, are highly selective for 
PKA.24 Finally, we have found that H-89, a PKA inhibitor, blocks the phosphorylation of sensor 
2.1 by mitochondrial preparations (Figure 2.12). These results are consistent with the notion that 
peptide 2.1 serves as a selective PKA sensor. As noted above (Figure 2.9), we expected that the 
PKA activity associated with intact mitochondria would be a combination of enzyme present on 
the outer membrane and enzyme oriented into the intermembrane space. We addressed this 
possibility by treating mitochondria with trypsin, which should selectively hydrolyze the outer 
membrane proteins exposed to the external milieu (Figure 2.10B), but not hydrolyze matrix- or 
intermembrane space-embedded proteins. Indeed, an outer membrane marker (TOM 20) is 
completely digested in trypsin-treated mitochondria, whereas a matrix marker (Hsp 60) is 
unperturbed. Previous studies with trypsin-exposed mitochondria demonstrated that an 
intermembrane space marker is protected against proteolysis as well.9(a) Subsequent analysis of 
PKA activity (cAMP exposure) in trypsin-treated mitochondria revealed a drop in PKA activity 
from 24 (4 pg PKA/μg mitochondria to 10 ( 1 pg PKA/μg mitochondria, implying a 1:1.4 ratio of 
intermembrane space: outer membrane (external) PKA. Finally, mitochondria were sonicated to 
                                                 
23 (1) Wharton, D. C.; Tzagoloff, A. Methods Enzymol. 1967, 10, 245–250. (2) Rice, J. E.; Lindsay, J. G. In 
Subcellular Fractionation; Graham, J. M., Rickwood, D., Eds.; IRL Press: Oxford, England, 1997; pp 107-142. 
 
24 (1) Su, J.; Bringer, M. R.; Ismagilov, R. F.; Mrksich, M. J. Am. Chem. Soc. 2005, 127, 7280–7281. (2) Min, D. H.; 
Su, J.; Mrksich, M. Angew. Chem., Int. Ed. 2004, 43, 5973–5977.  (3) He, Y.; Yeung, E. S. Electrophoresis 2003, 
24, 101–108. 
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completely disrupt their structural integrity, thereby exposing all mitochondria-associated PKA, 
including any matrix-embedded enzyme. Total mitochondrial PKA activity (cAMP treatment) is 
equivalent to 165 ± 24 pg PKA/μg mitochondria, approximately 5.7 times greater than that 
observed with intact mitochondria. These values suggest that the relative distribution of PKA 
activity in the matrix (165 ± 24 pg PKA/ μg mitochondria - 24 ± 4 pg PKA/μg mitochondria = 
141 pg PKA/μg mitochondria), the intermembrane space (10 ± 1 pg PKA/μg mitochondria), and 
the outer membrane (24 ± 4 pg PKA/μg mitochondria - 10 ± 1 pg PKA/μg  mitochondria = 14 pg 
PKA/μg mitochondria) in bovine heart mitochondria is 85 : 6 : 9, respectively. The latter 
compares favorably with the electron microscopy work of Papa and colleagues,18 who reported 
that 90% of the PKA present in mitochondria is found the matrix and the intermembrane space. 
However, our analysis could be complicated by endogenous protein phosphatases if they are 
present in different amounts in the three distinct mitochondrial compartments. Consequently, an 
analogous series of experiments were conducted in the presence of a phosphatase inhibitor 
cocktail. The experimentally determined ratio (79 : 8 : 13) of matrix/intermembrane space/outer 
membrane PKA activity corresponds to that acquired in the absence of phosphatase inhibitors. In 
summary, we have developed a protein kinase sensing system with a robust dynamic range and 
used it to characterize the compartmentalized location of PKA activity in mitochondria. Given 
the important role of PKA in mediating the dynamics of mitochondrial biochemistry, the ability 
to monitor protein kinase activity should prove useful in assessing the mitochondrial response 
from both healthy individuals and from patients with mitochondrial-based disorders.25 
 
MATERIALS AND METHODS 
                                                 
25 Carlucci, A.; Lignitto, L.; Feliciello, A. Trends Cell. Biol. 2008, 18, 604–613. 
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General reagents and solvents were purchased from Fisher or Sigma-Aldrich. Novasyn TGR 
Resin and all natural Fmoc-protected amino acids were purchased from EMD Biosciences Inc. 
HCTU [1H-benzotriazolium-1-[bis(dimethylamino)methylene]-5-chloro-hexafluorophosphate 
(1),3-oxide] was purchased from Peptides International (Louisville, KY, U.S.A.). Fluorescent 
dyes (7-(diethylamino)coumarin-3-carboxylic acid, Coumarin 343 [11-oxo-2,3,6,7-tetrahydro-
1H,5H,11H-pyrano[2,3-f]pyrido[3,2,1-ij]quinoline-10-carboxylic acid], and Atto 425-NHS ester 
were purchased from Sigma-Aldrich. Fmoc-aminooctanoic acid (Fmoc-Aoc-OH) was purchased 
from Advanced ChemTech (Louisville, KY, U.S.A.). Bovine heart mitochondria was purchased 
from MitoSciences, and trypsin (sequencing grade) and PKA were purchased from Promega. The 
antibodies against the PKA catalytic subunit, Tom 20, and Hsp60 were purchased from BD 
Biosciences, and the goat antimouse secondary antibody was purchased from Santa Cruz 
Biotechnology. Total mitochondrial protein was quantified using the BCA protein assay (Pierce). 
Immunoblots were performed using Snap i.d. (Millipore), and visualized using an AlphaInnotech 
FluorChem FC2 imager. The intactness of the isolated mitochondria was assessed via a 
previously described protocol.30,31 PKA murine catalytic subunit (cat.) plasmid and the GST-14-
3-3τ plasmid were generous gifts from Dr. Susan Taylor and Dr. Alistair Aitken, respectively. 
 
Synthesis of Fluorophore-Labeled PKA Substrates. Peptides were synthesized using standard 
Fmoc solid-phase synthesis on a Prelude peptide synthesizer (Protein Technologies Inc., Tucson, 
AZ, U.S.A.). Novasyn TGR resin was swelled for 30 min in dichloromethane (DCM) before 
synthesis. Amino acids were then sequentially coupled using 5.0 equiv of amino acid, 4.9 equiv 
of HCTU, 20 equiv of diisopropylethylamine (DIPEA) in N,Ndimethylformamide (DMF) (2 × 5 
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min) followed by DMF wash (6 × 30 s). The Fmoc-protecting group was removed using 20% 
piperidine in DMF (2 × 2.5 min) followed by a DMF wash (6 × 30 s). The free N-terminal amine 
was used for subsequent on-resin fluorophore labeling. Fluorescent dyes diethylcoumarin and 
Coumarin 343 were coupled to the N-terminal amine using 5.0 equiv of fluorophore, 4.9 equiv of 
HCTU, 20 equiv of DIPEA in DMF (1× 60 min). Atto425-NHS ester was coupled using 1.0 
equiv of dye and 20 equiv of DIPEA in DMF (1 × 60 min). The resin was washed (3× DMF, 
IPA, DCM) and then cleaved and deprotected using a 95:2.5:2.5 trifluoroacetic acid 
(TFA)/H2O/triisopropylsilane (TIPS). The peptides were isolated via filtration, precipitated with 
ice-cold ether, and centrifuged to isolate the precipitate. The precipitates were air-dried, 
dissolved in DMSO, and purified using HPLC (3% to 40% acetonitrile gradient against water 
with 0.1% TFA over 40 min). The peak corresponding to the peptide was collected, freeze-dried, 
and characterized by electrospray ionization mass spectrometry: 2.1 Cou-Aoc-GRTGRRFSYP-
amide [Exact Mass calculated: 1579.84, found: 1580.84 (M + H)+], 2.2 Atto425-Aoc- 
GRTGRRFSYP-amide [Exact Mass calculated: 1719.98, found: 1720.97 (M + H)+], 2.3 
Cou343-Aoc-GRTGRRFSYP-amide [Exact Mass calculated: 1603.82, found: 1604.85 (M + 
H)+], 2.5 Cou-Aoc-GRTGRRFAYP-amide [Exact Mass calculated: 1562.8, found: 782.6 (M + 
2H)2+, 522.2 (M + 3H)3+], 2.6 Cou-Aoc-GATGRRFSYP- amide [Exact Mass calculated: 
1494.69, found: 1495.80 (M + H)+], 2.7 Cou-Aoc-GRTGARFSYP-amide [Exact Mass 
calculated: 1494.69, found: 1495.77 (M + H)+], 2.8 Cou-Aoc-GRTGRAFSYP-amide [Exact 
Mass calculated: 1495.69, found: 1495.78 (M + H)+], 2.9 Cou-Aoc-GATGRAFSYP-amide 
[Exact Mass calculated: 1409.58, found: 1409.72 (M + H)+], 2.10 Cou-Aoc-GATGARFSYP-
amide [Exact Mass calculated: 1409.58, found: 1409.73 (M + H)+], 2.11 Cou-Aoc-
GRTGAAFSYP-amide [Exact Mass calculated: 1409.58, found: 1409.72 (M + H)+], and 12 Cou-
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Aoc-GATGAAFSYP-amide [Exact Mass calculated: 1323.6, found: 1324.5 (M + H)+].  
 
Identification of Lead Quencher Dye 2.4 The concentration of peptide 1 was adjusted using a 
molar excitation coefficient of 60,000 M-1 cm-1 at 430 nm. GST-tagged 14-3-3τ (purified to a 
single band at 56 KDa on 12.5% SDS PAGE) was dialyzed four times in 50 mM Tris pH 7.5, 
prior to use, and its concentration was determined using the Bradford assay. Concentrations of 
each of the 47 assembled dyes (See Table 2.9) were adjusted on the basis of weight. PKA 
enzyme (2.08 mg/mL) was purchased from Promega. Peptide 2.1 (1 μM) was incubated with 10 
μM GST-tagged 14-3-3τ, 1 mM ATP, 2 mM DTT, 5 mM MgCl2, and 50 mM Tris-HCl at pH 7.5, 
in a quartz 96-well plate (Hellma). Each dye was added to a separate well at 5 μM. PKA (10 nM) 
was added to each well, and the enzyme-dependent increase in fluorescence (λex 420 nm, λem 
475 nm) was determined with a plate reader (Molecular Devices Spectra Max Gemini EM). Dyes 
D1, D6, D18, D33, and D39 showed >2-fold enhancements in fluorescence. 
 
Phosphorylation of Sensor 2.1 and Dephosphorylation of Phospho Sensor Peptide PKA-
catalyzed phosphorylation of sensor 2.1 was performed using the conditions in “Optimization of 
Enzyme-Dependent Fold-Change” described below. The mass of the resulting phosphorylated 
peptide was found to be 830.6 (M + 2H)2+, 554.1 (M + 3H)3+ (Exact Mass calculated 1658.8). 
The phosphorylated lead peptide was dephosphorylated using Protein Phosphatase 1 (NEB) in 
the presence of 50 mM HEPES pH 7.5, 100 mM NaCl, 2 mM DTT, 0.01% Brij 35, and 1 mM 
MnCl2. The mass of the resulting dephosphorylated peptide was found to be 789.5 (M + 2H)
2+ 
(Exact Mass calculated 1577.8). 
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Acquisition of Apparent Km and Vmax Values Phosphorylation dependent increase in coumarin 
fluorescence intensity of peptides 2.1-2.3 was monitored on a Photon Technology QM-1 
spectrofluorimeter at 30 °C. Standard curves were used to correlate fluorescence intensity with 
concentration of product formed. For generating the standard curve, various substrate 
concentrations were incubated, in duplicate, with 5 nM PKA at 25 °C over 30 h (in the presence 
of 320 μM dye, 20 μM 14-3-3τ, 1 mM ATP, 5 mM MgCl2, 2 mM DTT, and 50 mM Tris HCl pH 
7.5). The fluorescence intensity after complete phosphorylation was plotted against 
concentration, and parameters obtained from a linear regression of the data were used to convert 
the fluorescence intensity to product concentration. For determining the initial velocities, 
different concentrations of the peptide substrate was equilibrated with 20 μM 14-3-3τ, 1 mM 
ATP, 5 mM MgCl2, 2 mM DTT, in 50 mM Tris buffer pH 7.5, for 10 min. PKA (5 nM) was 
added, and the reaction progress curves were obtained. Reaction rates were determined from the 
slope under conditions where 5-8% substrate had been converted to product in duplicate 
(typically from 200 to 300 s). The resulting slopes (initial velocity, Vo) for each of the progress 
curves were plotted versus the concentration of substrate. A nonlinear regression analysis 
(SigmaPlot version 8.02 software) was used to fit the data to the rectangular hyperbola model. 
 
Optimization of Enzyme-Dependent Fold-Change Peptide 2.1 (1 μM) was incubated with 1 
mM ATP, 2 mM DTT, 5 mM MgCl2, 50 mM Tris-HCl at pH 7.5, in different wells of a quartz 
96-well plate. To each well, were added systematically varied concentrations of dye 2.4 (0-600 
μM) and GST-tagged 14-3-3τ (0-40 μM) followed by 10 nM PKA. Enzyme-dependent 
enhancement in fluorescence (λex 420 nm, λem 475 nm) was determined with a plate reader 
(Molecular Devices Spectra Max Gemini EM). The maximum fluorescence increase was 
61 
 
observed with 320 μM dye 2.4 and 20 μM GST-tagged 14-3-3τ. These optimized conditions were 
used to assay peptides 2.1-2.3 using a Photon Technology QM-4 spectrofluorimeter. The 
enzyme-dependent fold changes obtained under these conditions are reported in Table 2.1 and 
are shown in Figure 2.3. 
 
Acquisition of Apparent KD Values for 4 with Peptides 2.1 and 2.6-2.12. Varying 
concentrations of 2.4 ranging from 0.02 to 200 μM, were added to 1 μM of the coumarin-labeled 
peptides in 100 mM Tris HCl pH 7.5 buffer. Fluorescence data (λex 420 nm, λem 475 nm) was 
acquired using a Photon Technology QM-4 spectrofluorimeter at 30 °C. Correction for the inner 
filter effect was made as previously reported.26 Molar absorbtivities (λex 420 nm, λem 475 nm) 
were calculated from single absorbance spectra at [2.4]) 16 μM. After correcting for the inner 
filter effect, the percentage of quench was plotted against the concentration of the dye. 
Concentration of the dye-peptide complex was determined on the basis of the change in 
fluorescence emission intensity. The data were fit using the nonlinear regression mode of 
SigmaPlot ver.8.02. The calculated KD values are reported in Table 2.5. 
 
Job Plot for Determination of Stoichiometry. Fluorescence emission (λex 420 nm, λem 475 
nm) of varying concentrations of peptide 2.1 (0.2, 0.6, 1.0, 1.4, 1.8 μM) and dye 2.4 (65% purity) 
(1.8, 1.4, 1, 0.6, 0.2 μM) at a fixed total concentration of 2 μM was acquired in duplicate, on a 
Photon Technology QM-4 spectrofluorimeter at 30 °C (Figure 2.6). 
 
Mitochondria-Based Experiments. A standard curve for PKA concentration versus activity 
was generated using 1 μM peptide 2.1, 32 μM dye 2.4, 10 μM 14-3-3τ, 1 mM ATP, 5 mM 
                                                 
26 Levine, R. L. Clin. Chem. 1977, 23, 2292–2301. 
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MgCl2, 2 mM DTT, 1 mM cAMP, in 50 mM Tris HCl at pH 7.5. Assays were conducted in 
duplicate at two concentrations of total mitochondria protein (14 μg and 55 μg) using intact 
mitochondria (MitoSciences), trypsin-treated mitochondria (mitochondria samples incubated 
with 1:50 trypsin/total mitochondrial protein for 1 h at 37 °C, followed by treatment with 20-fold 
excess of soybean trypsin inhibitor) and sonicated mitochondria, [mitochondria sonicated 
(Ultrasonic Processor, Tekmar, Cincinnati, OH, U.S.A.) for 30 s on ice]. Initial rates were 
converted into pg of active PKA per μg of mitochondria using the standard curve. Rates in the 
presence of Ser/Thr phosphatase inhibitor cocktail (P2850 Sigma) were acquired at the 
recommended 1:100 dilution. 
 
Trypsin Treatment of Mitochondria. Mitochondria were incubated with trypsin (1:50 
trypsin/total mitochondrial protein) for 1 h at 37 °C followed by treatment with a 20-fold excess 
of soybean trypsin inhibitor. The outcome of the trypsin digestion was validated by Western blot 
using an outer membrane marker, Tom 20, and a matrix marker, Hsp60. 
 
Western Blot Analyses. Twenty micrograms of total protein was loaded onto 4-12% bis-tris-
polyacrylamide gels, separated by electrophoresis, and electroblotted onto PVDF membranes. 
The membranes were then blocked in 0.5% nonfat dry milk followed by incubation with the 
appropriate primary antibody (C subunit of PKA 1:1000, Tom 20 1:1000, and Hsp60 1:5000) for 
10 min. The membranes were then washed three times with 0.1% Tween-20 in PBS followed by 
incubation with a goat antimouse secondary antibody conjugated to horseradish peroxidase 
(1:2000) for 10 min. The membranes were washed with 0.1% Tween-20 in PBS (3×), PBS (3×), 
and 0.5% NaCl (3×) and detection of horseradish peroxidase performed using the ECL Plus 
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reagent (GE). 
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Table 2.3 Library of quencher dyes. Phosphorylation-induced fluorescence fold changes of 
peptide 1 in the presence of the quencher dyes (non-optimized conditions). 
 
 
Dye Name Fold Change 
D1 Acid Green 27 3.95 
D2 Acid Blue 40 1.36 
D3 Evans Blue 1.88 
D4 Acid Alizarin Violet N 1.53 
D5 Acid Blue 80 1.57 
D6 Reactive Blue 2 2.51 
D7 N,N-dimethylnitrosoaniline 1.21 
D8 Cresol Red 1.47 
D9 Phenol Red 1.2 
D10 Methyl Orange 1.18 
D11 Bromophenol Blue 1.49 
D12 BUFFER 1.16 
D13 Xylene Cyanol FF 1.15 
D14 Disperse Yellow 3 1.15 
D15 Ethyl Orange 1.27 
D16 Methylene Blue 1.14 
D17 Brilliant Blue R 1.16 
D18 Eriochrome Black T 2.04 
D19 Alizarin Red 1.31 
D20 Malachite Green oxalate 1.16 
D21 Phenolphthalein 1.17 
D22 Carminic Acid 1.15 
D23 Nuclear Fast Red 1.16 
D24 Acid Fuchsin 1.18 
D25 Acridine Orange 1.17 
D26 Acridine Yellow G 1.11 
D27 Aniline Blue WS 1.2 
D28 Azure A 1.13 
D29 Azure B bromide 1.12 
D30 Basic Fuchsin 1.17 
D31 Bismark Brown Y 1.17 
D32 Brilliant Yellow 1.65 
D33 Bromocresol Purple 2.33 
D34 Chlorazol Black E 1.2 
D35 Chlorophenol Red 1.2 
D36 Chrysoidine Y 1.16 
D37 Erythrosin 1.17 
D38 Ethyl Violet 1.14 
D39 Naphthol Blue Black 2.27 
D40 Methylthymol Blue 1.31 
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D41 Methyl Violet 1.14 
D42 Ponceau S 1.24 
D43 Rose Bengal 1.2 
D44 Rosolic Acid 1.16 
D45 Safranin O 1.18 
D47 Tartrazine 1.18 
D48 Trypan Blue 1.55 
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Figure 2.3 ATP(γ)S serves as a weak ATP analog in the PKA-catalyzed 
thiophosphorylation of peptide 2.1. Experiments were performed with 10 μM 14-
3-3, 5 mM MgCl2, 2 mM DTT, 50 mM Tris HCl at pH 7.5, 1 μM peptide 2.1, and 
30 μM 2.4 in the presence of 1 mM ATP or 1 mM ATP(γ)S. 0.5 nM PKA was 
added after 100 s and the reaction progress was monitored and plotted as fold 
change verses time. The kinase reaction was significantly slower with ATP(γ)S, 
however the peptide was thiophosphorylated under these conditions. Mass found 
m/z 1673.2 (calculated m/z 1673.8). 
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Figure 2.4 Fluorescence fold-change as a function of time in the absence (0 μM) and 
presence of 14-3-3. Experiments were performed with 5 mM MgCl2, 2 mM DTT, 50 
mM Tris HCl at pH 7.5, 1 μM peptide, 30 μM 2.4, 1 mM ATP, and varying 
concentrations of 14- 3-3. 0.5 nM PKA was added at 100 s to initiate the reaction. 
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Figure 2.5 Fluorescence fold change as a function of time in the absence of 
fluorescent quencher 2.4. Experiments were performed with 10 μM 14-3-3, 5 mM 
MgCl2, 2 mM DTT, 50 mM Tris HCl at pH 7.5, 1 μM peptide 1, 1 mM ATP, and 
two different concentrations of PKA [1 nM (blue curve) and 2 nM (red curve)] to 
initiate the reaction. 
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Figure 2.6 3-dimensional structure of a 14-3-3 domain/phosphopeptide 
complex. The tryptophan residues of the 14-3-3 domain are highlighted in lime 
green, whereas the remainder of the 14-3-3 domain is shown as a grey cartoon. 
The N-terminus of the phosphopeptide is indicated with an arrow. Coordinates 
were downloaded from the Protein Data Bank (PDB ID 1QJA). 
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Figure 2.11 Mitochondrial-driven fluorescence enhancement is cAMP-
dependent. Experiments were performed using 1 mM ATP, 5 mM MgCl2, 2 
mM DTT in 50 mM Tris HCl at pH 7.5, 1 μM peptide sensor 2.1, 30 μM 2.4, 
and 10 μM 14-3-3 incubated for 2 min, after which time 0.22 mg/mL of total 
mitochondrial lysate was added. After incubating for another 2 min, 1 mM 
cAMP was added. The reaction progress was monitored and plotted as 
fluorescence intensity versus time. 
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Figure 2.12 The PKA inhibitor H-89 blocks the fluorescent enhancement 
driven by (A) the C subunit (IC50 = 26 ± 9 μM) and (B) by cAMP-treated 
mitochondria. The experiments were performed under standard conditions (1 
mM ATP, 5 mM MgCl2, 2 mM DTT, 1 μM peptide 2.1,10 μM 14-3-3, 30 μM 
2.4, 50mM Tris HCl at pH 7.5). For the experiments shown in (B), 
mitochondria were added after a 2 min pre-incubation. H-89 was subsequently 
introduced following a second 2 min incubation. 
  
CHAPTER 3 
A BROAD SPECTRUM DARK QUENCHING DYE: CONSTRUCTION OF 
TRYPSIN AND PHOTOLABILE FLUORESCENT REPORTERS 
 
INTRODUCTION  
 
A wide variety of fluorescent biosensors have been described for a host of biomolecules, 
including nucleic acid sequences,1 proteases,2 kinases,3 metal ions,4 and other stimuli. Typically, 
fluorescent biosensors are designed containing a fluorescent donor species coupled to an 
acceptor species capable of modulating the biosensors’ fluorescence in response to stimuli. Many 
biosensors commonly employ a design motif whereby the excitation energy of one fluorophore is 
transferred to a second fluorophore, which emits light at a longer wavelength than that of the 
initially excited species. An alternative strategy employs a single fluorophore/quencher motif that 
furnishes a profluorescent species. The latter exhibits a fluorescent change when acted upon by 
biomolecules that separate the fluorophore from the quencher. The “relief from fluorescent 
quenching” strategy takes up only half of the spectral window space of conventional Förster 
                                                 
1 (1) Tyagi, S. and Kramer, F. R. Nat. Biotech. 1996, 14, 303-308. (2) Tyagi, S., Marras, S. A. E. and Kramer, F. R. 
Nat. Biotech. 2000, 18, 1191. 
 
2 (1) Ogawa, M., Kosaka, N., Longmire, M., Urano, Y., Choyke, P. L. and Kobayashi, H. Mol. Pharm. 2009, 6, 386-
395. (2) Wakata, A., Lee, H.-M., Rommel, P., Toutchkine, A., Schmidt, M. and Lawrence, D. S. J. Am. Chem. Soc., 
2010, 132, 1578-82. 
 
3 (1) Ting, A. Y., Kain, K. H., Klemke, R. L. and Tsien, R. Y. Proc. Natl. Acad. Sci. 2001, 98, 15003-8. (2) Violin, 
J. D., Zhang, J., Tsien, R. Y. and Newton, A. C. J. Cell Biol. 2003, 161, 899-909. 
 
4 (1) Sikdar, A.; Roy, S.; Haldar, K.; Sarkar, S.; Panja, S. S. Journal of fluorescence 2013. (2) Gong, Y.-J.; Zhang, 
X.-B.; Zhang, C.-C.; Luo, A.-L.; Fu, T.; Tan, W.; Shen, G.-L.; Yu, R.-Q. Anal. Chem. 2012, 84, 10777–84. 
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resonance energy transfer (FRET) sensors. This is especially useful for microscopy-based 
experiments, where multiple readouts, using several different channels, are common. Additional 
potential advantages associated with relief-from-quenching constructs are that (1) only a single 
fluorophore is required, thereby reducing the expense of synthesis and (2) enhanced structural 
flexibility since it is not dependent upon the use of a limited set of functional FRET fluorophore-
fluorophore pairs. However, these potential advantages are only available if the quencher enjoys 
a broad wavelength spectrum that can accept excited state energy from a wide variety of 
fluorophores.  
For example, two commonly used dark quenchers include 3.1 Dabcyl (4-(4’-
dimethylaminophenylazo)benzoic acid, λmax = 425 nm, QR (Quenching Range) = 375 – 500 nm) 
and Dansyl (4-(4’-dimethylaminoazobenzene-4’-sulfonyl, λmax = 339 nm, QR = 300 – 400 nm). 
 
Scheme 3.1 Structures of the dark quenchers Dabcyl 3.1, Black Hole Quencher 3 3.2, and 
CDQ 3.3. The red arrow indicates an azo bond subject to reduction, which eliminates the 
ability of the compound to serve as a dark fluorescence quencher. 
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Dabcyl is commonly used as a FRET quencher of the fluorophore EDANS (5-[(2-
aminoethyl)amino]naphthalene-1-sulfonic acid; λex = 430 nm, λem = 479 nm).5 However, the 
absorption maxima of Dabcyl and Dancyl are shorter than 500 nm, which limits their usefulness 
to blue and green fluorophores with emissions of < 500 nm for through space fluorescence 
quenching. This limits the usefulness of Dabcyl and Dansyl to fluorophores not applicable to 
fluorescence microscopy. 
Other dark quenchers are limited to specific ranges within the red or near infrared spectra 
window for through space quenching mechanisms. The combined Black Hole Quencher (BHQ) 
family covers the visible and near-IR spectral range, relying on a FRET mechanism.6  This 
family includes BHQ-0 (λmax = 495 nm, quenching range (QR) = 430 – 520 nm), BHQ-1 (λmax = 
534 nm, QR = 480 – 580 nm), BHQ-2 (λmax = 579, QR = 559 – 670 nm), BHQ-3 3.2 (λmax = 672, 
QR = 620 – 730 nm).7 As noted, each quencher has an approximately 110 nm spectral window 
where the quencher is capable of through space fluorescence quenching. As well as containing 
limited spectral window for through space quenching, BHQ quenchers contain (like Dabcyl and 
Dansyl mentioned above) an azo moiety that is subject to reduction. This has been demonstrated 
to abolish fluorescent quenching in the reductive environment of the cell (Figure 3.1).8  Leriche 
et al. successfully applied the susceptibility of azo bonds to reduction to the synthesis of a 
FRET–based biosensor of capsase-3 activity that included the quencher CDQ 3.3 ((4-hydroxy-2-
                                                 
5 Matayoshi, E. D.; Wang, G. T.; Krafft, G. a; Erickson, J. Science 1990, 247, 954–8. 
 
6 Marras, S. a E.; Kramer, F. R.; Tyagi, S. Nucleic acids research 2002, 30, e122. 
 
7 Biosearch Technologies. Black Hole Quencher Dyes: The Inescapable Solution. 
https://www.biosearchtech.com/support/applications/dyes-from-biosearch-technologies/black-hole-
quencher%C2%AE-dyes (accessed March, 15 2013). 
 
8 (1) Linder, K. E.; Metcalfe, E.; Nanjappan, P.; Arunachalam, T.; Ramos, K.; Skedzielewski, T. M.; Marinelli, E. 
R.; Tweedle, M. F.; Nunn, A. D.; Swenson, R. E. Bioconjugate Chem. 2011, 22, 1287–97. (2) Chung, K. T.; 
Stevens, S. E.; Jr., Cerniglia, C. Crit. Rev. Microbiol. 1992, 18, 175–190. (3) Leriche, G.; Budin, G.; Darwich, Z.; 
Weltin, D.; Mély, Y.; Klymchenko, A. S.; Wagner, A. Chem. Comm. 2012, 48, 3224–6. 
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methoxy-phenylazo) benzoic acid). Upon addition of the reducing agent dithionite, the CDQ 
quencher lost its ability to quench fluorescence. 
In addition to the BHQ quencher family, the QSY family of dark fluorescent quenchers 
has been found to quench a series of fluorophores in the visible and near IR range via through 
space mechanisms.9 This quencher family includes QSY-35 (λmax = 475 nm, QR = 430 – 520 
nm), QSY-7 (λmax = 560 nm, QR = 500 – 600 nm), QSY-9 (λmax = 562, QR = 500 – 600 nm), and 
QSY-21 (λmax = 661 nm, QR = 575 – 700 nm).10 QSY quenchers have similar spectral windows 
as the BHQ series for through space energy transfer of between 100 - 125 nm. Although the 
QSYs lack an azo functionality and are thus not subject to undesired reduction, they are also 
much less synthetically accessible than the BHQs. 
While the BHQ and QSY quencher series have the ability to quench fluorophores over 
the entire visible spectral range, careful selection of the fluorophore/quencher pair is necessary to 
ensure effective quenching. Our aim was to identify a dark fluorescent quencher effective with a 
wide range of fluorophores and apply this to the construction of multicolored protease substrates. 
We describe herein a dark fluorescent quencher that is effective over a wide wavelength range, 
thereby enabling the construction of multicolored family of protease substrates. 
 
RESULTS 
 
We’ve recently identified a host of fluorescent quenchers for several fluorophores by 
                                                 
9 Life Technologies. Molecular Probes nonfluorescent quenchers and photosensitizers. 
http://www.invitrogen.com/site/us/en/home/References/Molecular-Probes-The-Handbook/tables/Molecular-Probes-
nonfluorescent-quenchers-and-photosensitizers.html (accessed March, 15 2013). 
 
10 Marcotte, P. a; Richardson, P. L.; Richardson, P. R.; Guo, J.; Barrett, L. W.; Xu, N.; Gunasekera, A.; Glaser, K. B. 
Anal. Biochem. 2004, 332, 90–9. 
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screening a library of 47 negatively charged dyes with fluorophore substituted, positively 
charged peptides.11 The strategy employs electrostatics to rapidly screen and assess quenching 
efficacy of dye-quencher/fluorophore pairs. Several of the lead dye-quenchers (e.g. acid green 
27, bromocresol purple, naphthol blue black, Acid Blue 40 3.4 etc.) possess a broad-spectrum 
absorbance, thereby rendering their application to fluorophores that emit in the visible and near-
IR range. We chose Acid Blue 40 (AB40) 3.4 as our lead, prepared a carboxylic acid-containing 
derivative (cAB40 3.7), and used the latter to construct profluorescent protease and photolabile 
sensors. 
 
Readily available phenylacetic acid derivative 3.6 was converted to the 4-amiophenyl 
acetic acid derivative 3.7 via Ullman coupling with bromaminic acid 3.5 (Scheme 3.2).12   
                                                 
11 Agnes, R. A.; Jernigan, F. E.; Sharma, V.; Shell, J. R.; Lawrence, D. S. J. Am. Chem. Soc. 2010, 132, 6075-6080. 
 
12 Weyler, S.; Baqi, Y.; Hillmann, P.; Kaulich, M.; Hunder, A. M.; Müller, I. A.; Müller, C. E. Bioorg. Med. Chem. 
Lett. 2008, 18, 223-227. 
 
Scheme 3.2 Structure of Acid Blue 40 (AB40) 3.4 and synthesis of carboxy Acid Blue 40 
(cAB40) 3.7. 
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Briefly, 3.5 and 3.6 were heated to reflux for 24 h in aqueous CuSO4 and NaHCO3. Any 
unreacted 3.6 was removed by washing the cooled reaction mixture with CH2Cl2. Following 
purification via flash chromatography the desired compound 3.7 was acquired in 37% yield. 
Using 3.7, Trypsin substrates and a photolabile reporter were synthesized. First, Fmoc-Lys(Mtt)-
OH was coupled to the Novasyn TGR-Resin to afford 3.8 (Scheme 3.3). Second, the 4-
methyltrityl (Mtt) protected amine was deprotected and acylated with HCTU [1H-
benzotriazolium-1 [bis(di-methylamino)-methylene]-5-chloro-hexafluoro-phosphate (1),3-
oxide]-activated cAB40 3.7 to furnish 3.9. Third, trypsin substrates 3.10 - 3.17 were prepared by 
sequentially coupling Fmoc-Arg-OH and Fmoc-Gly-OH to 3.9 via solid phase peptide synthesis. 
The photosensitive reporter 3.18 was constructed in an analogous fashion by sequentially 
coupling the photolabile 4-[4-[1-(Fmoc)Ethyl]-2-Methoxy-5-Nitrophenoxy]Butanoic Acid
 
Scheme 3.3. Solid phase synthesis of protease sensors 3.10 - 3.17 and photolabile reporter 
3.18. a. HCTU/DIPEA/DMF. b. 7% TFA/7% TIS/84% CH2Cl2. c. 1.1 eq. cAB40/1.0 eq. 
HCTU/20 eq. piperidine/DMF. d. 20% piperidine/DMF. e. Fmoc-amino acid coupling (repeat 
steps d and e for subsequent couplings). f. 95% TFA/2.5% TIPS/2.5% H2O. 
 
  
7
8
 
Substrate/Cassette 
λmax 
Excitation 
λmax 
Emission 
Fold Enhancement upon 
Trypsinolysis or Photolysis 
Quenching 
efficiency 
Förster Distance 
(Å) 
      
(3.10) DEAC-GRK(cAB40)-amide 430 479 22.5 ± 3.9 95.6 48 
      
(3.11) Cou343-GRK(cAB40)-amide 445 490 6.2 ± 1.0 83.9 74 
      
(3.12) FAM-GRK(cAB40)-amide 494 520 6.5 ± 0.3 84.6 55 
      
(3.13) TAM-GRK(cAB40)-amide 565 580 75.0 ± 7.6 98.7 69 
      
(3.14) Atto610-GRK(cAB40)-amide 610 635 77.3 ± 5.0 98.7 75 
      
(3.15) Atto700-GRK(cAB40)-amide 681 714 18.2 ± 1.2 94.5 61 
      
(3.16) TAM-GRK(BHQ-2)-amide 565 580 64.0 ± 5.0 98.4 48 
 
 
 
   
(3.17) TAM-GRK(QSY-7)-amide 565 580 75.4 ± 3.3 98.7 55 
 
 
 
   
(3.18) TAM-G-Ø-K(cAB40)-amide 565 580 109.5 ± 6.2 99.1 69 
 
 
 
   
Table 3.1 Photophysical properties of the trypsin substrates 3.10 – 3.17 and the photolabile reporter 3.18. Fold enhancement upon 
trypsinolysis or photolysis and the substrate percent quench is also included.  
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(Fmoc-Ø-OH) and Fmoc-Gly-OH. Fluorophores were condensed to the peptide N-terminus and 
the resultant products simultaneously deprotected and cleaved from the resin with 95% 
trifluoroacetic acid (TFA). An array of fluorophores that cover the entire visible spectrum up to 
the near IR were employed for peptides 3.10 - 3.15, including diethylaminocoumarin (DEAC; λex 
= 430 nm, λem = 479 nm), coumarin 343 (Cou343; λex = 445 nm, λem = 490 nm), fluorescein 
(FAM; λex = 494 nm, λem = 520 nm), tetramethylrhodamine (TAM; λex = 565 nm, λem = 580 nm), 
atto610 (λex = 610 nm, λem = 635 nm), and atto700 (λex = 681 nm, λem = 714 nm) (Figure 3.1).  
 
Following synthesis, peptides 3.10 - 3.17 were treated with trypsin and fluorescent 
enhancements were observed. As is evident from Table 1, large enhancements in fluorescence 
were obtained for TAM (75-fold), atto610 (77-fold), DEAC (22.5-fold), and atto700 (18.2-fold) 
peptides. By contrast, the observed increase in fluorescence intensity for the shorter wavelength 
fluorophores Cou343 (6.2-fold), and FAM (6.5-fold) although significant, are more modest. The 
 
Figure 3.1 AB40 absorbance spectrum (black) and the emission spectra of DEAC (purple), 
Cou343 (navy blue), FAM (light blue), TAM (green), atto610 (orange), and atto700 (red). 
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fluorescent fold change of the photolabile cassette 3.18 was also determined. Irritation at 360 nm 
induces the well-established transfer of one of the oxygens of the nitro functionality to the 
nearby benzylic position creating the hemiaminal 3.20 (Scheme 3.4). The intermediate 
hemiaminal 3.20 decomposes, generating two fragments, one with the now highly fluorescent 
TAM fluorophore (3.21) and the other with the AB40 quenching partner (3.22). Photocleavage 
of 3.18 was complete within 2 minutes of illumination, delivering a greater than 100-fold 
fluorescent enhancement (Figure 3.2). A word of caution is in order with respect to the 
fluorescent enhancements reported in this study and elsewhere, particularly with regard to 
profluorescent reporters. We found it challenging to remove the last traces of free fluorophore, 
which could dramatically alter the observed fluorescence enhancement. 
 
Scheme 3.4 Photolysis of TAM-G-Ø-K(cAB40)-amide 18. Illumination at 360 nm induces 
the well-established transfer of one of the oxygens of the nitro functionality to the nearby 
benzylic position. The intermediate hemiaminal decomposes, generating two fragments, one 
with the now highly fluorescent TAM fluorophore and the other with the AB40 quenching 
partner. 
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Förster distances for peptides 3.10 – 3.18 were calculated using the PhotochemCAD 
software suite (Table 3.1).13 The fluorophore emission and AB40 absorbance spectra were 
collected and imported into the software package. A refractive index for 1:1 DMSO/H2O was 
used along with a 𝜅2 value of 2/3, indicative of free molecular rotation.14 The DEAC and cAB40 
pair displays the shortest Förster distance (48 Å) whereas the atto610/cAB40 pair exhibits the 
longest (75 Å). FRET radii were also calculated for the commercially available quenchers QSY-
7 and BHQ-2 (with TAM as the fluorophore) and found to be 48 Å and 55 Å, respectively. The 
TAM/cAB40 pair displays a Förster distance (69 Å) that compares favorably to the values for 
QSY-7 and BHQ-2. Quenching efficiency was also calculated from the fluorescent fold change 
data for each substrate. The quenching efficiency value for the TAM-GRK(AB40)-amide 
                                                 
13 (1) Du, H.; Fuh, R.-C. A.; Li, J.; Corkan, L. A.; Lindsey, J. S. Photochem. Photobiol. 1998, 68, 141-142. (2) 
Dixon, J. M.; Taniguchi, M.; Lindsey, J. S. Photochem. Photobiol. 2005, 81, 212-213. 
 
14 LeBel, R. G.; Goring, D. A. I. J. Chem. Eng. Data 1962, 7, 100-101. 
 
Figure 3.2 Fluorescent enhancement of TAM-G-PL-K(AB40)-amide (3.17) as a function of 
photolysis time. 
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substrate 3.13 were found to compare favorably with BHQ-2 substrate 3.16 and QSY-7 substrate 
3.17. 
Next, we chose to investigate the absorbance spectra of substrates with minimal (3.10), 
slight (3.11), and complete (3.13) overlap with the cAB40 quencher. The substrate absorption 
spectra (Fl-GRK(cAB40)-amide) was compared with peptides lacking the fluorophore (NH2-
GRK(cAB40)-amide) or quencher (Fl-GRK(NH2)-amide). Additionally, the fluorophore and 
quencher absorbance spectra were combined to create a single additive spectrum. The 
absorbance spectrum of substrate 3.10 displayed changes in absorbance in comparison with the 
combined spectra of peptides DEAC-GRK(NH2)-amide 3.23 and NH2-GRK(AB40)-amide 3.24   
(Figure 3.3). A red shift in the shape of the cAB40 peak was evident, as well as blue shift in the 
fluorophore excitation from 450 to 437 nm was observed. Like substrate 3.10, the absorbance 
spectrum of substrate 3.11 displayed changes in comparison with the absorbance spectrum of 
 
Figure 3.3 Absorbance spectrum of substrate DEAC-GRK(cAB40)-amide 3.10 (Blue), 
DEAC-GRK(NH2)-amide 3.23 (Red), NH2-GRK(AB40)-amide 3.24 (Green), as well as an 
additive spectrum of 3.23 and 3.24 (Purple). 
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Figure 3.4 Absorbance spectrum of substrate Cou343-GRK(cAB40)-amide 3.11 (Blue), 
Cou343-GRK(NH2)-amide 3.25 (Red), NH2-GRK(AB40)-amide 3.24 (Green), as well as an 
additive spectra of 3.25 and 3.24 (Purple). 
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Figure 3.5 Absorbance spectrum of substrate TAM-GRK(cAB40)-amide 3.13 (Blue), TAM-
GRK(NH2)-amide 3.26 (Red), NH2-GRK(AB40)-amide 3.24 (Green), as well as an additive 
spectra of 3.26 and 3.24 (Purple). 
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peptides Cou343-GRK(NH2)-amide 3.25 and NH2-GRK(AB40)-amide 3.24 (Figure 3.4). A 
largeincrease in molar absorptivity in the 300 - 400 nm range as well as a decrease in the 500 - 
600 nm range is evident. The absorbance spectrum of substrate 3.13 displayed few changes in 
comparison with peptides TAM-GRK(NH2)-amide 3.26 and NH2-GRK(AB40)-amide 3.24 
(Figure 3.5).  
Next, we chose to investigate external effects such as viscosity, on the fluorescence of the 
substrates. Increased viscosity attenuates interaction between the fluorophore and quencher, 
decreasing the rate at which a donor and acceptor can collide and transfer energy or electrons, 
thereby decreasing quenching.13,15  With this in mind, we compared the viscosity dependent 
fluorescence of substrates 3.10 (DEAC-GRK(cAB40)-amide), 3.11 (Cou343-GRK(AB40)-
amide), and 3.13 (TAM-GRK(AB40)-amide) with respect to peptides lacking the cAB40 
quencher (peptides DEAC-GRK(NH2)-amide 3.19, Cou343-GRK(NH2)-amide 3.21, and TAM-
GRK(NH2)-amide) 3.22 (Figure 3.6). In preforming the experiment with coumarin derivatives, it 
is important to include the unquenched coumarin fluorophore, since coumarin fluorescence is 
known to be effected by changes in viscosity.16  The normalized fluorescence change of substrate 
3.10 shows increasing fluorescence as a function of viscosity over peptide 3.23 (20-fold). This is 
approximately similar to the fluorescence change observed from trypsinolysis (22.5-fold). 
Substrate 3.11 displays a fluorescence change over the background at lower weight percentages 
of PEG400, however this effect is not observed at higher viscosities. Substrate 3.13 displays no 
effect to increases in viscosity.  
Environmental effects were further investigated with the addition of Hydroxypropyl Beta 
                                                 
15 Wakata, A.; Cahill, S. M.; Blumenstein, M.; Gunby, R. H.; Jockusch, S.; Marti, A. a; Cimbro, B.; Gambacorti-
Passerini, C.; Donella-Deana, A.; Pinna, L. A; Turro, N. J.; Lawrence, D. S. Org. Lett. 2008, 10, 301–4. 
 
16 (1) Wagner, B. D. Molecules (Basel, Switzerland) 2009, 14, 210–37. (2) Choi, J. Y.; Park, E. J.; Chang, S. H.; 
Kang, T. J. Bulletin of the Korean Chemical Society 2009, 30, 1452–1458. 
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Figure 3.6 Normalized viscosity dependent fluorescence change of substrates DEAC-
GRK(cAB40)-amide 3.10 (A, Blue Diamond), Cou343-GRK(AB40)-amide 3.11 (B, Blue 
Diamond), and TAM-GRK(cAB40)-amide 3.13 (C, Blue Diamond) versus substrates DEAC-
GRK(NH2)-amide 3.23 (A, Red Square), Cou343-GRK(NH2)-amide 3.25 (B, Red Square), 
and TAM-GRK(NH2)-amide 3.26 (C, Red Square). Error bars are present for each 
measurement, however they may be too tight to observe. 
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Figure 3.7 Normalized Hydroxypropylbetacyclodextrin (HP-β-CD) dependent fluorescence 
change of substrates DEAC-GRK(cAB40)-amide 3.10 (A, Blue Diamond), Cou343-
GRK(AB40)-amide 3.11 (B, Blue Diamond), and TAM-GRK(cAB40)-amide 3.13 (C, Blue 
Diamond) versus substrates DEAC-GRK(NH2)-amide 3.23 (A, Red Square), (Cou343-
GRK(NH2)-amide) 3.25 (B, Red Square), and (TAM-GRK(NH2)-amide) 3.26 (C, Red 
Square). Error bars are present for each measurement, however they may be too tight to 
observe. 
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Cyclodextrin (HP-β-CD) to peptides 3.10, 3.11, and 3.13. HP-β-CD has been demonstrated to 
bind coumarins17 and TAMRA18 to form supramolecular inclusion complexes. Therefore, the 
addition of HP-β-CD should work to prevent the interaction of the fluorophore and quencher and 
relieve quenching in a similar manner as increasing viscosity. With this in mind, we compared 
the HP-β-CD concentration dependent fluorescence of peptide substrates 3.10, 3.11, and 3.13 
with the corresponding peptides 3.23, 3.25, and 3.26 which lack the cAB40 quencher (Figure 5). 
The fluorescence of substrate 3.10 dramatically increases as a function of HP-β-CD 
concentration over the baseline fluorescence observed by substrate 3.23 (25-fold). Substrate 3.11 
does show an increase of 1.5-fold in the normalized fluorescence change over the baseline of 
peptide 3.25, but this fails to match the enhancement upon trypsinolysis of 6.2-fold. The 
fluorescence of substrate 3.13 shows no effect to HP-β-CD. 
 
DISCUSSION 
 
The dark quencher cAB40 serves as an efficient broad spectrum quencher in protease 
substrates using a wide variety fluorophores relevant in fluorescence microscopy. Protease 
substrates with a wide variety of photophysical properties are effectively quenched, with 
fluorescence increases upon proteolysis of 75-fold and 100-fold in the case of photolysis. As is 
clear from Figure 3.1, AB40 absorbance displays significant overlap with the emission signals of 
TAM, atto610, and to a somewhat lesser extent with atto700, which is consistent with a FRET-
                                                 
17 (1) Chakraborty, A.; Seth, D.; Chakrabarty, D.; Sarkar, N. Spectrochimica acta. Part A, Molecular and 
biomolecular spectroscopy 2006, 64, 801–8. (2) Ghosh, S.; Mondal, S. K.; Sahu, K.; Bhattacharyya, K. (3) Karnik, 
N. A.; Prankerd, R. J.; Perrin, J. H. Chirality 1991, 3, 124–128. The journal of physical chemistry. A 2006, 110, 
13139–44. (4) Velic, D.; Knapp, M.; Köhler, G. J. Mol. Struct. 2001, 598, 49–56. 
 
18 Nguyen, T.; Joshi, N. S.; Francis, M. B. Bioconjugate Chem., 2006, 17, 869–72. 
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based quenching mechanism. Curiously, although there is minimal overlap between the emission 
of DEAC with the cAB40 absorbance spectrum, nonetheless this species displays a trypsin-
mediated fluorescent enhancement analogous to that of the atto700 derivative 3.15. In light of 
this, we chose to further investigate the mechanism and delivery of quenching.   
Dark quenchers can modulate fluorescence through two processes consisting of (1) 
electron transfer mechanisms or (2) energy transfer mechanisms.19  Electron transfer involves the 
transfer of an electron either to or from a ground or excited state donor, resulting in a return to 
the ground state. Energy transfer mechanisms consist of nonradiative (1) Dexter or (2) Förster 
energy transfer. The Dexter energy transfer mechanism requires an overlap of frontier molecular 
orbitals preceding electron exchange, which results in acceptor excitation and donor relaxation.20 
FRET occurs via an overlap of dipolar electric fields that precede energy transfer. After dipole 
overlap occurs, energy transfer proceeds from an excited state fluorophore to an acceptor through 
resonance of oscillating electronic dipoles.21  The acceptor then undergoes relaxation via 
radiative or non-radiative processes. 
Additionally, each quenching mechanism is affected by changes in molecular diffusion, 
which can affect the mechanism for electron or energy delivery. Delivery processes from donor 
to acceptor can be divided into three types: (1) the formation of donor/acceptor complex 
continuously held as a pair (ie static quenching), (2) a diffusional related processes that helps 
associate the donor and acceptor (ie dynamic quenching), or (3) a conductor that facilities energy 
or electron transfer between the donor and acceptor. The formation of a ground state 
                                                 
19 Turro, N. J., Ramamurthy, V., Scaiano, J. C.  Modern Molecular Photochemistry of Organic Molecules. Sausalito, 
Calif.: University Science Books, 2010. 
 
20 Dexter, D. L. J. Phys. Chem. 1953, 21, 836. 
 
21 T. Förster, Fluorenzenz Organische Verbindungen. Vandenhoech and Ruprecht: Göttingen, 1951. 
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donor/acceptor complex that exists before photon absorption is termed “static quenching”. A 
hallmark of static quenching is an altered fluorophore absorbance spectrum because 
donor/acceptor interactions occur in the ground state, and are hence visible to the observer.22  
Diffusional related energy or electron delivery processes that occur in the excited state are 
termed “dynamic quenching”. Dynamic quenching requires the excited state donor and acceptor 
enter into close proximity for quenching to occur. Because of this, dynamic quenching is 
susceptible to external effects such as temperature or viscosity.  The third delivery mechanism 
requires a conductive tether capable of transporting energy or electrons (e.g. the through bond 
energy transfer mechanism23).  
Due to the large fluorophore emission/quencher absorbance overlap of the 
TAMRA/cAB40 pair, we expected a FRET based mechanism to primarily be responsible for the 
high quenching efficiency as is observed in BHQ and QSY quencher series. However, electron 
transfer or Dexter energy transfer could still be possible. We expected to observe some degree of 
ground state complex formation (or static quenching) for each substrate, since the fluorophore 
and quencher are covalently bound, and unable to freely diffuse apart. The absorbance spectra of 
substrates 3.10 and 3.11 indicate the presence of a static quenching mechanism due to the 
changes in absorbance (Figure 3.3, 3.4). However, substrate 3.13 displays only minor changes in 
absorbance indicating the lack of a static quenching mechanism (Figure 3.5).  
The effects of PEG400 and HP-β-CD were investigated for evidence of dynamic 
quenching. The viscosity (22.5 fold) and HP-β-CD (25 fold) normalized fluorescent increases of 
substrate 3.10 approximately matches the 22.5-fold enhancement observed from trypsinolysis 
(Figure 4A, 5A). This indicates the presence of a diffusional related delivery mechanism of 
                                                 
22 Lakowicz J. R.: Principles of Fluorescence Spectroscopy. 3rd ed. New York: Kluwer Academic/Plenum, 2006. 
 
23 Fan, J.; Hu, M.; Zhan, P.; Peng, X. Chem. Soc.Rev. 2013, 42, 29–43. 
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energy transfer (i.e. dynamic quenching). The environmental effects of increasing viscosity and 
HP-β-CD of substrate 3.11 are somewhat ambiguous. Increasing viscosity does not produce an 
increase over the baseline fluorescence provided by 3.21 but not to the extent seen during 
trypsinolysis (6-fold) (Figure 3.7B). Substrate 3.13 shows no effect to viscosity and HP-β-CD 
(Figure 4C, 5C). Both substrate 3.11 and 3.13 demonstrate the absence of a dynamic quenching 
mechanism.  
Overall, the absorbance, viscosity, and HP-β-CD experiments allow us to determine the 
mechanism of energy delivery in each substrate. Substrate 3.10 is likely a combination of static 
and dynamic quenching due to the changes observed in the absorbance spectrum of the substrate 
(likely static quenching) and the relief of quenching due to the environmental effects of viscosity 
and HP-β-CD (likely dynamic quenching).24 The lack of large changes in the absorbance of 
substrate 3.13, as well as the absence of changes in normalized fluorescence upon exposure to 
PEG400 or HP-β-CD, indicates a lack of a static or dynamic quenching mechanism. Due to this, 
we believe energy transfer occurs via a radiative energy transfer mechanism, whereby quenching 
occurs via fluorophore emission preceding quencher absorption. This is somewhat different than 
a Förster resonance energy transfer mechanism, where energy transfer is nonradiative and occurs 
through resonance of electronic dipoles in the excited state,19 although there is some debate over 
this issue.25 Since the photophysical properties of substrate 3.11 fall between that of 3.10 and 
3.13, energy delivery could be occurring as a combination of mechanisms. However, we know 
quenching in substrates 3.10 and 3.11 occurs via a static mechanism due to the observed changes 
in absorbance spectrum.   
                                                 
24 Birks, J. B.; Salete, M.; Leite, S. C. P. Journal of Physics B: Atomic and Molecular Physics 1970, 3, 417–424. 
 
25 (1) Andrews, D. L.; Bradshaw, D. S. European Journal of Physics 2004, 25, 845–858. (2) Andrews, D. L. 
Chemical Physics 1989, 135, 195–201. 
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CONCLUSIONS 
 
cAB40 is an effective broad-spectrum dark quencher of a variety of fluorophores, 
enabling it to be used in the construction of multi-colored protease sensors, as well as a reporter 
of photolysis (with up to a 100- fold increases fluorescence observed). Although bond cleavage-
induced fluorescent enhancement varies by fluorophore, the most pronounced changes are 
observed with fluorophores possessing emission spectra commonly employed in microscopy. 
The cAB40 quencher was shown to have different mechanisms of energy delivery for various 
fluorophores, due to changes observed in absorbance spectra, and differing responses to 
increased viscosity and concentrations of Hydroxypropyl Beta Cyclodextrin (HP-β-CD). 
Substrate 3.10 was shown to have large changes in absorbance spectra (relative to peptides 
containing solely DEAC or cAB40) and found to be no longer quenched with increasing 
viscosity and concentrations of HP-β-CD. These results point to combined dynamic and static 
mechanism for delivery of energy from the fluorophore to the quencher.  Substrate 3.13 showed 
only minor changes in its absorbance spectrum and no effect upon exposure to increasing 
viscosity and concentrations of HP-β-CD. This leads us to believe energy transfer occurs in this 
case due to a radiative energy transfer mechanism. Overall, this work represents an easily 
synthesized dark quencher capable of quenching a broad spectrum of fluorophores, which can be 
used in the construction of protease substrates and other probes for bioimaging. 
 
MATERIALS AND METHODS 
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General Procedures General reagents and solvents were purchased from Fisher or Sigma-
Aldrich. Novasyn TGR Resin, Fmoc-Lys(Mtt)-OH (N-α-Fmoc-N-ε-4-methyltrityl-L-lysine), and 
all Fmoc protected natural amino acids were purchased from EMD Biosciences Inc. HCTU [1H-
benzotriazolium-1 [bis(dimethylamino)methylene]-5-chloro-hexaﬂuorophosphate (1),3-oxide] 
was purchased from Peptides International (Louisville, KY, U.S.A.). TAM (5-
carboxytetramethylrhodamine), and FAM (5-carboxyfluorescein) were purchased from 
Chempep, Inc. (Wellington, Fl, U.S.A). DECou (7-(diethylamino)coumarin-3-carboxylic acid), 
Cou343 ([11-oxo-2,3,6,7-tetrahydro-1H,5H,11H-pyrano[2,3-f]pyrido[3,2,1-ij]quinoline-10-
carboxylic acid), atto610 NHS-ester, and atto700 NHS-ester were purchased from Sigma-
Aldrich. Fmoc-Photolabile Linker (Fmoc-Ø-OH) 3.19 (4-{4-[1-(9-
fluorenylmethyloxycarbonyl)ethyl]-2-methoxy-5-nitrophenoxy}butanoic acid) was purchased 
from Advanced ChemTech (Louisville, KY, U.S.A.). Flash Chromatography was performed on a 
Biotage (Charlotte, N.C., U.S.A.) Isolera One System using a 120 gram C18 reverse phase 
column. Trypsin from bovine pancreas was purchased from Sigma-Aldrich.  
 
Synthesis of cAB40 3.7 The sodium salt of bromaminic acid 3.5 (1-amino-4-bromo-9,10-
dihydro-9,10-dioxo-2-anthracenesulfonic acid sodium salt, 0.500 g, 1.23 mmol), 4-
aminophenylacetic acid 3.6 (0.166 g, 1.1 mmol), sodium carbonate (0.197 g, 1.58 mmol), copper 
(II) sulfate (28 mg, 0.179 mmol) and water (50 mL) were added to a 100 mL flask. The color of 
the solution turned from a bright red to a dark blue after stirring and heating the mixture to reflux 
for 24 h, indicating product formation.  The aqueous mixture was washed with dichloromethane 
(DCM) (3 x 50 mL) and the solvent removed via rotary evaporation. The resulting solid was 
dissolved in methanol, filtered, and the solvent removed via rotary evaporation. The furnished 
 93 
solid was purified via reverse-phase flash chromatography using an acetonitrile to water gradient 
(3% to 95%) over 30 min to furnish the desired material as a dark blue solid in 37.2% yield. 1H 
NMR (400 MHz, DMSO-d6) δ 9.62 (broad, 5H), 8.212 (t, J = 9.2 Hz, 1H), 8.208 (t, J = 8.8 Hz, 
1H), 8.044 (s, 1H), 7.787 (t, J = 3.2 Hz, 1H), 7.787 (t, J = 4.4Hz, 1H), 7.236 (d, J = 8.4 Hz, 2H), 
7.240 (d, J = 8.4 Hz, 2H), 3.611 (s, 2H), 2.537 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 182.506, 
181.971, 172.859, 144.138, 142.695, 141.011, 137.861, 134.155, 133.613, 133.202, 132.858, 
131.349, 130.815, 126.090, 126.017, 123.034, 122.735, 111.513, 109.543; HRMS (ESI-) m/z 
calc’d for C22H15N2O7S- [M-]: 451.0605, m/z found: 451.0607.  
 
Synthesis of Fluorophore/Dye-labeled Peptides Peptides were synthesized using standard 
Fmoc solid-phase synthesis on a Prelude peptide synthesizer (Protein Technologies Inc., Tucson, 
AZ, U.S.A.). Novasyn TGR resin was swelled for 30 min in DCM before synthesis. Fmoc-
Lys(Mtt)-OH was then coupled using 5.0 equiv AA, 4.9 equiv of HCTU, 20 equiv of 
diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF) (2 × 5 min) followed by a 
DMF wash (6 × 30 s). The Lys 4-methyltrityl protecting group was then deprotected using 7% 
TFA/7% TIS/86% DCM. The deprotected side chain amine was then acylated using 1.1 equiv 
cAB40, 1.0 equiv HCTU, and 20.0 equiv DIPEA in DMF (2 x 2 h).  The Fmoc-protecting group 
was removed using 20% piperidine in DMF (2 × 2.5 min) followed by a DMF wash (6 × 30 s). 
Fmoc-Arg-OH and Fmoc-Gly-OH were then to the free N-terminus of the peptide using the 
conditions described for the coupling and deprotection of Fmoc-Lys(Mtt)-OH. In the case of 14, 
the Fmoc-Ø-OH photolabile amino acid was coupled instead of Fmoc-Arg-OH. The N-terminal 
Fmoc was then removed using 20% piperidine in DMF (2 × 2.5 min) and fluorophores were 
coupled using one of two methods. (1) The fluorophores DECou, Cou343, 5’-FAM, TAM, and 
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ROX were coupled to the N-terminal amine using 5.0 equiv of ﬂuorophore, 4.9 equiv of HCTU, 
and 20 equiv of DIPEA in DMF (1× 60 min) followed by a wash (3× DMF, IPA, DCM). (2) The 
fluorophores atto610-NHS ester and atto700-NHS ester were coupled using 1.0 mg of dye and 
20 equiv of DIPEA in DMF (1 × 60 min) followed by a wash (3X DMF, IPA, DCM). The 
synthesis of peptides 15, 17, and 18 followed the exact same procedure as above, but the Mtt 
protecting group deprotection and cAB40 coupling was skipped. The synthesis of peptide 16 
followed the exact same procedure as above, but fluorophore coupling was skipped to leave a 
free N-terminal amine. After synthesis was complete, the peptide was cleaved from the resin and 
deprotected using a 95:2.5:2.5 TFA:H2O:triisopropylsilane (TIPS) cleavage cocktail. The 
peptides were isolated via ﬁltration, precipitated with ice-cold ether, and centrifuged. The 
precipitates were air-dried, dissolved in DMSO, and puriﬁed using HPLC (3% to 95% 
acetonitrile to water gradient with 0.1% TFA over 30 min using a 25 cm x 21.2 mm C18 
column). Peptides 3.10 – 3.18 were collected, freeze-dried, and characterized by matrix-assisted 
laser desorption/ionization mass spectrometry (Matrix: alpha cyano-4-hydroxycinnaminic acid, 
mono-isotopic): DECou-GRK(AB40)-amide 3.10 [Exact Mass calculated: 1035.391, found: 
1035.355 (M+H)+], Cou343-GRK(AB40)-amide 3.11 [Exact Mass calculated: 1059.391, found: 
1059.351 (M+H)+], FAM-GRK(AB40)-amide 3.12 [Exact Mass calculated: 1150.349, found: 
1150.333 (M+H)+], TAM-GRK(AB40)-amide 3.13 [Exact Mass calculated: 1205.451, found: 
1205.476 (M+H)+], atto610-GRK(AB40)-amide 3.14 [Exact Mass calculated: 1165.529, found: 
1165.556 (M+H)+], atto700-GRK(AB40)-amide 3.15 [The structure of atto700 has not been 
published, exact mass could not be calculated, found: 1340.512], TAM-GRK(BHQ2)-amide 3.16 
[Exact Mass calculated: 1259.575, found: 1259.606 (M+H)+], TAM-GRK(QSY7)-amide 3.17 
[Exact Mass calculated: 1410.613, found: 1410.612 (M+H)+], TAM-G-Ø -K(AB40)-amide 3.18 
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[Exact Mass calculated: 1329.456, found: 1329.427 (M+H)+]. Peptides 3.23 – 3.25 were 
collected, freeze-dried, and were characterized by positive electrospray ionization quadrupole 
mass spectrometry (ESI+-QMS): DEAC-GRK(NH2)-amide 3.23 [Exact Mass calculated: 602.3, 
found: 602.3 (M+H)+], NH2-GRK(cAB40)-amide 3.24 [Exact Mass calculated: 793.3, found: 
793.3 (M+H)+], Cou343-GRK(NH2)-amide 3.25 [Exact Mass calculated: 626.3, found: 626.3 
(M+H)+], TAM-GRK(NH2)-amide 3.26 [Exact Mass calculated: 771.4, found: 771.4 (M+H)
+].   
 
Photolysis Protocol The photolabile peptide 3.16 (1 μM) was incubated in a 1:1 solution of 
DMSO/H2O containing 1 mM dithiothreitol and 25 mM Tris pH 7.4 buffer. An aliquot was 
removed to collect a base line fluorescence measurement using a Photon Technology QM-4 
spectrofluorimeter (Birmingham, NJ). The aliquot was returned to stock solution and mixed 
thoroughly. The sample was then photolyzed using 290 nm to 390 nm (365 nm maximum light 
intensity) light by an Oriel Hg arc lamp (power supply model 69907 with a 200 Watt Hg lamp, 
NewPort, North Billerica, MA) using a UG.1 UV bandpass filter (Newport, North Billerica, MA) 
at various time points at room temperature. After the photolysis period, an aliquot was removed 
and the fluorescence of the photolyzed material determined. This cycle was repeated until three 
consecutive fluorescence measurements remained constant to establish a maximum fluorescence 
enhancement. 
 
Trypsin Protocol Peptides 3.7 – 3.14 (1 μM) were incubated in 25 mM Tris pH 7.4 buffer 
containing 1 mM dithiothreitol in a 200 μL quartz cuvette at 30 ˚C. After 5 min, a fluorescent 
baseline was collected using a Photon Technology QM-4 spectrofluorimeter (Birmingham, NJ). 
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Once a stable baseline had been established, 2 µL of trypsin (50 µM) was added and the 
fluorescence enhancement was monitored.  
 
Characterization Data 
 
Mass Spectrometry Data 
 
 
 
Figure 3.8: HRMS of cAB40 3.7: m/z calc’d for C22H15N2O7S- [M-]: 451.0605, m/z found: 
451.0607.  
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AB40 (negative ion mode, accurate mass; detail of preceding spectrum): 
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Assignments of additional confirmatory peaks: 
m/z  formula  r+db  measurement error (ppm) assignment 
407.0702 C21H15O5N2S  15.5  -1.168    [M-H-CO2]
-
 
903.1274 C44H31O14N4S2  31.5  -1.103    [2M-H]
- 
925.1095 C44H30O14N4S2Na 31.5  -0.855    [2M-2H+Na]
-
 
941.0831 C44H30O14N4S2K 31.5  -1.177    [2M-2H+K]
-
 
961.1804 C46H37O14N6S2  31.5  -1.055    [2M-2H+NH4+CH3CN]
-
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Figure 3.9: MALDI-TOF (alpha cyano-4-hydroxycinnaminic acid, mono-isotopic) of DECou-
GRK(AB40)-amide 3.10: m/z calc’d for C50H57N11O12S [M+H]+: 1035.391, m/z found: 
1035.355.  
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Figure 3.10: MALDI-TOF (alpha cyano-4-hydroxycinnaminic acid, mono-isotopic) of Cou343-
GRK(AB40)-amide 3.11: m/z calc’d for C50H57N11O12S [M+H]+: 1059.391, m/z found: 1059.351 
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Figure 3.11: MALDI-TOF (alpha cyano-4-hydroxycinnaminic acid, mono-isotopic) of FAM-
GRK(AB40)-amide 3.12: m/z calc’d for C57H54N10O15S [M+H]+: 1150.349, m/z found: 
1150.333. 
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Figure 3.12: MALDI-TOF (alpha cyano-4-hydroxycinnaminic acid, mono-isotopic) of TAM-
GRK(AB40)-amide 3.13: m/z calc’d for C61H65N12O13S [M+H]+: 1205.451, m/z found: 
1205.476. 
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Figure 3.13: MALDI-TOF (alpha cyano-4-hydroxycinnaminic acid, mono-isotopic) of atto610-
GRK(AB40)-amide 3.14: m/z calc’d for C61H73N12O10S [M+H]+: 1165.529, m/z found: 
1165.556. 
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Figure 3.14: MALDI-TOF (alpha cyano-4-hydroxycinnaminic acid, mono-isotopic) of atto700-
GRK(AB40)-amide 3.15: Unable to calculate exact mass due to unpublished atto 700 structure, 
m/z found: 1340.512. 
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Figure 3.15: MALDI-TOF (alpha cyano-4-hydroxycinnaminic acid, mono-isotopic) of TAM-
GRK(BHQ2)-amide 3.16: m/z calc’d for C128H150N31O22 [M+H]+: 1259.575, m/z found: 
1259.606. 
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Figure 3.16: MALDI-TOF (alpha cyano-4-hydroxycinnaminic acid, mono-isotopic) of TAM-
GRK(QSY7)-amide 3.17: m/z calc’d for C78H84N13O11S [M+H]+: 1410.613, m/z found: 
1410.612. 
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Figure 3.17: MALDI-TOF (alpha cyano-4-hydroxycinnaminic acid, mono-isotopic) of TAM-G-
Ø-K(AB40)-amide 3.18: m/z calc’d for C78H84N13O11S [M+H]+: 1329.456, m/z found: 1329.427. 
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Figure 3.18: ESI(+)-QMS of DEAC-GRK(NH2)-amide 3.23: m/z calc’d for C28H44N9O6+ [M]+: 
602.3, m/z found: 602.3. 
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Figure 3.19: ESI(+)-QMS of NH2-GRK(cAB40)-amide 3.24: m/z calc’d for C36H45N10O9S+ 
[M]+: 793.3, m/z found: 793.3 
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Figure 3.20: ESI(+)-QMS of Cou343-GRK(NH2)-amide 3.25: m/z calc’d for C30H44N9O6+ [M]+: 
626.3, m/z found: 626.3. 
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Figure 3.21: ESI(+)-QMS of TAM-GRK(NH2)-amide 3.26: m/z calc’d for C39H51N10O7+ [M]+: 
771.4, m/z found: 771.4. 
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Figure 3.22: 13C NMR (400 MHz, CDCl3) of cAB40 3.7 
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Figure 3.23: 1H NMR (400 MHz, DMSO-d6) of cAB40 3.4 
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Assessments of Purity 
 
Assessments of purity of DECou-GRK(AB40)-amide 3.10 
Figure 3.24: RP-HPLC injection of DECou-GRK(AB40)-amide 3.10 on a 250 mm x 4.6 mm, 
5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear acetonitrile to 
water gradient over 35 min. A small amount of DMSO was present in the sample, which eluted 
at 3 min. 
 
 
Figure 3.25: RP-HPLC injection of DECou-GRK(AB40)-amide 3.10 on a Restek Viva 50 mm x 
2.1 mm, 5μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear 
acetonitrile to water gradient over 20 min. 
 
 
 
Assessments of purity of Cou343-GRK(AB40)-amide 3.11 
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Figure 3.26: RP-HPLC injection of Cou343-GRK(AB40)-amide 3.11 on an Alltech Apollo 250 
mm x 4.6 mm, 5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 35 min.  
 
 
Figure 3.27: RP-HPLC injection of Cou343-GRK(AB40)-amide 3.11 on a Restek Viva 50mm x 
2.1 mm, 5μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear 
acetonitrile to water gradient over 20 min. 
 
 
 
Assessments of purity of FAM-GRK(AB40)-amide 3.12 
 
Figure 3.28: RP-HPLC injection of FAM-GRK(AB40)-amide 3.12 on an Alltech Apollo 250 
mm x 4.6 mm, 5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 35 min. DMSO was present in the sample, which eluted at 3 
min. 
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Figure 3.29: RP-HPLC injection of FAM-GRK(AB40)-amide 3.12 on a Restek Viva 50 mm x 
2.1 mm, 5μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear 
acetonitrile to water gradient over 20 min. 
 
 
 
Assessments of purity of TAM-GRK(AB40)-amide 3.13 
 
Figure 3.30: RP-HPLC injection of TAM-GRK(AB40)-amide 3.13 on an Alltech Apollo 250 x 
4.6 mm, 5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 35 min.  
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Figure 3.31: RP-HPLC injection of TAM-GRK(AB40)-amide 3.13 on a Restek Viva 50 x 2.1 
mm, 5μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear acetonitrile 
to water gradient over 30 min. 
 
 
Assessments of purity of atto610-GRK(AB40)-amide 3.14 
 
Figure 3.32: RP-HPLC injection of atto610-GRK(AB40)-amide 3.14 on an Alltech Apollo 250 
x 4.6 mm, 5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 35 min.  
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Figure 3.33: RP-HPLC injection of atto610-GRK(AB40)-amide 3.14 on a Restek Viva 50 mm x 
2.1 mm, 5μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear 
acetonitrile to water gradient over 30 min. 
 
 
 
Assessments of purity of atto700-GRK(AB40)-amide 3.15 
 
Figure 3.34: RP-HPLC injection of atto700-GRK(AB40)-amide 3.15 on an Alltech Apollo 250 
mm x 4.6 mm, 5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 35 min.  
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Figure 3.35: RP-HPLC injection of atto700-GRK(AB40)-amide 3.15 on a Restek Viva 50 mm x 
2.1 mm, 5μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear 
acetonitrile to water gradient over 30 min. 
 
 
 
 
Assessments of purity of TAM-GRK(BHQ-2)-amide 3.16 
 
Figure 3.36: RP-HPLC injection of TAM-GRK(BHQ-2)-amide 3.16 on an Alltech Apollo 250 
mm x 22 mm, 5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 90 min. DMSO was present in the sample, which eluted at 7 
min. 
 
 
Figure 3.37: RP-HPLC injection of TAM-GRK(BHQ-2)-amide 3.16 on a Restek Viva 50 mm x 
2.1 mm, 5 μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear 
acetonitrile to water gradient over 30 min. 
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Assessments of purity of TAM-GRK(QSY7)-amide 3.17 
 
Figure 3.38: RP-HPLC injection of TAM-GRK(QSY7)-amide 3.17 on an Alltech Apollo 250 
mm x 22 mm, 5 μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 90 min. DMSO was present in the sample, which eluted at 7 
min. 
 
 
Figure 3.39: RP-HPLC injection of TAM-GRK(QSY7)-amide 3.17 on a Restek Viva 50 mm x 
2.1 mm, 5 μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear 
acetonitrile to water gradient over 30 min. 
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Assessments of purity of TAM-G-PL-K(AB40)-amide 3.18 
 
Figure 3.40: RP-HPLC injection of TAM-G-PL-K(AB40)-amide 3.18 on an Alltech Apollo 250 
mm x 4.6 mm, 5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 35 min.  
 
 
 
Figure 3.41: RP-HPLC injection of TAM-G-PL-K(AB40)-amide 3.18  on a Restek Viva 50 mm 
x 2.1 mm, 5μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear 
acetonitrile to water gradient over 20 min. 
 
 
Assessments of purity of DEAC-GRK(NH2)-amide 3.23 
 
Figure 3.42: RP-HPLC injection of DEAC-GRK(NH2)-amide 3.23 on an Alltech Apollo 50 mm 
x 2.1 mm, 5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 12 min.  
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Figure 3.43: RP-HPLC injection of TAM-G-PL-K(AB40)-amide 3.23 on a Restek Viva 50 mm 
x 2.1 mm, 5μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear 
acetonitrile to water gradient over 12 min. 
 
 
 
 
 
Assessments of purity of NH2-GRK(cAB40)-amide 3.24 
 
Figure 3.44: RP-HPLC injection of NH2-GRK(cAB40)-amide 3.24 on an Alltech Apollo 50 mm 
x 2.1 mm, 5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 12 min.  
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Figure 3.45: RP-HPLC injection of NH2-GRK(cAB40)-amide 3.24 on a Restek Viva 50 mm x 
2.1 mm, 5μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear 
acetonitrile to water gradient over 12 min. 
 
 
 
Assessments of purity of Cou343-GRK(NH2)-amide 3.25 
 
Figure 3.46: RP-HPLC injection of Cou343-GRK(NH2)-amide 3.25 on an Alltech Apollo 50 
mm x 2.1 mm, 5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 12 min.  
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Figure 3.47: RP-HPLC injection of Cou343-GRK(NH2)-amide 3.25 on a Restek Viva 50 mm x 
2.1 mm, 5μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear 
acetonitrile to water gradient over 12 min. 
 
 
 
Assessments of purity of TAM-GRK(NH2)-amide 3.26 
 
Figure 3.48: RP-HPLC injection of TAM-GRK(NH2)-amide 3.26 on an Alltech Apollo 50 mm x 
2.1 mm, 5μm C18 column. The injection was monitored at 220 nm using a 0 - 97% linear 
acetonitrile to water gradient over 12 min.  
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Figure 3.49: RP-HPLC injection of TAM-GRK(NH2)-amide 3.27 on a Restek Viva 50 mm x 2.1 
mm, 5μm C4 column. The injection was monitored at 220 nm using a 0 – 97% linear acetonitrile 
to water gradient over 12 min. 
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CHAPTER 4 
CONSTRUCTION OF A NANOPARTICLE-BASED SENSOR FOR cAMP-
DEPENDENT PROTEIN KINASE ACTIVITY 
(Reproduced with permission from unpublished results from Jernigan, F. E., Oien, N., Priestman, 
M., Sharma, V., Agnes, R., and Lawrence, D. S.) 
 
INTRODUCTION 
 
Protein kinases play a large role in the regulation of cellular processes via 
phosphorylation including mitosis,1 proliferation,2 survival,3 death,4 and metabolism.5 Many of 
these processes are regulated in a spatial fashion with precise control required for many cellular 
functions. For examples, the cyclic-AMP dependent protein kinase (PKA) is intimately related in 
the regulation of cell death and survival near the mitochondria.6 For the study of PKA’s role in 
apoptosis, we have previously developed a kinase 
                                                 
1 (1) Lapenna, S.; Giordano, A. Nature reviews. Drug discovery 2009, 8, 547–66. (2) Strebhardt, K. Nature reviews. 
Drug discovery 2010, 9, 643–60. 
 
2 Romeo, Y.; Zhang, X.; Roux, P. P. The Biochemical journal 2012, 441, 553–69. 
 
3 Horbinski, C.; Chu, C. T. Free radical biology & medicine 2005, 38, 2–11. 
 
4 Orrenius, S. Toxicology letters 2004, 149, 19–23. 
 
5 Michel, J. J. C.; Scott, J. D. Annual review of pharmacology and toxicology 2002, 42, 235–57. 
 
6 See discussion and references in Chapter 1: Introduction.  
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sensor which includes an extraordinary dynamic range.7 This sensor was used to elucidate the 
suborganellular distribution of mitochondrial PKA activity in fractionated mitochondria. But the 
system suffers from three major drawbacks that limit its use intracellularly: (1) the photophysical 
properties of the fluorophores used are not ideal for microscopy, (2) the reliance on multiple 
chemical components (i.e. binding a 14-3-3τ domain) to produce a fluorescence enhancement, 
and (3) delivery of the biosensor to cytoplasm and/or the surface of the mitochondria. Modifying 
the photophysical properties of the sensor should be as simple as changing the fluorophore and 
rescreening the resulting peptide against a series of dyes to find a sensor that displays a large 
fluorescent enhancement upon phosphorylation. However, removing the 14-3-3τ dependence is a 
larger problem. One way to solve the problem may be covalently attaching 14-3-3τ to a 
fluorescently labeled PKA consensus sequence, along with the attachment of a quencher. The 
                                                 
7 Agnes, R. S.; Jernigan, F.; Shell, J. R.; Sharma, V.; Lawrence, D. S. Journal of the American Chemical Society 
2010, 132, 6075–80. 
 
Scheme 3.2 Reproduced from Chapter 3 of this work. Structure of Acid Blue 40 (AB40) 3.4 
and synthesis of carboxy Acid Blue 40 (cAB40) 3.7. 
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quencher Acid Blue 40 has been modified to include a carboxylic acid capable of covalent 
attachment (Scheme 3.2). Another method would include screening a variety of quenchers for 
14-3-3τ-independent behavior. This is the more attractive solution, since the chemistry of 14-3-
3τ-independent sensor would be more straightforward. Yet even if the biosensor synthesis is 
straightforward, delivery to the cytoplasm also remains a major issue. Luckily, much work has 
been described in this area. Cytoplasmic delivery of biomolecules has been accomplished using 
the HIV-1 TAT sequence,8 mitochondrial-penetrating peptides,9 lipid anchors10 and 
nanoparticles.11 Using one of these four methods, cytoplasmic delivery of our unimolecular PKA 
biosensor should be possible. Following this direction, we have made significant progress 
towards the construction of a unimolecular PKA sensor for intracellular use. 
 
                                                 
8 (1) Fröbel, J.; Rose, P.; Müller, M. Philosophical transactions of the Royal Society of London. Series B, Biological 
sciences 2012, 367, 1029–46. (2) Sawant, R.; Torchilin, V. Molecular bioSystems 2010, 6, 628–40. 
 
9 (1) Kelley, S. O.; Stewart, K. M.; Mourtada, R. Pharmaceutical research 2011, 28, 2808–19. (2)  Pereira, M. P.; 
Kelley, S. O. Journal of the American Chemical Society 2011, 133, 3260–3. (3) Horton, K. L.; Pereira, M. P.; 
Stewart, K. M.; Fonseca, S. B.; Kelley, S. O. Chembiochem : a European journal of chemical biology 2012, 13, 
476–85. 
 
10 Rajendran, L.; Udayar, V.; Goodger, Z. V. Trends in pharmacological sciences 2012, 33, 215–22. 
 
11 (1) Elsabahy, M.; Wooley, K. L. Chemical Society reviews 2012, 41, 2545–61. (2) Kamaly, N.; Xiao, Z.; 
Valencia, P. M.; Radovic-Moreno, A. F.; Farokhzad, O. C. Chemical Society reviews 2012, 41, 2971–3010. 
 
Scheme 4.1 Structure of TAMRA labeled PKA substrate. Peptide contains a PKA consensus 
sequence with a 5’-TAMRA fluorophore attached to the N-terminus via an aminooctanoic 
acid linker. 
4.1 
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RESULTS AND DISCUSSION 
 
The most important steps toward intracellular use of the PKA biosensor relies on: (1) 
removing the dependence on 14-3-3τ to produce a fluorescent enhancement and (2) improving 
the photophysical properties of the fluorophore. We chose the fluorophore 5’-TAMRA (TAM) 
since it is red-shifted and relatively bright when compared with fluorophores of the previous 
system coumarin-based “deep quench” system (see Chapter 2). A TAM labeled substrate was 
synthesized using solid phase peptide synthesis, including a PKA consensus sequence, an 
Figure 4.1 PKA sensor fold enhancements using the quencher Acid Blue 40. Assay in the 
presence of 150 mM KCl buffer containing Tris pH 7.4 Buffer (Red), 1 mM KCl buffer 
containing Tris pH 7.4 Buffer (Black), 150 mM KCl buffer containing Tris pH 7.4 Buffer in 
the presence of H-89 (100 μM). 
4.1 
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aminooctanoic acid linker, and TAM attached to the N-terminus (Scheme 4.1). A C-terminal 
proline, which is required for binding to the 14-3-3τ domain was not included. This peptide was 
screened in the presence of 48 negatively charged dyes (Table 2.3) for 14-3-3τ independent 
behavior. Of these 48 dyes, the quenchers Acid Blue 40 and Aniline Blue yielded the largest 
fluorescent enhancement upon phosphorylation (respectively, 12-fold and 14-fold). Thorough 
further development of the assay, we were able to increase the fold enhancement to 25-fold 
(Figure 4.1). This was accomplished by optimization of the MgCl2 concentration (changed from 
5 mM to 1 mM, which is more physiologically relevant) and increased purification of the 
substrate peptide. We observed slowly decreasing fold enhancements as the peptide aged. 
However, purification via reverse-phase HPLC would restore the fold enhancement back to the 
maximum observed immediately after the synthesis of the peptide. 
 
We then attempted to attach the dye to the peptide directly, anticipating that 
phosphorylation of the peptide would still produce a fluorescent enhancement. Since the 
modification of Acid Blue 40 to an analog capable of covalent attachment had been previously 
 
Scheme 4.2 Structure of PKA biosensor peptide including cAB40. The PKA consensus 
sequence was modified to include an N-terminal aminooctanoic acid covalently attached to the 
fluorophore TAMRA and C-terminal lysine covalently attached to the fluorescent Quencher 
AB40.  
4.2 
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accomplished (see chapter 3 of this work), a peptide containing the TAMRA and cAB40 was 
synthesized (Scheme 4.3). However, when this peptide was phosphorylated, no fluorescent 
enhancement was observed. Although this result was not completely unexpected, it is 
unsurprising since the overlap between the TAMRA emission and fluorophore (Figure 3.4), 
making the mechanism of quenching likely due to a through space mechanism. Since the cAB40 
quencher and TAMRA fluorophore are attached to the peptide (where distances are measured in 
angstroms), perhaps they are not capable moving far enough away to create any noticeable 
change in quenching after phosphorylation. We hypothesized the TAMRA fluorophore and 
AB40 quencher would be required to be placed further apart to produce any noticeable change in 
fluorescence after phosphorylation.  
Many strategies exist for increasing the distance between the PKA substrate and cAB40 
quencher. We chose to pursue a strategy of covalent attachment to amine functionalized silica 
nanoparticles and hypothesized that this would allow a population of TAMRA labeled peptides 
to move further away from the cAB40 quencher, and enable the system to produce a fluorescent 
enhancement despite covalent attachment.  As an added benefit, nanoparticles have the added 
 
Scheme 4.3 Labeling of 90 nm silica nanoparticles with a fluorescent PKA substrate.  Silica 
nanoparticles (90 nm diameter) were first amine derivatized by refluxing with 3-
aminopropyltrimethoxysilane in toluene. Amines were then acylated using a modified 
fluorescent PKA substrate.  
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advantage of improved cytoplasmic delivery.11 However, before constructing a nanoparticle 
containing both the fluorescent substrate and cAB40 quencher, we chose to investigate the 
interaction of silica nanoparticles labeled with a TAMRA labeled PKA substrate with free AB40 
3.4. Nanoparticles were synthesized by first derivatizing the surface of silica nanoparticles (90 
nm diameter) to contain free amines using 3-aminopropyltrimethoxysilane (Scheme 4.4). Free 
amines on the nanoparticle surface were then acylated with carboxy derivatized PKA substrate 
4.3 using EDC in H2O to yield the PKA substrate-labeled nanoparticles 4.4. 
 
Initially, we were concerned about TAMRA self-quenching on the silica nanoparticle 
surface. Nanoparticles 4.4 were diluted to various concentrations in buffer and the fluorescence 
was measured (Figure 4.2). At increasing concentration of nanoparticles, fluorescence does not 
increase linearly, indicating what is likely self-quenching. This is to be expected as TAMRA is 
known to self-quench at high concentrations. However, at lower concentrations, the fluorescence 
0.E+00
2.E+04
4.E+04
6.E+04
8.E+04
1.E+05
1.E+05
0 0.01 0.02 0.03
F
lu
o
re
s
c
e
n
c
e
[] SiO2 Nanoparticles (mg/mL)
Figure 4.2 Beer’s law plot of PKA-labeled SiO2 Nanoparticles. The fluorescence was 
measured an increasing concentrations of nanoparticles. Error bars are present, however they 
may be too small to observe.   
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does appear to increase linearly. Next, quenching of PKA substrate-labeled nanoparticles 4.4 
upon addition of AB40 3.4 was investigated (Table 4.1). Quenching of the PKA substrate-
labeled nanoparticles 4.4 (0.005 mg/mL) increased upon each addition of AB40 3.4, with a 
maximum 22-fold quench at 48 uM AB40 3.4. While a 22-fold quench is not as deep as the 
system with free PKA substrate, if half the fluorescence could be recovered upon 
phosphorylation, the system would be very promising. 
 
To create a unimolecular system, we attached both the modified PKA substrate 4.3 and 
the cAB40 quencher 3.7 to the surface of 90 nm silica nanoparticles (Scheme 4.5). First, the 
surface of silica nanoparticles (90 nm diameter) was derivatized to contain free amines using 3-
aminopropyltrimethoxysilane. As we were unsure what concentration of cAB40 on the surface 
would create an optimum fluorescence upon phosphorylation, a 32-member combinatorial 
library was constructed by varying the concentration of PKA substrate and cAB40 with respect 
[] AB40 3.4 (μM) % quench Fold Quench 
0 0 1.0 
6 74 3.9 
12 83 6.0 
18 88 8.5 
24 90 10.0 
32 92 12.6 
36 93 14.9 
42 95 18.3 
48 95 21.7 
 
Table 4.1 Quenching observed after addition of AB40 quencher to PKA-substrate labeled 
nanoparticles in buffer. 
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to the number of free amines present on the surface of 1 mg of nanoparticles (see Materials and 
Methods). Nanoparticles were then screened for the highest fluorescent enhancement upon 
phosphorylation. The 300:10:1 (quencher : PKA substrate : amine) and 240:10:1 (quencher : 
PKA substrate : amine) ratios had the largest dynamic range of 2.2-fold and 2.1-fold, 
respectively. To prove the fluorescent enhancement was enzyme dependent, the assay was run in 
the presence and absence of PKA, and showed an enchantment only in the presence of enzyme 
(Figure 4.3).  
While a 2.2-fold enhancement is greater than most GFP-based fluorescent reporters (see 
introduction) it is not as dramatic as the 35-fold enhancement we observed with the free PKA 
 
Scheme 4.4 Construction of Unimolecular PKA sensor 4.5.  Silica nanoparticles (90 nm 
diameter) were first amine derivatized by refluxing with 3-aminopropyltrimethoxysilane in 
toluene. Amines were then acylated using a modified fluorescent PKA substrate 4.3 and the 
quencher cAB40 3.7.  
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substrate 4.2 and the AB40 quencher 3.4. With a 2.2-fold fluorescence enhancement, it is 
questionable whether the sensor could be used for sensitive measurements of PKA activity. With 
this in mind, we tested the sensitivity of the 300:10:1 (quencher 3.7 : PKA substrate 4.3 : amine) 
sensor. The sensor appears to be concentration dependent (Figure 4.4). While the biosensor does 
display enzyme dependence, its utility has only been demonstrated in vitro. In biological 
samples, thousands of various cellular components could limit the fluorescent response. As a 
result, we chose to demonstrate the effects of high salt concentrations which we thought could 
potentially disrupt the interaction between the fluorescent substrate and quencher. The 
fluorescent enhancement of the 300:10:1 (quencher : PKA substrate : amine) PKA biosensor was 
investigated at high salt concentrations (Figure 4.5). High salt concentration did have an effect 
on the fluorescent enhancement of the assay, reducing the fluorescent enhancement upon 
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Figure 4.3 Fluorescent enhancement of 240:10:1 (quencher 3.7: PKA substrate 4.3 : 
nanoparticle amine) SiO
2
 nanoparticles in the presence (Blue) and absence of PKA (Red). 
Assay was initiated via PKA addition at 40s.  
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phosphorylation from 2.2-fold (1 mM KCl) to 1.8-fold (150 mM KCl) to 1.4-fold (300 mM 
KCl). While this is disappointing, it is not unexpected, since the PKA substrate peptide and 
AB40 quencher are both highly charged, making interference from high salt concentrations 
likely.  
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Figure 4.4 Fluorescent enhancements of the 300:10:1 (quencher 3.4 : PKA substrate 4.6: 
nanoparticle amine) sensor at 20 nM (Red), 15 nM (Orange), 10 nM (Green), 5 nM (Blue), 
and 0 nM (Purple) of PKA. PKA-C addition initiated the reaction at 30 seconds. 
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Figure 4.5 PKA nanoparticle (300  : 10 : 1, Quencher : Peptide : Amine) assays performed 
with 1 mM KCl (A, 2.2-fold), 150 mM KCl (B, 1.8-fold), and 300 mM KCl (C, 1.4-fold) 
containing Tris pH 7.4 buffer. 
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CONCLUSIONS 
 
Significant progress has been made toward the creation of a unimolecular sensor for PKA 
activity. The synthesis and purification of the SiO2 nanoparticle biosensor is relatively straight-
forward. The biosensor shows enzyme-dependent fluorescent enhancements using a robust 
fluorophore with good photophysical properties. High concentrations of salt do have a negative 
effect, but do not completely eliminate the fluorescent response, suggesting further experiments 
with biological samples may be successful. As an additional benefit, the nanoparticle-based 
structure should facilitate delivery to the cytoplasm. However, further development of this assay 
is necessary before intracellular use should be attempted, particularly to further increase the 
robustness of the fluorescent response upon phosphorylation.  
 
MATERIALS AND METHODS 
 
General reagents and solvents were purchased from Fisher or Sigma-Aldrich. Novasyn TGR 
Resin, Fmoc-Lys(Mtt)-OH (N-α-Fmoc-N-ε-4-methyltrityl-L-lysine), and all Fmoc protected 
natural amino acids were purchased from EMD Biosciences Inc. HCTU [1H-benzotriazolium-1 
[bis(dimethylamino)methylene]-5-chloro-hexaﬂuorophosphate (1),3-oxide] and Fmoc-Aoc-OH 
(N-α-Fmoc-octanoic acid) was purchased from Peptides International (Louisville, KY, U.S.A.). 
5’-TAMRA (5-carboxytetramethylrhodamine) was purchased from Chempep, Inc. (Wellington, 
Fl, U.S.A). Flash Chromatography was performed on a Biotage (Charlotte, N.C., U.S.A.) Isolera 
One System using a 120 gram C18 reverse phase column. The catalytic subunit of the cyclic-
AMP dependent Protein Kinase was purchased from Promega. Bulk silica nanoparticles (90 nm 
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in diameter) and 3-aminopropyltrimethoxysilane (APTMS) were purchased from Sigma-Aldrich. 
 
Peptide Synthesis. (Including Rhodamine PKA Substrate RhAocGRTGRRFSY-amide and 
modified substrate RhAocGRTGRRFSYE-amide) The peptide was synthesized using standard 
Fmoc solid-phase synthesis on a Prelude peptide synthesizer (Protein Technologies Inc., Tucson, 
AZ, U.S.A.). Briefly, Novasyn TGR resin was swelled for 30 min in DCM before synthesis. The 
first Fmoc-protected AA was then coupled using 5.0 equiv AA, 4.9 equiv of HCTU, 20 equiv of 
diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF) (2 × 5 min) followed by a 
DMF wash (6 × 30 s). The Fmoc-protecting group was removed using 20% piperidine in DMF 
(5 × 2.5 min) followed by a DMF wash (6 × 30 s). The remaining amino acids were then to the 
free N-terminus of the peptide using the conditions described for the coupling and deprotection 
of Fmoc-Tyr-OH. The N-terminal Fmoc was then removed using 20% piperidine in DMF (5 × 
2.5 min) and the 5-TAM fluorophore was coupled using 5.0 equiv of ﬂuorophore, 4.9 equiv of 
HCTU, and 20 equiv of DIPEA in DMF (1× 60 min) followed by a wash (3× DMF, IPA, DCM). 
After fluorophore coupling, the peptides were cleaved from the resin and deprotected using a 
95:2.5:2.5 TFA:H2O:triisopropylsilane (TIPS) cleavage cocktail. The peptides were isolated via 
ﬁltration, precipitated with ice-cold ether, and centrifuged. The precipitates were air-dried, 
dissolved in DMSO, and puriﬁed using HPLC (3% to 95% acetonitrile to water gradient with 
0.1% TFA over 30 min using a 250 mm x 21.2 mm C18 column). The peak corresponding to the 
peptide was collected, freeze-dried, and characterized by electrospray ionization mass 
spectrometry: TAM-Aoc-GRTGRRFSY-amide 1 [Exact Mass calculated: 1651.85, found: 826.9 
(M+2H)2+], TAM-Aoc-GRTGRRFSYK(AB40)-amide 2 [Exact Mass calculated: 2211.99, 
found: 1107.2 (M+2H)2+], TAM-Aoc-GRTGRRFSYE-amide 3 [Exact Mass calculated: 1779.88, 
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found: 890.8 (M+2H) 2+].  
 
Synthesis of Nanoparticle-based PKA sensor. A 32-member combinatorial library was 
constructed with various concentrations of peptide 4.3 and quencher 3.4, and 1 mg/mL amine 
functionalized SiO2 nanoparticles (90 nm). Nanoparticles (1 mg/mL, 50 mL) were refluxed with 
3-aminopropyltrimethoxysilane (2 mL, 8.5 mmol) in toluene overnight. The nanoparticles were 
then washed with MeOH (3x) and then DMF (3x). The number of amines per mg of 
nanoparticles was determined using the Kaiser test followed by quantitation via absorbance at 
570 nm. Following the quantitation of amines, a 32-member library was constructed by varying 
the ratio of Quencher 3.4 and Peptide 4.3 to the number of amines contained in 1 mg of 
nanoparticles. An example reaction (10 : 1 : 1) would include 1 mM Quencher 3.4, 100 μM 
Peptide 4.3, and 100 μM free nanoparticle amine in 1 mL DMF. Also included would be 20 eq. 
PyBOP, 20 eq. HOBT, and 100 eq. DIPEA (with respect to free amine concentration). After 
shaking overnight, each reaction would be washed (3 x DMF) then resuspended in H2O (1 mL).  
 
 
Table 4.2 Unimolecular PKA biosensor library constructed by varying the concentration of 
Quencher 3.4 and Peptide 4.3 versus the number of free amines determined via the Kaiser 
test. 
1 Peptide : 1 Amine 10 Peptide : 1 Amine 100 Peptide : 1 Amine
Quencher 3.7 Peptide 4.3 NP Amine Quencher 3.7 Peptide 4.3 NP Amine Quencher 3.7 Peptide 4.3 NP Amine
10 1 1 10 10 1 10 100 1
20 1 1 20 10 1 20 100 1
40 1 1 40 10 1 40 100 1
80 1 1 80 10 1 80 100 1
160 1 1 160 10 1 160 100 1
240 1 1 240 10 1 240 100 1
360 1 1 360 10 1 360 100 1
480 1 1 480 10 1 480 100 1
Quencher 3.7 : Peptide 4.3 : Nanoparticle Amine
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The Cyclic-AMP Dependent Protein Kinase Assay. Peptide 4.1 or 4.2 (1 μM) was incubated 
with 1 mM ATP, 1 mM DTT, 1 mM MgCl2, 1 mM KCl, and 25 mM Tris-HCl at pH 7.4 in a 
quartz cuvette. To the cuvette including peptide 4.1 or 4.2 (1 μM), the dye Acid Blue 40 3.4 (30 
μM) was added followed by 10 nM PKA. Additional assays were performed with peptide 4.1, 
including an assay including 150 mM KCl and 100 μM of the PKA inhibitor H-89. To the 
cuvette including peptide 4.2, no dye was added followed by 10 nM PKA. Enzyme-dependent 
enhancement in fluorescence (λex 550 nm, λem 580 nm) was determined with each system using a 
Photon Technology QM-4 spectrofluorimeter (Birmingham, NJ). 
 
Quenching Quantitation using substrate-labeled Nanoparticles. Nanoparticles (4.4, 0.005 
mg/mL) were incubated with 1 mM ATP, 1 mM DTT, 1 mM MgCl2, 1 mM KCl, and 25 mM 
Tris-HCl (total volume 196 μL) at pH 7.4 in a quartz cuvette. Acid Blue 40 was added in 6 μM 
increments (0.5 μL per addition to 200 uL final volume, 2.4 mM stock solution).  Fluorescence 
(λex 550 nm, λem 580 nm) was determined using a Photon Technology QM-4 spectrofluorimeter 
(Birmingham, NJ). 
 
The Nanoparticle-based cyclic-AMP Dependent Protein Kinase Assay. Nanoparticles (4.5) 
(0.005 mg/mL) were incubated with 1 mM ATP, 1 mM DTT, 1 mM MgCl2, 1 mM KCl, and 25 
mM Tris-HCl at pH 7.4 in a quartz cuvette. The catalytic subunit of PKA (0 to 20 nM) was 
added to initiate the reaction. Additional assays were performed with the nanoparticles, including 
an assay including 150 mM and 300 mM KCl (Figure 4.11). Enzyme-dependent enhancement in 
fluorescence (λex 550 nm, λem 580 nm) was determined with each system using a Photon 
Technology QM-4 spectrofluorimeter (Birmingham, NJ). 
CHAPTER 5 
SYNTHESIS AND DEVELOPMENT OF FLUORESCENT BIOSENSORS FOR 
THE PROTEASOME 
 
INTRODUCTION 
 
It has become clear that the future of cancer chemotherapy rests in the inhibition of entire 
abnormal pathways via multiple inhibitors as part of a chemotherapy cocktail.1 As abnormal 
signal transduction via the ubiquitin-proteasome system is a known to play a role in numerous 
cancers,2 proteasome inhibitors have been included in various cocktails. For example, a 
chemotherapy cocktail currently under investigation consist of inhibitors of the proteasome and 
histone deacetylases (HDAC).3 While this inhibitor cocktail has been demonstrated to be 
                                                 
1 Grant, S. Best practice & research. Clinical haematology  2008, 21, 629–37. 
 
2 (1) Grande, E.; Earl, J.; Fuentes, R.; Carrato, A. Expert review of anticancer therapy 2012, 12, 457–67. (2) Dalla 
Via, L.; Nardon, C.; Fregona, D. Future medicinal chemistry 2012, 4, 525–43. (3) Rahimi, N. Molecular cancer 
therapeutics 2012, 11, 538–48. (4) Yang, H.; Zonder, J. A.; Dou, Q. P. Expert opinion on investigational drugs 
2009, 18, 957–71. 
 
3  (1) Emanuele, S.; Lauricella, M.; Carlisi, D.; Vassallo, B.; D’Anneo, a; Di Fazio, P.; Vento, R.; Tesoriere, G. 
Apoptosis : an international journal on programmed cell death 2007, 12, 1327–38. (2) Hideshima, T.; Chauhan, D.; 
Richardson, P.; Mitsiades, C.; Mitsiades, N.; Hayashi, T.; Munshi, N.; Dang, L.; Castro, A.; Palombella, V.; Adams, 
J.; Anderson, K. C. The Journal of biological chemistry 2002, 277, 16639–47. (3) Catley, L.; Weisberg, E.; 
Kiziltepe, T.; Tai, Y.; Hideshima, T.; Neri, P.; Tassone, P.; Atadja, P.; Chauhan, D.; Munshi, N. C.; Anderson, K. C. 
2006, 108, 3441–3449. (4) Place, R. F.; Noonan, E. J.; Giardina, C. Biochemical pharmacology 2005, 70, 394–406. 
(5) Dai, Y.; Chen, S.; Kramer, L. B.; Funk, V. L.; Dent, P.; Grant, S. Clinical cancer research : an official journal of 
the American Association for Cancer Research 2008, 14, 549–58. 
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effective, little is known about the mechanism of action. Partly this is due to the lack of readily 
available tools to monitor the activities of HDACs and the ubitiquin-proteasome system. Due to 
this, new assays capable of monitoring multiple catalytic activities of the ubiquitin-proteasome 
system should be a high priority in the field. It is important that the assays be continuous, 
capable of use in parallel and, eventually, intracellularly using confocal microscopy. Also, the 
assays must be capable of observer control via a photolabile protecting group (see Introduction 
for an in depth discussion). In this preliminary study, we chose to focus work on the 
development of biosensors for the Chymotrypsin-like (Ch-L) and Caspase-like activities (Ca-L) 
of the ubiquitin-proteasome system using a robust fluorophore compatible with confocal 
microscopy.  
It is important to understand the complexity of proteasome and the difficulties associated 
with proteasome assay development.  As discussed in Chapter 1, the 19S subunit of the 
proteasome contains three catalytic activities as a part of three different subunits: (1) the β2 
subunit trypsin-like activity (T-L), (2) the β5 subunit Ch-L activity, and (3) the β1 subunit Ca-L 
activity.4 Each active site is thought to be allosterically regulated,5 and the effect of one inhibitor 
on the other active sites is unknown, although there is some debate over this issue.6 Due to this, 
each subunit must be monitored simultaneously using an assay with different consensus 
sequence specificity. As discussed above (see Chapter 1), substrate recognition by the 19S 
proteasomal subunit occurs via an ubitiquin tag which is critically important for usual 
proteasome function. At first it was unclear whether peptide substrates of the proteasome would 
                                                 
4 (1) Finley, D. Annual review of biochemistry 2009, 78, 477–513. (2) Marques, A. J.; Palanimurugan, R.; Matias, A. 
C.; Ramos, P. C.; Dohmen, R. J. Chemical reviews 2009, 109, 1509–36. 
 
5 Kisselev, A. F.; Akopian, T. N.; Castillo, V.; Goldberg, A. L. Molecular cell 1999, 4, 395–402. 
 
6 Schmidtke, G.; Emch, S.; Groettrup, M.; Holzhutter, H. G. The Journal of biological chemistry 2000, 275, 22056–
63. 
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function as substrates unless tagged with ubitiquin and recognized by the 19S regulatory particle. 
Fortunately, while ubitiquin tags are necessary in some cases for substrate recognition, the 26S 
proteasome has been found to degrade nonubiquitylated, unstructured proteins in an ATP-
independent fashion.7 It has also been demonstrated that unstructured proteins are capable of 
entering the catalytic channel of the 26S proteasomal subunit via the C-terminus or N-terminus.8 
Nonubiquitylated, unstructured peptides should enter the 26S particle of the proteasome via the 
C-terminus or N-terminus and rapidly be cleaved.  
Fluorescent assays have previously been developed for each activity of the proteasome, 
yet each contains distinct disadvantages. Commercially available Ch-L9 and Ca-L10 proteasome 
assays included blue fluorophores not ideal for confocal microscopy. Further work has been done 
in the development of a Ch-L substrate using a far red fluorophore suitable for microscopy.11 
However, the Ca-L and T-L fluorescent substrates included Tryptophan or Histidine as a 
quencher and may not be applicable across the visible spectrum. In this work, we aimed to create 
Ca-L and Ch-L substrates with robust fluorophores while including a quenching moiety relevant 
                                                 
7 (1) Baugh, J. M.; Viktorova, E. G.; Pilipenko, E. V. Journal of molecular biology 2009, 386, 814–27. (2) Liu, C.-
W.; Li, X.; Thompson, D.; Wooding, K.; Chang, T.; Tang, Z.; Yu, H.; Thomas, P. J.; DeMartino, G. N. Molecular 
cell 2006, 24, 39–50. 
 
8 Berko, D.; Tabachnick-Cherny, S.; Shental-Bechor, D.; Cascio, P.; Mioletti, S.; Levy, Y.; Admon, A.; Ziv, T.; 
Tirosh, B.; Goldberg, A. L.; Navon, A. Molecular cell 2012 Oct 3, 1–11. 
 
9 (1)  Wong, D. J.; Nuyten, D. S. A.; Regev, A.; Lin, M.; Adler, A. S.; Segal, E.; van de Vijver, M. J.; Chang, H. Y. 
Cancer research 2008, 68, 369–78. (2) Huang, L.; Ho, P.; Chen, C.-H. FEBS letters 2007, 581, 4955–9. (3) 
Filimonenko, M.; Stuffers, S.; Raiborg, C.; Yamamoto, A.; Malerød, L.; Fisher, E. M. C.; Isaacs, A.; Brech, A.; 
Stenmark, H.; Simonsen, A. The Journal of Cell Biology 2007, 179, 485–500. (4) Gomez, A. M.; Vrolix, K.; 
Martínez-Martínez, P.; Molenaar, P. C.; Phernambucq, M.; van der Esch, E.; Duimel, H.; Verheyen, F.; Voll, R. E.; 
Manz, R. a; De Baets, M. H.; Losen, M. Journal of immunology (Baltimore, Md. : 1950) 2011, 186, 2503–13. (5) 
Sharma, M.; Burré, J.; Südhof, T. C. Science translational medicine 2012, 4, 147ra113. 
 
10 (1) Brooks, A. D.; Jacobsen, K. M.; Li, W.; Shanker, A.; Sayers, T. J. Molecular cancer research : MCR 2010, 8, 
729–38. (2) Cali, J. J.; Niles, A.; Valley, M. P.; O’Brien, M. A.; Riss, T. L.; Shultz, J. Expert opinion on drug 
metabolism & toxicology 2008, 4, 103–20. 
 
11 Wakata, A.; Lee, H.-M.; Rommel, P.; Toutchkine, A.; Schmidt, M.; Lawrence, D. S. Journal of the American 
Chemical Society 2010, 132, 1578–82. 
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across the visible spectrum.  
 
RESULTS AND DISCUSSION  
 
In this chapter, we describe the synthesis and specificity of proteasome sensors for the 
Ca-L and Ch-L subunit of the proteasome. A previously described Ch-L biosensor11 included 
excellent photophysical properties, proteasome-subunit specificity, and a large dynamic range. 
However, the Ch-L biosensor relied on tryptophan or histidine, which may not quench other 
fluorophores necessary to visualize all three catalytic activities of the proteasome. Instead, we 
applied our recently described dark quencher cAB40 (3.4, see chapter 3) which is known to 
deeply quench a wide variety of fluorophores. We chose the fluorophore 5’-TAMRA (5’-
carboxytetramethylrhodamine) as it is appropriate for microscopy (typically includes long 
λex/λem, large ε, and high Φ). 5’-TAMRA derivatives were synthesized for all preliminary work 
due to the expense of Atto or Dylight fluorophores.  
By applying known consensus sequences for the proteasomal subunit activities, a library 
was constructed using glycine as a linker to lysine residue acylated with fluorophore or 
quencher. Three optimized consensus sequences for each activity are: 
1) Trypsin-like (β2 subunit): NH2-LRR-COOH12 
2) Caspase-like (β1 subunit): NH2-nLPnLD-COOH13 
3) Chymotrypsin-like (β5 subunit) : NH2-HHSL-COOH14 
                                                 
12 Bogyo, M.; Shin, S.; McMaster, J. S.; Ploegh, H. L. Chemistry & Biology 1998, 5, 307–320. 
 
13 Kisselev, A. F.; Garcia-Calvo, M.; Overkleeft, H. S.; Peterson, E.; Pennington, M. W.; Ploegh, H. L.; Thornberry, 
N. a; Goldberg, A. L. The Journal of biological chemistry 2003, 278, 35869–77. 
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Using these consensus-sequences, trypsin-like (β2 subunit) fluorescent substrates were 
synthesized including a 5’-TAMRA (TAM) fluorophore attached to the N-terminus and cAB40 
3.4 attached to the C-terminus via a C-terminal lysine as well as the reverse. Glycines (n = 0, 1, 
2) were added as a linker between the acylated lysine and the consensus sequence (Table 5.1). As 
stated in the introduction, less structured substrates are known to freely diffuse into the 20S 
catalytic particle, bypassing the regulatory machinery of the proteasome.  
At this point, we decided to focus on the development of Ch-L and Ca-L biosensors, and 
chose to forgo work on the T-L activity biosensor. While all sixteen Ch-L and Ca-L biosensors 
were substrates for the corresponding activity of the proteasome, we found that Ca-L and Ch-L 
substrates 5.5, 5.6, and 5.7 had the highest specific activities and corresponding fluorescent 
enhancements (Table 5.2). We decided to focus on these six substrates. In attempting to obtain 
the Km and Vmax we discovered the solubility of the substrates is low at concentrations above 10 
                                                                                                                                                             
14 Harris, J.; Alper, P.; Li, J.; Rechsteiner, M.; Backes, B. Chemistry & biology 2001, 8. 
Substrate Chymotrypsin-like (Ch-L) Caspase-like (Ca-L) Trypsin-like (T-L) 
5.1 AB40-HHSLK(TAM)-amide AB40-nLPnLDK(TAM)-amide AB40-LRRK(TAM)-amide 
5.2 AB40-HHSLGK(TAM)-amide AB40-nLPnLDGK(TAM)-amide AB40-LRRGK(TAM)-amide 
5.3 AB40-HHSLGGK(TAM)-amide AB40-nLPnLDGGK(TAM)-amide AB40-LRRGGK(TAM)-amide 
5.4 AB40-GHHSLGK(TAM)-amide AB40-GnLPnLDGK(TAM)-amide AB40-GLRRGK(TAM)-amide 
5.5 TAM-HHSLK(AB40)-amide TAM-nLPnLDK(AB40)-amide TAM-LRRK(AB40)-amide 
5.6 TAM-HHSLGK(AB40)-amide TAM-nLPnLDGK(AB40)-amide TAM-LRRGK(AB40)-amide 
5.7 TAM-HHSLGGK(AB40)-amide TAM-nLPnLDGGK(AB40)-amide TAM-LRRGGK(AB40)-amide 
5.8 TAM-GHHSLGK(AB40)-amide TAM-GnLPnLDGK(AB40)-amide TAM-GLRRGK(AB40)-amide 
 Table 5.1 24-member library of sensors synthesized for the proteasome. Glycine linkers were 
added to increase flexibility of substrate and decrease secondary structure of peptide. 5’-
TAMRA and cAB40 were added to each consensus sequence at the N-terminal amine and C-
terminal lysine as well a second substrate in reverse to construct a 32-member library.  
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μM make the concentrations of substrate necessary for accurate Km and Vmax values unattainable. 
Therefore, instead of collecting Km and Vmax data, we found the specific activity of each 
substrate near our working substrate concentration (2.5 μM). For Ch-L activity, substrates Ch-L 
5.5 and Ch-L 5.7 had the best specific activities around 0.110 nmol/min/mg enzyme. The 
fluorescent enhancement upon proteolysis (fold) for Ch-L 7 was 10-fold higher making it the 
better overall biosensor. However, as was the case in chapter 3, we found the fold enhancements 
are a function of the purity of the substrate. This suggests that Ch-L 5.7 could be less pure, and 
equally as capable as Ch-L 5.5.   For Ca-L activity, biosensor 5.5 is clearly the best substrate, 
having the highest specific activity, as well as large fluoresce enhancements upon proteolysis. 
Using Ca-L and Ch-L substrates 5.5, 5.6, and 5.7, we calculated the IC50 (μM) of four inhibitors 
known to be specific for certain catalytic subunits of the 20S proteasome at constant biosensor 
concentration (2.5 μM). We used the proteasome subunit specific inhibitors: 
 
Peptide 
Specific Activity Fluorescent enhancement upon 
proteolysis (fold) (nmol/min/mg enzyme) 
1 µM 2.5 µM 5 µM 1 µM 2.5 µM 5 µM 
Ch-L 5.5 0.065 ± 0.003 0.114 ± 0.003 0.138 ± 0.006 33.5 ± 1.0 34.1 ± 0.7 30.4 ± 0.7 
Ch-L 5.6 0.039 ± 0.001 0.073 ± 0.001 0.103 ± 0.001 43.0 ± 2.2 40.5 ± 1.8 37.7 ± 2.0 
Ch-L 5.7 0.067 ± 0.002 0.110 ± 0.001 0.162 ± 0.003 47.0 ± 4.0 44.8 ± 1.7 41.3 ± 2.3 
Ca-L 5.5 1.16 ± 0.016 1.12 ± 0.033 0.78 ± 0.03 29.3 ± 1.9 25.1 ± 0.5 23.4 ± 0.5 
Ca-L 5.6 0.14 ± 0.005 0.13 ± 0.004 0.13 ± 0.01 33.7 ± 0.9 27.8 ± 0.7 20.5 ± 0.2 
Ca-L 5.7 0.55 ± 0.017 0.44 ± 0.018 0.33 ± 0.02 15.7 ± 0.7 14.5 ± 0.7 13.3 ± 0.5 
 
Table 5.2 Specific activities and fluorescent enhancements upon proteolysis of Ch-L and Ca-
L biosensors. Km and Vmax data could not be obtained due to lack of solubility at high 
concentrations of substrate. 
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(1) Ac-APnLD-H15 for Caspase-like activity 
(2) Epoxomicin16 for Chymotrypsin-like activity 
(3) MG13217 for both the Caspase-like and Chymotrypsin-like activities 
(4) Lactacystin18 for the Chymotrypsin-like and Trypsin-like activities 
The IC50 (μM) for each inhibitor was calculated for each peptide substrate (Table 5.3). The Ca-L 
inhibitor Ac-APnLD-H shows selectivity for our Ca-L substrates over Ch-L, with the IC50 of our 
optimized Ch-L 5.7 substrate around 100 μM and the Ca-L substrates all over 100 uM. 
Epoxomicin (specific for Ch-L activity) demonstrates selectivity for the Ch-L substrates 5.5, 5.6, 
and 5.7 which are all near 0.02 μM with Ca-L substrates all over 10 μM. The Ca-L and Ch-L 
inhibitor MG132 inhibits the Ch-L (near 0.01 μM) substrates substantially better than the Ca-L 
(near 40 μM) activity. The Ch-L and T-L subunit specific inhibitor Lactacystin demonstrates 
selectivity for Ch-L 5.5, 5.6, and 5.7 over substrates Ca-L 5.5, 5.6, and 5.7. Our substrates 
demonstrate the selectivity that should be observed with each inhibitor.  
                                                 
15 Kisselev, A. F.; Garcia-Calvo, M.; Overkleeft, H. S.; Peterson, E.; Pennington, M. W.; Ploegh, H. L.; Thornberry, 
N. a; Goldberg, A. L. The Journal of biological chemistry 2003, 278, 35869–77. 
 
16 Meng, L.; Mohan, R.; Kwok, B. H. B.; Elofsson, M.; Sin, N.; Crews, C. M. Proceedings of the National Academy 
of Sciences 1999, 96, 10403–10408. 
 
17 (1) Han, Y. H.; Moon, H. W. A. J. I. N.; You, B. O. R. A.; Park, W. O. O. H. Oncology Reports 2009, 22, 215–
221. (2) Bogyo, M.; Shin, S.; McMaster, J. S.; Ploegh, H. L. Chemistry & Biology 1998, 5, 307–320. (3) Chen, B.; 
Ma, Y.; Meng, R.; Xiong, Z.; Zhang, C.; Chen, G.; Zhang, A.; Dong, Y. Acta Biochimica et Biophysica Sinica 2010, 
42, 253–258. 
 
18 (1) Fenteany, G.; Standaert, R.; Lane, W.; Choi, S.; Corey, E.; Schreiber, S. Science 1995, 268, 726–731. (2) 
Nagamitsu, T.; Sunazuka, T.; Tanaka, H.; Ōmura, S.; Sprengeler, P. A.; Smith, A. B. Journal of the American 
Chemical Society 1996, 118, 3584–3590. 
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CONCLUSIONS  
  
Proteasome assays have been synthesized and developed for the Ch-L and Ca-L catalytic 
activities of the proteasome.  The assays rely on the fluorophore 5’-TAMRA, a robust 
fluorophore with good photophysical properties, and the broad spectrum cAB40 quencher 3.7 to 
produce a fluorescent enhancement upon cleavage by the proteasome. Substrate specificity was 
demonstrated for either the Ca-L or Ch-L subunit of the proteasome. This is promising, as a 
multicolored sensor could be constructed by simply substituting a far red fluorophore on the Ca-
L substrate along with cAB40 3.7. The T-L substrate needs further attention but it should be 
straightforward to characterize its fluorescence enhancement and proteasome subunit specificity. 
As with the Ca-L substrate, a robust green fluorophore could easily be substituted for 5’-
TAMRA on the T-L substrate.  With different fluorophores on all three subunit specific 
substrates, the three catalytic activities of the proteasome could be monitored simultaneously.  
Peptide 
IC50 (µM) 
Ac-APnLD-H Epoxomicin MG132 Lactacystin 
Ch-L 5.5 >>>100 0.024 ± 0.001 0.013 ± 0.003 1.65 ± 0.19 
Ch-L 5.6 >100 0.018 ± 0.001 0.009 ± 0.001 1.61 ± 0.08 
Ch-L 5.7 >100 0.044 ± 0.001 0.021 ± 0.008 2.44 ± 0.11 
Ca-L 5.5 94.9 ± 9.8 >10 40.6 ± 2.1 >25 
Ca-L 5.6 8.7 ± 2.3 >10 9.6 ± 2.4 >25 
Ca-L 5.7 109 ± 15.6 >10 41.3 ± 4.3 >25 
 
Table 5.3 IC50 (μM) values of four subunit specific proteasome inhibitors in the presence of 
biosensor substrate (2.5 μM). 
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MATERIALS AND METHODS 
 
General Procedures General reagents and solvents were purchased from Fisher or Sigma-
Aldrich. Novasyn TGR Resin, Fmoc-Lys(Mtt)-OH (N-α-Fmoc-N-ε-4-methyltrityl-L-lysine), and 
all Fmoc protected natural amino acids were purchased from EMD Biosciences Inc. HCTU [1H-
benzotriazolium-1 [bis(dimethylamino)methylene]-5-chloro-hexaﬂuorophosphate (1),3-oxide] 
was purchased from Peptides International (Louisville, KY, U.S.A.). 5’-TAMRA (5’-
carboxytetramethylrhodamine) was purchased from Chempep, Inc. (Wellington, Fl, U.S.A). 
Proteasome inhibitors and the 20S proteasome were purchased from BostonBiochem.   
 
Peptide Synthesis Peptides were synthesized using standard Fmoc solid-phase synthesis on a 
Prelude peptide synthesizer (Protein Technologies Inc., Tucson, AZ, U.S.A.). Novasyn TGR 
resin was swelled for 30 min in DCM before synthesis. Fmoc-Lys(Mtt)-OH was then coupled 
using 5.0 equiv AA, 4.9 equiv of HCTU, 20 equiv of diisopropylethylamine (DIPEA) in N,N-
dimethylformamide (DMF) (2 × 5 min) followed by a DMF wash (6 × 30 s). The Lys 4-
methyltrityl protecting group was then deprotected using 7% TFA/7% TIS/86% DCM. The 
deprotected side chain amine was then acylated using 1.1 equiv cAB40, 1.0 equiv HCTU, and 
20.0 equiv DIPEA in DMF (2 x 2 h).  The Fmoc-protecting group was removed using 20% 
piperidine in DMF (2 × 2.5 min) followed by a DMF wash (6 × 30 s). Peptide chain elongation 
was performed using the conditions described for the coupling and deprotection of Fmoc-
Lys(Mtt)-OH. The N-terminal Fmoc was then removed using 20% piperidine in DMF (2 × 2.5 
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min) and 5’-TAMRA was coupled using 5.0 equiv of ﬂuorophore, 4.9 equiv of HCTU, and 20 
equiv of DIPEA in DMF (1× 60 min) followed by a wash (3× DMF, IPA, DCM). After 
fluorophore coupling, the peptide was cleaved from the resin and deprotected using a 95:2.5:2.5 
TFA: H2O: triisopropylsilane (TIPS) cleavage cocktail. The peptides were isolated via ﬁltration, 
precipitated with ice-cold ether, and centrifuged. The precipitates were air-dried, dissolved in 
DMSO, and puriﬁed twice using HPLC ((1) 3% to 95% acetonitrile to water gradient with 0.1% 
TFA over 30 min using a 250 mm x 21.2 mm C4 column) followed by (2) 3% to 95% 
acetonitrile to water gradient with 0.1% TFA over 30 min using a 250 mm x 21.2 mm C18 
column). The peak corresponding to the peptide was collected, freeze-dried, and characterized by 
electrospray ionization mass spectrometry: TAM-nLPnLDK(AB40)-amide Ca-L 5.5 [Exact 
Mass calculated: 1428.6, found: 715.0 (M+2H)2+], TAM-nLPnLDGK(AB40)-amide Ca-L 5.6 
[Exact Mass calculated: 1472.6, found: 737.05 (M+2H)2+], TAM-nLPnLDGGK(AB40)-amide 
Ca-L 5.7 [Exact Mass calculated: 1542.6, found: 772.1 (M+2H)2+], TAM-HHSLK(AB40)-amide 
Ch-L 5.5 [Exact Mass calculated: 1463.6, found: 732.7 (M+2H)2+], TAM-HHSLGK(AB40)-
amide Ch-L 5.6 [Exact Mass calculated: 1521.6, found: 761.7 (M+2H)2+], TAM-
HHSLGGK(AB40)-amide Ch-L 5.7 [Exact Mass calculated: 1580.6, found: 791.5 (M+2H)2+]. 
 
Specific Activity and Fluorescent Enhancement Assays Specific activities and fluorescent 
enhancements were calculated for all six Ch-L and Ca-L peptides. Biosensor substrates (1, 2.5 
and 5 μM) were incubated in a pH 8.0 buffer containing 20 mM HEPES, 0.5 mM EDTA, and 
0.035% w/v SDS. Once the plate reader (Molecular Devices Spectra Max Gemini EM) had 
reached equilibration, 20S proteasome was added (47 nM) and the fluorescence monitored. After 
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three assays, the specific activity and fold enhancement upon proteolysis was calculated for each 
substrate. 
 
Inhibitor IC50 value determination IC50 values were determined using specific commercially 
available proteasome inhibitors for each Ca-L and Ch-L substrate. Each peptide substrate (Ch-L 
5.5, 5.6, 5.7 and Ca-L 5.5, 5.6, 5.7) was incubated with six concentrations of Ac-APnLD-H, 
Epoxomicin, MG132, and Lactacystin. The concentrations of each inhibitor used depended on 
the published IC50 value of the inhibitor, with three concentrations above and below the 
published IC50 value. Specifically, peptide substrate (2.5 μM) was incubated with six differed 
concentrations of inhibitor at 37 °C in pH 8.0 buffer containing 20 mM HEPES, 0.5 mM EDTA, 
and 0.035% w/v SDS. Proteasome (37 nM, purified rabbit 20S proteasome) was added and the 
reaction was monitored via fluorescence. Upon completion of the reaction at various inhibitor 
concentrations, kinetic data was entered into Sigmaplot and fit to a dose response curve to 
generate IC50 values for each inhibitor/substrate pair.  
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